1
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Abbreviated Title: Lupron &18F FLT in allo-HSCT
CC Protocol #: 11-C-0136
NCT# [STUDY_ID_REMOVED]Version Date: December 28, 2017Amendment: T
Titleof Study: Multi-institutional Prospective Pilot St udy of Lupron to Enhance Lymphocyte 
Immune Reconstitution following Allogeneic Bone Marrow Transp lantation in Post-pubertal 
Children and Adults with Molecular Imaging EvaluationNIH Principal Investigator: Christopher Kanakry, M.D.
A-F
Experimental Transplantation & Immunology Branch
Center for Cancer Research,National Cancer Institute, National Institutes of Health10 Center Drive, Rm. 4-3142, MSC 1203Telephone: 240-760-6171Email: christopher.kanakry@nih.gov
Lead Associate Investigator: Ronald Gress, M.D.A-F
Branch Chief, ETIB, CCR, NCI, NIH
Medical Advisory  Investigator: Peter Choyke, M.D.A-F
Branch Chief, Molecular Imaging, NCI, CCR, NIH
NIH Associate Investigators: 
Daniele Avila, CRNP, ETIB, CCR, NCI, NIHA-EMeg Kenyon, CRNP, ETIB, CCR, NCI, NIHA-E
Stephanie Cotton, RN, OCD, CCR, NCI, NIH A-BJennifer Sadler, RN, OCD, CCR, NCI, NIHA-B
Bazetta Blacklock Schuver, RN, OCD, CCR, NCI, NIH
A-BKaren Kurdziel, MD, MIP, CCR, NCI, NIHA-F
Deborah Citrin, MD, ROB, CCR, NCI, NIHA-FSeth M. Steinberg, PhD, BDMS, CCR, NCI, NIH
B, E
Kristen Cole, RN, OCD, CCR, NCI, NIHA-BConstance Yuan, MD, PhD, LP, CC, NIHE-F
Dennis Hickstein, MD, ETIB, CCR, NCI, NIHA-FBonnie Yates, RN, POB, CCR, NCI, NIHA-B
Fran Hakim, PhD, ETIB, CCR, NCI, NIHE-FCindy Delbrook, RN, OCD, CCR, NCI, NIHA-B
James Kochenderfer, MD, ETIB, CCR, NCI, NIHA-FTerry Fry, MD, POB, CCR, NCI, NIHA-F
Nirali Shah, MD, POB, CCR, NCI, NIHA-FMaya Lodish, MD, NICHDA-F
Steven Z. Pavletic, MD, ETIB, CCR, NCI, NIHA-FJennifer Kanakry, MD, ETIB, CCR, NCI, NIHA-F
2
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Tracey Chinn RN, ETIB, CCR, NCI, NIHA-BDavid Stroncek, MD, DTM, CC, NIHE-F
Ellen Carroll, RN, OCD, CCR, NCI, NIHA-BMaria Liza Lindenberg, MD, MIP, CCR, NIHA-F
Brenna Hansen, RN, OCD, CCR, NCI, NIHA-BWilly Flegel, MD, DTM, CC, NIHE-F
Jennifer Mann, CRNP, ETIB, CCR, NCI, NIHA-E
Site Principal Investigator: Jennifer Holter, M.D., University of Oklahoma
Site Principal Investigator Kirsten Williams, MD., Childrenâ€™s National Medical                                    
Center, Washington
Referral Contact: Bazetta Blacklock Schuver, RN
Study Coordinator: Jennifer Sadler, RN
240-760-6175
Email: jennifer.sadler@nih.gov
Non-NIH Associate Investigators:
For each person listed above, roles are identified with the appropriate letter
A.Obtain information by intervening or interacting with living individuals for research purposes
B.Obtaining identifiable private in formation about living individuals
C.Obtaining the voluntary informed cons ent of individuals to be subjects
D.Makes decisions about subject eligibility
E.Studying, interpreting, or analyzing identifiable private information or data/specimens for 
research purposes
F.Studying, interpreting, or analyzing de-identif ied data or specimens for research purposes
G.Some/all research activities performed outside NIH
IND Information: IND Number:  111119IND Sponsor:  Center for Cancer Research, NCI
Commercial Agents:                    Lupron Depot ,Cyclophosphamide, Methotrexate, Tacrolimus, 
Fludarabine, Busulfan  Jennifer Wilder, RN., Leidos Inc. 
A-B
3
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Multi-institutional data:
University of Oklahoma
Principal Investigator: Jennifer Holter, M.D.Associate Professor of Hematology/Oncology and BMT
Associate Investigator:            George Selby, MDInstitution: University of Oklahoma
MPA or SPA Number: Federal-Wide Assurance program FWA#00003191.
Complete Address: 920 Stanton L. Young, WP 2040Oklahoma City, OK 73104  
Phone Number: 405-271-4022 Ext 48397 Contact Elizabeth Cambron
E-mail: jholter2@ouhsc.edu
Name of IRB Contact: Meg Ribaudo, Director
Complete Address: 1000 Stanton L Young Blvd, Suite 176, Oklahoma City, OK 73117
Phone Number: 405-271-2045
E-mail of Contact: meg-ribaudo@ouhsc.edu
Name of Pharmacy Contact: N/A
Childrenâ€™s National Medical Center(CNMC)
Principal Investigator: Kirsten Williams, M.D.Assistant Professor of Pediatri cs/Hematology/Oncology and BMT
Institution: Childrenâ€™s National Medical Center
MPA or SPA Number: Federal-Wide Assurance program FWA# 00004487.
Complete Address: 111 Michigan Ave NWWashington DC, 20010
Phone Number: 202-476-2694
E-mail: kmwillia@cnmc.org
Name of IRB Contact: Fahmida Hoq, MD
Complete Address: 111 Michigan Ave NW
4
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Washington DC, 20010
Phone Number: 202-476-5000
E-mail of Contact: FHoq@childrensnational.org
Name of Pharmacy Contact: N/A
5
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
PRÃ‰CIS
Background:
xImpaired lymphocyte immune reconstitution is associated with morbidity and mortality 
following allogeneic hematopoietic stem cell transplantation (HSCT).
xData suggest that one of the limitations of immunity after HSCT is the lack of thymus 
recovery and proper B cell development. 
xAndrogen withdrawal has been shown to enhance T and B lymphopoiesis. 
xLupron is an approved, safe, gona dotropin releasing hormone (GnRH) 
agonist/antagonist. 
xNoninvasive imaging modalities to study immune reconstitution would be invaluable to predict optimal or impaired immune recovery permitting early institution of therapies. 
xFLT is 3â€™-deoxy-3 18F-fluorothymidine, a radiolabeled thymidine analogue that 
illustrates dividing hemat opoietic cells and may pred ict immune recovery after 
allogeneic HSCT.  
xFLT has been used safely in patients w ho have received intensive chemotherapy.
Objectives:
xPrimary: To determine if Lupron improves B lymphocyte reconstitution after HSCT.
xPrimary: To assess whether 18F FLT PET/CT could predict early engraftment/immune reconstitution in marrow and thymus after allogeneic HSCT. 
xPrimary: To assess safety of Lupron after 2
ndHSCT evaluated in a separate arm. 
Eligibility:
xPatients > 9 years old and pube rtal and/or >15 year and Â”55 years, with aggressive 
leukemia (Acute Myelogenous Leukemia (A ML), myelodysplastic syndromes (MDS) 
with high risk cytogenetics, Acute Lym phocytic Leukemia (ALL), CMML, certain CML)
requiring HSCT will be enrolled at NCI.
x$W8QLYHUVLW\RI2NODKRPD$JH !\HDUVROGDQGÂ”\HDUVIRU UHFLSLHQW
xPatients > 4 and < 24 years with the above diseases will be enrolled at Childrenâ€™s National Medical Center.
Design:
xThis is a prospective pilot study, the primary  aims of which are: 1) to assess whether 
Lupron enhances lymphocyte recovery after HSCT and 2) whether FLT imaging can be 
used to predict engraftment/immune reconstitution, and 3) whether Lupron and FLT are 
tolerable for second HSCT.
xAt NCI and Univ of Oklahoma, post-pubertal pediatric male patie nts (<18 years) will 
be randomized to receive a 3 month (11.25 mg ) injection and adu lt male patients will 
be randomized to receive 4-month preparation of Lupron (30 mg) or placebo two weeks before the preparative regimen for first BM T.  Women and all individuals undergoing 
6
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2ndBMT will receive Lupron at these doses per age and be evaluated in the treated 
cohort. At Childrenâ€™s Nationa l Medical Center, the patie nts will not receive Lupron 
outside of the context of clinical care, and will receive myeloablative HSCT as per 
standard of care with FLT imaging for engraftment as the only primary endpoint. 
xA target of 68 evaluable adult patients will be enrolled on this trial, which may necessitate up to 118 patients (118 donors) enrolled to reach this target at NCI and University of Oklahoma.  A total of 10 pediatric patients will be enrolled at Childrenâ€™s National Medical Center for FLT imaging only. Sixteen of these patients will be enrolled to undergo second BMT.
xAt NCI, adults greater than 18 years old both female and adult male patients
undergoing 2
ndBMT will receive 4-month preparation of Lupron (30 mg) two weeks 
before the preparative regimen.  All patie nts will undergo FLT imaging to evaluate 
whether this may predict HSCT response or failure (relapse). This will be a pilot arm 
of 16 patients total. 
xThe planned length of this trial is 7 years with interim analyses at day 100 and day 365.   
xSome of the patients are anticipated to be ev aluated using FLT (to include only patients 
needed for the immunological primary endpoi nt, not increasing total patient numbers).
23 adult NCI patients in total will undergo FLT PET/CT imaging on day -1, at day +5 
or day +9, at 4 weeks, and at a future point to include evidence of GVHD relapse, or immune recovery. An estimate d 50 patients (including subset of the 23 patients 
undergoing serial scanning) will be imaged approx imately at 1 year for evaluation of 
thymus reconstitution. The total possible numbers will include no more than 118 
patients to achieve the 68 evaluable adults  for the immunological primary endpoint. 
However, all NCI patients will undergo a sing le 1 year FLT for evaluation of thymus 
reconstitution.  10 pediatric patients at CNMC will undergo FLT PET/CT imaging on 
Day -1, day+9, and day +28 (if possible). Initial images will be correlated with engraftment and other secondary endpoints.
xStudy endpoints to include: 1) safety of L upron in the context of allogeneic BMT, 2) 
lymphocyte reconstitution after Lupron adminis tration, 3) the incidence of acute and 
chronic GVHD and infectious complica tions, 4) remission rates after HSCT.
7
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
TABLE OF CONTENTS
PRÃ‰CIS......................................................................................................................... .................. 5  
TABLE OF CONTENTS................................................................................................................ 7  
1 INTRODUCTION ................................................................................................................ 14  
1.1 Study Objectives ............................................................................................................ 14  
1.1.1  Primary Objectives.................................................................................................. 14  
1.1.2  Secondary Objectives.............................................................................................. 14  
1.2 Background and Rationale............................................................................................. 15  
1.2.1  Impaired Immune Reconstitution afte r Stem Cell Transplantation ........................ 15  
1.2.2  Androgen Withdrawal Enhances T and B Lymphopoiesis..................................... 16  
1.2.3  Lupron for Androgen Suppression.......................................................................... 18  
1.2.4  Lupron Safety Profile.............................................................................................. 18  
1.2.5  Lupron Pharmacology............................................................................................. 18  
1.2.6  FLT imaging modality ............................................................................................ 19  
1.2.7  18F FLT Safety Profile ............................................................................................ 21  
1.2.8  18F FLT Pharmacology ........................................................................................... 21  
1.2.9  FLT Availability ..................................................................................................... 22  
1.2.10  Trial Plan................................................................................................................. 22  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT....................................................... 23  
2.1 Eligibility Criteria .......................................................................................................... 2 3 
2.1.1  Inclusion Criteria: Transplant Recipient................................................................. 23  
2.1.2  Exclusion Criteria: Transplant Recipient................................................................ 25  
2.1.3  Inclusion Criteria: Matched Related Transplant Donor.......................................... 26  
2.1.4  Exclusion Criteria: Matched Related Transplant Donor......................................... 26  
2.1.5  Inclusion Criteria- Matched Unrelated Donor ........................................................ 27  
2.1.6  Inclusion Criteria-18F FLT Candidate Transplant Recipient ................................. 27  
2.1.7  Exclusion Criteria-18F FLT Candidate Transplant Recipient ................................ 27  
2.2 Screening Evaluation and Criteria for HSCT ................................................................ 27  
2.2.1  Recipient ................................................................................................................. 27  
2.2.2  Matched Rela ted Donor .......................................................................................... 29  
2.3 Registration Procedures ................................................................................................. 30  
2.3.1  Protocol Entry Date................................................................................................. 30  
8
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2.3.2  Registration............................................................................................................. 30  
2.3.3  University of Oklahoma Donors and Recipients .................................................... 30  
2.3.4  Childrenâ€™s National Medical Cent er Donors and Recipients.................................. 31  
2.4 Randomization Procedures ............................................................................................ 31  
2.4.1  Female Recipients................................................................................................... 31  
2.4.2  Male Recipients ...................................................................................................... 31  
3 STUDY IMPLEMENTATION ............................................................................................ 32  
3.1 Study Design.................................................................................................................. 3 2 
3.1.1  NCI and University of Oklahoma for 1stBMT....................................................... 32  
3.1.2  Childrenâ€™s National Medical Center ....................................................................... 33  
3.2 Drug Administration ...................................................................................................... 33  
3.2.1  Lupron..................................................................................................................... 33  
3.2.2  18F-FLT ................................................................................................................... 33  
3.3 On Study Protocol Evaluation Pre-Transplant Work-up ............................................... 34  
3.3.1  Within 4 weeks of Transplant Date ........................................................................ 34  
3.3.2  FLT on Study Evaluations ...................................................................................... 34  
3.4 Biologic Studies............................................................................................................. 35  
3.4.1  Immune Reconstitution........................................................................................... 35  
3.4.2  Immunologic Studies .............................................................................................. 36  
3.4.3  Objectives/Specific Aims........................................................................................ 36  
3.4.4  Methodology........................................................................................................... 36  
3.5 Collaborative research Studies....................................................................................... 37  
3.6 Donor Collection............................................................................................................ 38  
3.6.1  Matched Unrelated Donors..................................................................................... 38  
3.6.2  Matched Relate d Donors......................................................................................... 38  
3.7 Preparative Regimen for HSCT and GVHD Prophylaxis.............................................. 39  
3.7.1  Central Access ........................................................................................................ 39  
3.7.2  Remission Status..................................................................................................... 39  
3.7.3  Conditioning Regimen............................................................................................ 39  
3.7.4  GVHD Prophylaxis................................................................................................. 41  
3.7.5  Growth Factors (GCSF).......................................................................................... 41  
3.8 Transplant Procedure for 1stand 2ndBMT..................................................................... 42  
9
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
3.8.1  Day 0....................................................................................................................... 42  
3.8.2  Transplant Outcome Determinations ...................................................................... 42  
3.9 Post-transplant monitoring (1stand 2ndBMT) ............................................................... 42  
3.9.1  Day 0 to day +100................................................................................................... 42  
3.9.2  Specific evaluation time points (1stand 2ndBMT) ................................................. 43  
3.9.3  Long term follow-up guidelines (1stand 2ndBMT)................................................ 43  
3.9.4  FLT on study evaluations........................................................................................ 44  
3.10  Criteria for Removal from Protocol Therapy and Off Study Criteria............................ 44  
3.10.1  Criteria for Removal from  Protocol Therapy.......................................................... 44  
3.10.2  Off-Study Criteria ................................................................................................... 45  
3.10.3  Off Protocol Therapy and Off Study Procedure at NCI ......................................... 45  
3.10.4  Participating S ite Off-Study Notification ............................................................... 45  
4 SUPPORTIVE CARE........................................................................................................... 46  
4.1 Infection Prophylaxis..................................................................................................... 46  
4.1.1  Infectious Diseas e Surveill ance:............................................................................. 47  
4.2 Management of Engraftment Syndrome........................................................................ 47  
4.3 Treatment of Graft-Ve rsus-Host Disease....................................................................... 47  
4.4 Menses Suppression and Contraception ........................................................................ 48  
4.5 Blood Product Support................................................................................................... 48  
4.6 Nutritional Support ........................................................................................................ 49  
4.7 Anti-Emetic Usage......................................................................................................... 49  
4.8 Intravenous Immune Globulin (IVIG) ........................................................................... 49  
4.9 Hepatic Function Support .............................................................................................. 49  
4.10  Central Nervous System Prophylaxis ............................................................................ 50  
4.11  Fluid Management During First 30 Days Following Transplantation........................... 50  
4.12  Ancillary Support........................................................................................................... 50  
4.13  Supportive Care For Relapse ......................................................................................... 50  
4.14  Additional cell infusions for graft failure , impending graft failure, or poor graft 
function. .................................................................................................................................... 50  
5 DATA COLLECTION AND EVALUATION..................................................................... 50  
5.1 Data Collection .............................................................................................................. 50  
5.1.1  Adverse event recording ......................................................................................... 52  
10
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
5.2 Response Criteria........................................................................................................... 52  
5.2.1  Primary Endpoints .................................................................................................. 52  
5.2.2  Secondary Endpoints .............................................................................................. 52  
5.3 Toxicity Criteria............................................................................................................. 53  
6 STATISTICAL SECTION ................................................................................................... 53  
6.1 Subject Accrual.............................................................................................................. 53  
6.1.1  Statistics and Feasibility ......................................................................................... 53  
7 HUMAN SUBJECTS PROTECTIONS ............................................................................... 56  
7.1 Rationale For Subject Selection..................................................................................... 56  
7.2 Participation of Children................................................................................................ 56  
7.3 Participation of Subjects Unable to Give Consent......................................................... 57  
7.4 Evaluation of Benefits an d Risks/Discomforts.............................................................. 57  
7.4.1  Recipient ................................................................................................................. 57  
7.4.2  Risks in relation to benefit for Donor ..................................................................... 58  
7.4.3  Pediatric Patients..................................................................................................... 58  
7.5 Consent and Assent Proce ss and Documentation .......................................................... 58  
7.5.1  Consent for minors when they reach the age of majority ....................................... 59  
7.5.2  Telephone consent and re -consent procedure ......................................................... 60  
7.5.3  Informed consent of Spanish speaking subjects ..................................................... 60  
7.5.4  Short form consent process for ot her non-English speaking patients..................... 60  
8 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN
61 
8.1 Definitions...................................................................................................................... 61  
8.1.1  Adverse Ev ent......................................................................................................... 61  
8.1.2  Suspected advers e reaction ..................................................................................... 61  
8.1.3  Unexpected adve rse reaction .................................................................................. 61  
8.1.4  Serious..................................................................................................................... 61  
8.1.5  Serious Adverse Event............................................................................................ 61  
8.1.6  Disability................................................................................................................. 62  
8.1.7  Life-threatening adverse drug expe rience............................................................... 62  
8.1.8  Protocol Deviation (NIH Definition)...................................................................... 62  
8.1.9  Non-compliance (NIH Definition).......................................................................... 62  
11
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
8.1.10  Unanticipated Problem............................................................................................ 62  
8.2 NCI-IRB and Clinical Director Reporting..................................................................... 62  
8.2.1  NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths
62 
8.2.2  NCI-IRB Requirements for PI Reporting at Continuing Review ........................... 63  
8.2.3  NCI-IRB Reporting of IND Safety Reports............................................................ 63  
8.3 NCI Guidance for Reporting Expedited Adve rse Events for Multi-Center Trials ........ 64  
8.4 IND Sponsor Reporting Criteria .................................................................................... 64  
8.5 Data Recording of Unrelated Donors from NMDP ....................................................... 64  
8.6 Data and Safety Monitoring Plan................................................................................... 64  
8.6.1  Principal Investigator/Research Team .................................................................... 64  
8.6.2  Sponsor Monitoring Plan ........................................................................................ 65  
8.6.3  Safety Monitoring Committee (SMC) .................................................................... 65  
9 Multi-Institutional Guidelines............................................................................................... 66  
9.1.1  IRB Approvals ........................................................................................................ 66  
9.1.2  Amendments and Consents..................................................................................... 66  
9.1.3  Data and Specimen Coll ection Procedures ............................................................. 66  
9.1.4  Data Center Audits.................................................................................................. 66  
9.1.5  Protocol Monitoring Committees ........................................................................... 66  
10 PHARMACEUTICAL INFORMATION............................................................................. 66  
10.1  Lupron depot.................................................................................................................. 66  
10.1.1  Chemical name........................................................................................................ 66  
10.1.2  Chemical structure .................................................................................................. 67  
10.1.3  Commercial Formulation........................................................................................ 67  
10.1.4  Storage .................................................................................................................... 67  
10.1.5  Stability................................................................................................................... 67  
10.1.6  Route of administration........................................................................................... 67  
10.1.7  Dose ........................................................................................................................ 67  
10.1.8  Drug Interactions .................................................................................................... 67  
10.1.9  Known toxicities for patients >18........................................................................... 67  
10.1.10  Known toxicities for patients <18........................................................................... 68  
10.2  Cyclophosphamide......................................................................................................... 69  
12
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10.2.1  Chemical name........................................................................................................ 69  
10.2.2  Chemical structure .................................................................................................. 69  
10.2.3  Commercial Formulation........................................................................................ 70  
10.2.4  Storage .................................................................................................................... 70  
10.2.5  Stability................................................................................................................... 70  
10.2.6  Route of administration........................................................................................... 70  
10.2.7  Dose ........................................................................................................................ 70  
10.2.8  Drug Interactions .................................................................................................... 70  
10.2.9  Known toxicities ..................................................................................................... 70  
10.3  Total Body Irradiation.................................................................................................... 71  
10.3.1  Chemical name........................................................................................................ 71  
10.3.2  Known toxicities ..................................................................................................... 71  
10.4  FLT ............................................................................................................................ .... 71  
10.4.1  Chemical Name....................................................................................................... 71  
10.4.2  Commercial Formulation........................................................................................ 71  
10.4.3  Storage .................................................................................................................... 71  
10.4.4  Chemical Structure.................................................................................................. 71  
10.4.5  Method of Administration....................................................................................... 72  
10.4.6  Availability ............................................................................................................. 72  
10.4.7  Known Toxicites..................................................................................................... 72  
10.5  Fludarabine (Fludara, Berlex Laboratories)................................................................... 72  
10.5.1  Chemical Name....................................................................................................... 72  
10.5.2  Supply ..................................................................................................................... 72  
10.5.3  Preparation .............................................................................................................. 72  
10.5.4  Storage and Stability............................................................................................... 72  
10.5.5  Administration ........................................................................................................ 72  
10.5.6  Toxicities................................................................................................................. 72  
10.6  Busulfan (Busulfex)....................................................................................................... 73  
10.6.1  Source ..................................................................................................................... 73  
10.6.2  Storage and Stability............................................................................................... 73  
10.6.3  Administration ........................................................................................................ 73  
10.6.4  Toxicities................................................................................................................. 73  
13
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10.6.5  Drug Interactions .................................................................................................... 73  
11 REFERENCES ..................................................................................................................... 74  
12 APPENDICES ..................................................................................................................... .7 8 
12.1  Appendix 1: Performance Scales................................................................................... 78  
12.2  Appendix 2A: Recipient (arm 1 and 2).......................................................................... 80  
12.3  Appendix 2B: Donor  (arm 1 and 2) .............................................................................. 82  
12.4  Appendix 3a: FLT ( 1stBMT)........................................................................................ 83  
12.5  Appendix 4A: Adult (>22 ye ars) BMT Roadmap ......................................................... 85  
12.6  Appendix 4B: Pediatric (<22 years) BMT Roadmap .................................................... 89  
12.7  Appendix 5: Research Specimens.................................................................................. 93  
12.8  Appendix 6: Immunization Post-Transplant.................................................................. 94  
12.9  Appendix 7: Management of  Engraftment Syndrome................................................... 95  
12.10  Appendix 8A: Grading and Management of  Acute Graft-Versus-Host-Disease........... 97  
12.11  Appendix 8B .................................................................................................................. 99  
12.12  Appendix 8C: Signs and Symptoms of cGVHD ......................................................... 102  
12.13  Appendix 8D: cGVHD Score Sheet ............................................................................ 104  
12.14  Appendix 9: ETIB Policy for Sample Handling.......................................................... 107  
12.14.1  Sample Processing ................................................................................................ 107  
12.14.2  Labeling ................................................................................................................ 107  
12.14.3  Storage/Tracking in the Preclinical Development and Clinical Monitoring Facility 
(PDCMF) ............................................................................................................................ 107  
12.14.4  Protocol Completion/Sa mple Destruction ............................................................ 108  
12.14.5  Handling for subjects at other Participating Institutions....................................... 109  
12.15  Appendix 10: Data Collection elem ents Required by Protocol................................... 110  
12.16  APPENDIX  11:  Problem Report Form...................................................................... 113  
14
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.1.1 Primary Objectives
xTo determine whether Lupron leads to accelerated B cell recovery after allogeneic 
hematopoietic stem cell transplantation (after 1stand 2ndBMT).
xTo assess whether 18F FLT PET/CT could predict early engraftment/immune 
reconstitution in marrow and thymus after allogeneic HSCT (1stBMT only).
xTo assess safety of Lupron after 2ndHSCT and evaluate whethe r FLT can predict relapse 
(evaluated after 2ndBMT)
1.1.2 Secondary Objectives
xTo investigate whether Lupron will accelerate thymic reconstitution after allogeneic HSCT using CT scan thymic index, flow cytometric measurements of naÃ¯ve T cells, 
peripheral blood TREC on sorted CD4+ and CD8+  T cells, and Spectratype analysis of T 
cell receptor diversity on sort ed CD4+ and CD8+ T cells (1
stBMT)
xTo assess the feasibility of 4 month Lupron in male patients after allogeneic HSCT in 
post-pubertal individuals (after 1stand 2ndBMT).
xTo investigate whether Lupron will decrease the incidence of acute or chronic graft-versus-host disease (GVHD) after allogeneic  HSCT, comparing the Lupron treated and 
untreated groups using NIH developed criterion for the definition of clinical and biopsy-
proven acute and chronic GVHD (after 1
stBMT).
xTo evaluate if Lupron will decrease the incidence of infectious complications in recipients of allogeneic HSCT, comparing the number and clinical severity of infectious 
complications between patients who received Lupron as compared to those that did not
(after 1
stBMT).
xTo evaluate if Lupron will enhance graft-versus-tumor (GVT) effects by comparing the 
remission rates of patients who did vs. did not receive Lupron (after 1stBMT). To 
compare the outcomes of the pilot patients after 2ndHSCT in terms of relapse as 
compared to historical controls. 
xTo evaluate if Lupron treatment results in other changes in immune  reconstitution (e.g. 
dendritic cell reconstitution, monocyte rec onstitution, and immunoglobulin recovery)
(after 1stBMT).
xTo demonstrate that 18F FLT imaging is sa fe in the peri-transplant period (after 1st
BMT).
FLT endpoints include: 1) Ability of 18F FL T-PET to document preparative regimen 
ablation success 2) Evaluate the potential of 18F FLT/PET imaging to predict 
engraftment at week one 3) Assessment of GVHD using 18F FLT, 4) Assess relapse 
using FLT (after 1stand 2ndBMT).
15
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
1.2 B ACKGROUND AND RATIONALE
1.2.1 Impaired Immune Reconstitution after Stem Cell Transplantation
Impaired immune reconstitution contributes to morbidity and mortality after allogeneic stem cell 
transplant.  Data suggest that this is due to th e delayed and often distur bed recovery of T and B 
cells post-transplant.  Although the innate immune  system regenerates functionally and quickly 
post-transplant, the recovery of T and B lymphocytes  is delayed for many months to years. This 
delay in lymphocyte cell recovery compared to other leukocytes is more pronounced in adult patients as compared to children.  As shown in Figure 1 and Figure 2below, the two figures 
compare the percentage of normal leukocyte r ecovery in peripheral bl ood between adults and 
children.  These show that B cell recovery in children approaches 50% by day 180 and 100% by 
day 270 and CD4+ numbers approach 100% at 2 years.  In contrast, for adults, B cell recovery is 30% at day 180 and 80% at day 270 with CD 4 recovery delayed indefinitely [1]
Figure 1
Figure 2
Not only are the absolute numbers of T and B lymphocytes decreased post-transplant, the 
function of these populations remains compromised even after normal numbers are achieved.  In 
part, this is due to the mechanism of lymphoid reconstitution post-transplant.  In contrast to 
normal ontogeny where the thymus provides the vast  majority of T cells to the peripheral pool, 

16
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
post-transplant T cell regeneration relies upon the mechanism of  peripheral expansion for T cell 
recovery.   In the thymus, T cells are produced de novo from marrow precursors.  These T cells 
undergo T cell receptor (TCR) rearrangement, re sulting in naÃ¯ve T cells with diverse TCRs, 
capable of recognizing a wide array of infectious  or tumor antigens.  These developing T cells 
undergo positive and negative sel ection, permitting the deletion of autoreactive clones.  In 
contrast, when thymic function is poor as is  often the case after adult allo-HSCT, T cell 
reconstitution is accomplished through the rapid pro liferation of mature T cell clones, leading to 
a skewed, oligoclonal population of T ce lls with the potential for alloimmunity.[ 1] Poor thymic 
function has significant clini cal consequences in the setting of hematopoietic stem cell 
transplantation.  Impaired thymopoiesis is asso ciated with poor clearance of infections and 
diminished responses to vaccines (due  to resulting B cell dysfunction). [2-6 ] Successful T cell 
reconstitution also confers significant protection from relapse of malignant disease as well. [ 7-9]
Furthermore, impaired thymopoiesis is linked to the development and persistence of acute and 
chronic graft-versus-host disease. [ 6,10-12] Thus, improving thymopoiesis and thus 
lymphopoiesis may partially abrogate GVHD, en hance immune surveillan ce, and improve HSCT 
outcomes. 
Similar to the effects of peripheral expansion on T cells, mature memory B cells demonstrate a 
restricted repertoire post-HSCT. [ 13] In contrast, B cells produced in the marrow through de 
novo development (transitional B cells ) display a diverse repertoire. [ 13,14] These transitional 
B cells emerge gradually (within months) af ter HSCT and are not influenced by viral 
reactivations and GVHD, suggesting that this popul ation would be best used to identify the 
influence of immunotherapy on lymphocyte reconstitution after HSCT.  In addition, studies have suggested that transitional B cell development is delayed and diminished in older adults, those with reduced intensity conditioning for HSCT, findings similar to the influence of these factors on thymus derived T cell development. [ 15] Furthermore, there are data to suggest that 
transitional de novo B cell developm ent would be associated with enhanced tolerance that could 
translate to diminished GVHD. [ 16] Thus, because thymus recovery could take years in young 
adults, is likely influenced by infections and GVHD, while transitional B cell reconstitution is faster, less modulated by other post-transplant factors, B cells will be used for the primary 
endpoint of lymphocyte engraftment in this study.   Thymus recovery and restoration of T cell 
diversity will be included as important sec ondary endpoints though this will likely only be 
evaluable in the small subset of patients without relapse, GVHD, who survive greater than 2 years after HSCT. 
At this time, there are not data to determine the best source of HSCs between marrow and 
peripheral blood stem cells.  Marrow is chosen as th e stem cell source for this protocol due to: 1) 
this is the standard stem cell source in pediatrics, 2) there are evidence that marrow products lead to  less GVHD without compromising graft-versus-leukemia effects [ 17,18], and 3) all of the 
basic science work that models the lupron and FL T effects were performed with marrow grafts.  
In many adult oncology institutions, marrow remains the preferred source as well (including University of Oklahoma). 
1.2.2 Androgen Withdrawal Enhances T and B LymphopoiesisAndrogen inhibitors are excellent candidates for augmenting B lymphopoiesis and thymopoiesis.  
Many groups have demonstrated increase thymic size, weight, and thymocyte number following 
androgen withdrawal. [ 19-22] Murine and clinical data show that androgen withdrawal can 
17
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
reverse age-related thymic atrophy and reconstitute normal, young thymocyte subsets with 
subsequent increased pe ripheral T cell numbers. [23] Similarly, B lymphopoiesis is also 
increased after androgen withdrawal. [ 24] Data suggest that these increases in B and T cell 
numbers following androgen suppression are due to increases in de novo production of B and T cells in the marrow and thymus respectively. [ 21,25] As shown in Figure 3below, following 
androgen withdrawal in male mice (light grey box), B cell total numbers are dramatically increased in the marrow as compared to control (black box) at 1, 3, and 4 weeks (see Figure 3below, B subsets defined as B220+).  
Figure 3
Similarly, the thymus of mice treated with lupron was increased in size and thymocytes were increased in number as compared to controls.  Notably, because lupron initially leads to androgen release, followed by suppression, the thymus first involutes then expands with subsequent increase in thymocyte production.  As s hown in Figure 4 below, thymus weight (left) 
and thymocyte number (right) are initially decreased at 1 week after lupron (grey), then similar at 2 weeks, then increased after 4 weeks as compared to controls (black). 
Figure 4
Additionally, recent data suggest that T and B cell reconstitution is accelerated after stem cell 
transplant in murine allogeneic  transplant models after androg en withdrawal without decreasing 
graft-versus-tumor effect or worsening GVHD. [ 19] Our murine data demonstrate that the 
mechanism underlying the accelerated thymus rec overy after androgen withdrawal involves: 1. 0.00E+005.00E+061.00E+071.50E+072.00E+072.50E+073.00E+073.50E+074.00E+074.50E+07
0.00E+002.00E+074.00E+076.00E+078.00E+071.00E+081.20E+081.40E+081.60E+08
Thymus Weight (ng) Thymocyte # 0.00E+005.00E+071.00E+081.50E+082.00E+082.50E+083.00E+08
Thymus Weight (ng) Thymocyte #0.00E+002.00E+074.00E+076.00E+078.00E+071.00E+081.20E+081.40E+081.60E+08
Thymus Weight (ng) Thymocyte #
18
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Increase in thymus epithelial cell (TEC) proliferation, 2. Incr eased production of CCL25 by 
these TEC, 3. Increased early thymic progenitor entry of marrow precursors by CCL25 
interactions, 4. Accelerated development of thym ocytes due to CCL25 signaling, and 5. Overall 
enhanced thymopoiesis with increased expor t of naÃ¯ve selected diverse T cells [ 25].  Similarly, B 
cell increases after androgen withdrawal have also  been attributed to marrow stromal influences, 
resulting in accelerated de novo B cell development (rather than expansion of peripheral clones). 
[21] Given this mechanism and these murine and clinical data, androgen withdrawal has the 
potential to enhance de novo lymphopoiesis in young adults following HSCT with possible benefits of: improved infection and tumor clearance and diminished GVHD.  Because of the timing of the androgen release and thymic involution and the possibility that these effects occur in marrow stroma as well, male randomized subjects will receive the lupron injection approximately 1-2 weeks prior to HSCT to minimize the potential additive damage of thymus involution and radiotherapy. 
1.2.3 Lupron for Androgen SuppressionLupron is an FDA-approved gonadotropin-releasing hormone (GnRH) analog that has been used 
clinically for androgen suppression in prostate cancer pa tients for males [ 23,26] and for menses 
suppression during HSCT for females [ 27].  In males with prostate cancer, there are data to 
suggest enhanced thymic function following this agent. [ 23] Notably, most of these subjects 
were older individuals in whom free testosterone is substantially lower than younger subjects (0.2 +/- 0.081 vs. 0.43 +/- 0.098). [ 28] Thus, while patients may have  diminished circulating 
testosterone following chemotherapy, the levels were not lower than those of older men, and the subjects are likely to still exhibit immunolog ic changes after androgen withdrawal. [ 29] Because 
Lupron is an analog of GnRH, it leads to an initial burst of sex steroid release followed by suppression.  A study of administration and effica cy of Lupron in females for the suppression of 
menses revealed that the greatest efficacy was achieved when Lupron was given greater than 2 weeks prior to thrombocytopenia.  Similarly, our murine data has demonstrated that optimal administration for Lupron with regards to marrow transplantation is approximately 1-2 weeks pre-transplant.  This is because the initial stimu lation of GnRH leads to thymus involution and 1-
2 weeks following this will be a period of relative stabilization for the thymus, and possibly marrow stroma.  Thus, thymic epithelial cells will be at basal proliferation and less harmed by radiation damage.  Taken together, Lupron (4 month preparation) will be administered at approved doses 1-2 weeks prior to the preparative regimen.  
1.2.4 Lupron Safety ProfileLupron has a very good safety profile with only 3 re ported adverse events (testicular atrophy) in 
greater than 20% of 94 patients studied in two c linical trials for prostate cancer (see section 10for 
details).  There are data that HSCT alone leads to  testicular atrophy in male patients, thus this 
particular AE is not likely to be unique in lupron-treated subjects after HSCT.1.2.5 Lupron PharmacologyLupron (leuprolide acetate) is a synthetic nonapeptid e analog of GnRH that binds more strongly 
than the endogenous hormone.  The 4 month prep aration is 30 mg is dispensed in a prefilled 
dual-chamber syringe containing sterile ly ophilized microspheres which, upon mixing with 
diluent become a suspension that can be given as an intramuscular injection.  Within several 
days, a marked increase in serum sex steroid (testosterone) occurs followed by equilibration to 
19
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
baseline levels at 1 week and suppression by 2-4 weeks that is maintained until week 12 (data 
obtained from the prescription brochure).   Althoug h no specific drug interaction studies have 
been performed, drug interactions are unlikely to occur because the drug is only 46% plasma 
protein bound and degraded by peptidase not utilizing P-450 cytochromes.  Furthermore, the drug has been used in HSCT for women for mens es suppression without noted drug interactions.  
The effects are reversible as normal gonadal function is restored within 1-3 months upon 
discontinuation.
1.2.6 FLT imaging modality
Nuclear medicine imaging has been invaluable to assess tumor disease burden and response to 
therapy.  PET/CT uses 
18F-fluorodeoxyglucose (FDG) to identify cells that rapidly uptake 
glucose including tumor cells.   This modality has revealed: tumor metastases, responses to tumor after treatment cycle, tumor recurrence, and has been useful to accurately predict true complete response, correlating PET negativity with longterm survival [ 30-33].  Despite these 
data demonstrating the ut ility of this test for evaluation in lymphomas and cancer, FDG-PET is 
limited by lack of specificity.  Because FDG-PE T relies upon glucose incorporation into cells, 
the signal will be present not only in tumor cells, but also normal tissues such as brain and heart that require active glucose uptake and in infla mmatory lesions (due to uptake by macrophages 
and granulation tissues).
Figure 5 (from the investigatorâ€™s brochure 1-03-05)
A novel agent, FLT is 3â€™-deoxy-318F-fluorothymidine, a radiolabel ed thymidine analogue that 
illustrates dividing hema topoietic cells.  FLT is derived from the drug azidovudine (AZT) that 
uses thymidine kinase 1 for uptake into cells, part of the salvage pathway for DNA synthesis.  This enzyme is tightly controlled in normal cells and increases durin g cell division, permitting 
increased FLT uptake in dividing cells.  Furtherm ore, malignant cells have lost their regulation 
and thus have higher thymidine kinase 1 available, leading to even greater uptake of FLT than 
normal cells that divide  at higher rates [ 34].  Thus, this imaging agent has the potential to 
distinguish rapidly dividing cells from static ce lls and both of these from malignant cells based 
on degree of uptake of FLT.  FLT has been used to successfully stage and evaluate 
chemotherapy response in non-hodgkins lymphoma [ 35-38], breast cancer [ 39-41], and sarcoma 
[42].  In many of these studies, high background activity was noted within the marrow 
compartment, indicative of FLT uptake by hematopoietic cells.  FLT was then used to evaluate acute myelogenous leukemia in a pilot study, revealing higher SUV in patients with disease 
compared to controls.[ 43,44] Similarly, patients with aplastic anemia or myelofibrosis 
associated with lack of hematopoiesis had decreased uptake in the marrow compartment [ 44].O
FNNH
HOO
Me
O
O
OHNNH
HOO
Me
O
Thymidine FLT
20
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
FLT has been used to document response following treatment of AML [43] and has been shown 
to be accurate and reproducible following chemotherapy in patients treated for testicular 
carcinoma [ 45].  It can further document changes in marrow following directed radiotherapy 
dosing, which may allow for more accurate assessment of respons e to therapy in marrow-borne 
malignancies [ 45]. These data suggest that FLT could be  used to assess hematopoiesis in the 
marrow compartment, potentiall y illustrating empty vs. normal hematopoiesis vs. leukemia 
recurrence with greater sensitivity than single site marrow aspirates yield.
Figure 6: Normal uptake in bone marrow[ 44] Figure 7: Increased uptake in patient with MDS[ 44]
Dr. Holter, our collaborator, has modeled FLT (3â€™-deoxy-3â€™ 18F-fluorothymidine) in rat bone 
marrow transplantation and shown that by day 4, engraftment kinetics c ould be predicted and 
this time point preceded peripheral blood and full histologic evidence of marrow recovery. [ 46]
As stated above, not only is immune reconstitution a major barriers to successful HSCT, but also 
our modalities for evaluating this are often invasi ve (bone marrow aspirate) or less informative 
(peripheral blood evaluation).  In cord blood tran splantation, this is a clinically significant 
problem as non-engraftment and late engraftment of the donor cells is common and there are 
currently no early predictive tests for whether a patient will engraft la te or require a second 
conditioning regimen and new donor products.  Furthermore, even in matched adult donor 
transplantation where graft failure rates are low, there are often periods post-transplant where the 
peripheral blood cellular counts d ecline and the differential in cludes graft loss, medication 
toxicities, infections, and relapse.  Thus, a noninvasive imaging moda lity that could model 
engraftment kinetics would be invaluable to clinicians, potentially predicting graft failure early and narrowing the differential in the setting of cytopenias. These data prompted this clinical 
evaluation of FLT to determine if FLT could be used in conjunction with PET imaging at 
scheduled time points during HSCT for evaluation of engraftment.  These data could: 1) predict 
the rate of marrow engraftment and the length of neutropenia, 2) demonstrate evidence of 
minimal residual disease at the time of transp lant (the uptake should be null following 
myeloablative transplant preparative regimen), 3)  predict thymus recovery.  In this current 

21
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
protocol, adults and children with aggressive leukemias and MDS will have both the greatest 
opportunity for: 1) evaluation of  residual disease that should be positive by FLT at the time of 
transplant, 2) a differential in uptake over time as the myeloablative negative scan increases in uptake corresponding with increasing hematopoies is, and 3) the greatest chance for thymus 
recovery in adults to evaluate by FLT. 
1.2.7
18F FLT Safety Profile
18F FLT is currently in use in clinical trials and ha s currently been shown to be safe at the doses 
proposed in this study.  Although 18F FLT enters cells via an enzyme in the salvage pathway, it is 
not significantly incorporated into DNA due to  the lack of a 3â€™-hydroxyl group, which is 
necessary for DNA propagation.  Thus, although the agent remains within cells long enough for 
imaging, it will not persist long term  nor should it be mutagenic.   At the doses used in this study, 
several studies have been publis hed and no adverse events reporte d in patients w ith leukemia and 
MDS [ 43,44].  The planned dose is 0.07 mCi/kg with maximum dose of 3 mCi (maximum of 6.1
ug).  At higher doses exceeding a 1000 fold increase in 18F FLT from our planned dose, 18F FLT
has been associated with grade 3 hematologic toxicity (6/10 at 0.125 mg/kg q12 hours which 
equals area under the curve of 417 ng-h/mL and 5/15 patients at 200 ng-h/ml), hepatic failure 
(2/10 at dose of 200ng-h/mL and 10mg/day).  At a dose 1000 fold higher than our planned dose, mild peripheral neuropathy occurred (2/10 at dose of 50 ng-h/mL) [ 47].  No AEs attributable to 
18F FLT administered at tracer levels have been reported in the published literature. While no 
related AEs are expected, patients will be monitored very closely with regards to hepatic, neurologic, and hematologic parameter s following radiotracer injection.
Patients on this study who receive 
18F FLT/CT will be exposed to a maximum whole body dose 
(ED) of 6.2 rem whole body dose (ED), 1.2 rem from each 18F FLT/CT scan and 0.73 from each 
FDG PET/CT. For comparison, the average person in the United States receives a radiation 
exposure of 0.3 rem per year from natural back ground sources, such as from the sun, outer space, 
and from radioactive materials that are found naturally in the earthâ€™s air and soil. The dose that apatient will receive from this research study is  about the same amount that individual would 
normally receive in 20.5 years from thes e natural sources. A routine clinical 
18F FDG PET/CT is 
approximately 1.4 rem; for the purposes of this study, we have reduced the injected dose. 
1.2.818F FLT Pharmacology
18F FLT has a half life of 108 minutes [ 48].  The administered dose will be 0.07 mCi/kg with a 
maximum dose of 3 mCi per scan.  The drug is ex creted in the liver and kidney.  Transport of 
FLT across cell membranes occurs by ac tive transport and passive diffusion [ 49].  The drug 
solution is stored at room temperature in a gray  butyl septum sealed, sterile, pyrogen-free glass 
vial and has an expiration time of  8 hours. The injectable dose of 18F FLT for most studies will 
EHÂ”P&LNJRIIOXRULQH -18, not to exceed 3 mCi with a specific activity greater than 200
Ci/mmol at the time of injection.  In the dose of FLT, only a small fraction of the 18FF L T  
molecules are radioactive.  The amount of inj ected drug is < 6.1 ug (<25 nmol per dose) of 18F
FLT. 18F FLT is administered to subjects by intr avenous injection of < 10mL over 30 seconds.
There is no evidence that nonradioactive and radioactive FLT molecules display different biochemical behavior.  
22
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
1.2.9 FLT Availability
The Investigator-sponsored IND will be held by Karen Kurdziel, MD. 18F FLT will be obtained 
from commercial sources, either from Cardinal Health, Beltsville, MD, or PETNET Solutions 
Inc., Philadelphia, PA according to the DMFs filed with the FDA respectively for both 
institutions . 
1.2.10 Trial Plan
This study addresses 2 issues in  transplantation: 1) the problem  of delayed lymphoid engraftment 
after allogeneic transplantation in adults, a nd 2) the issue of evaluating engraftment of 
hematopoietic elements afte r allogeneic transplanta tion.  Patients undergoing 1stBMT with 
aggressive leukemia  and MDS who are $JHÂ•\HDUVROGDQGRUÂ•\HDUVROGDQGSXEHUWDODQG
Â”\HDUV will be enrolled and evaluated for remission status.  If the patient is not in remission 
upon study entry, the patient will progress to a chem otherapy regimen with the goal of obtaining 
complete remission.  Once the patient meets crite ria for complete remissi on, female patients and 
half of the male patients (randomized) will receive Lupron prior to initiation of a standard 
preparative regimen with standard GVHD prophyl axis.  Immunologic assessment of transitional 
B cells and IgM levels will be used for the pr imary endpoint of the issue of delayed lymphoid 
engraftment. This randomization and Lupron arm of the trial will be open at University of Oklahoma as well as NCI.
A subset of these patients will undergo imaging analysis with 
18F FLT as part of their 
evaluations. 18F FLT enrolled patients will be imaged at day -1, day 5 or 9, day 28 and a later 
time point to be determined by c linical events such as evidence of thymus recovery or GVHD. In 
addition, all newly enrolled NCI patients will be image d at 1 year for evaluation of thymus 
reconstitution with the exception of those in the serial scanning subset that have been imaged at a 
â€˜later timeâ€™ as discussed above.  Ten FLT pa tients enrolled at Child renâ€™s National Medical 
Center will be imaged at day -1, day +9, and if pos sible, day +28.  Patients will not be imaged at 
University of Oklahoma.
The primary endpoint for this element of the prot ocol will be toxicity with a secondary endpoint 
of imaging analysis at day 5 and day 28 and correl ation or prediction of en graftment as compared 
to a null baseline scan at day -1. Important secondary endpoints will also include other elements 
of engraftment (neutrophils, T cells, and dendritic cells), relapse/remission status, presence and severity of acute and chronic GVHD, severe infe ctious complications, and whether the later 
18F
FLT nuclear imaging scan may assist in these clinical diagnoses. 
Patients with aggressive leukemia  and MDS who have relapsed af ter HSCT and are greater than 
or equal to 18 years and Â”55 will be enrolled and evaluated for remission status. Patients will 
undergo 2ndHSCT, after receiving Lupron and will all be evaluated with 18F FLT imaging to 
explore the relapse rates and ability of FLT to predict relapse after 2ndHSCT.  The primary 
endpoints are: To assess sa fety of Lupron after 2ndHSCT and evaluate whether 18F FLT can 
predict relapse.  Patients will undergo 18F FLT imaging on day -1, and FLT and FDG imaging on 
day 28 and day 60 to predict rela pse.  Patients may also be image d before and after therapy for 
relapse (to not exceed 5 scans total per patient ). Note patients enrolle d on this protocol who 
relapse may receive another HSCT  product on this protocol but w ill not be eligible to undergo 
FLT imaging again.
23
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT 
2.1 E LIGIBILITY CRITERIA
2.1.1 Inclusion Criteria: Transplant Recipient
2.1.1.1 At NIH : Age Â•15 years old and/or Â•9 years old and pubertal and Â”55 years for 
recipient. Pubertal is defined by: prior menses at any time (females), documentation of   
clinical Tanner stage greater than 2 at some  point pre-chemotherapy or at the current 
visit.  (At this point, sex steroids have been produced for a few years which have driven initial pubertal development).  Tanner 2 is defined as: breast buds for females with 
coarse pubic hair, and coarse pubic ha ir and testes > 2.5cm for males.
2.1.1.2 At Childrenâ€™s Nati onal Medical Center only: age > 4 years old and < 24.
2.1.1.3 At University of Oklahoma: Age > 17 years old and Â”55 years for recipient.
2.1.1.4 A diagnosis of a hematologic malignancy fo r which stem cell transpla nt is standard of 
care:
2.1.1.4.1 Acute Lymphocytic Leukemia 
xAdult: (>22 years) > CR2 OR CR1 with e a high risk feature:
oMatched sibling donor for recipient treated on adult leukemia regimen [50, 51]
ot(9:22) or bcr-abl+; t(4:11), t(1: 19), t(8:14), 11q23 (MLL rearrangements)
complex cytogenetics (5 or more chro mosomal abnormalities), hypodiploidy (<44 
chromosomes). Note that patients with ALL blast crisis who emerge from CML are also eligible.
oPrimary induction failure, defined as failure  to achieve CR with primary induction 
chemotherapy 
oHigh WBC (>30,000 for B-cell ALL and >100,000 for T-cell ALL) at diagnosis
oPersistence of minimal residual disease despite induction chemotherapy
xPediatric (< 22 years): > CR2 ORCR1 with a high risk feature:
oMatched sibling donor for recipient treated on adult leukemia regimen [50, 51]
oPrimary induction failure (M3 (>25% with  greater 200 cells counted) marrow at 
day 29), M2 (5-25% blasts with greater than 200 cells counted) bone marrow or MRD > 1% at day 29 who then fail at day 43 with either an M2 or M3 BM or MRD > 1% 
oPersistent leukemia  and t(9;22) (MRD >1% day 29 or MRD > 0.01% end-
consolidation)
o11q23 (MLL) rearrangements detected by cy togenetic or PCR at initial diagnosis 
who are slow early responders (M2/M3 at day 14 or MRD> 0.01% at day 29)
oExtreme hypodiploidy (< 44 chromosomes or DNA index of <0.81) detected by 
cytogenetic/ploidy analysis 
24
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2.1.1.4.2 Acute Myelogenous Leukemia
xAdult: (>22 years) > CR2 OR CR1 with one of the following high risk features:
oAdverse or intermediate-r isk cytogenetics including:
ÂƒNormal cytogenetics [ 52]
Âƒcomplex karytoype (>2 abnormalities) [ 53]
Âƒinv (3) or t(3;3); t(11;19)(q23;p13.1); + 13; -17/17p-; -18; -20; (t(6;9); 
t(6;11); -7, 7q-; -5, 5q-; trisom y 8; t(3;5); t(9:11)(p22q23) [ 52,53]
Âƒmonosomy karyotype (presence of an autosomal monosomy in conjuntion 
with at least one other autosomal monosomy or structural abnormality. [52]
ÂƒAny other karyotype EXCEPT t(8;21), t(9;11), inv( 16), or t(16;16), and 
M3 (17; 17) [ 53]unless ckit mutation present and then eligible. [ 52]
ÂƒAML emerging from CML (blast crisis) are eligible 
oPrimary induction failure, defined as failure  to achieve CR with primary induction 
chemotherapy
oSecondary AML, defined as AML related to  antecedent MDS, MPN, or cytotoxic 
chemotherapy 
oHyperleukocytosis (WBC > 100,000 at diagnosis) 
oMutations in the FMS-like tyrosine kina se 3 (FLT3) gene (FLT3-LM; FLT-ITDs) 
[54-56]
oBilineage or biphenotypic leukemias are high risk features and eligible. 
xPediatric (< 22 years): > CR2 ORCR1 with a high risk feature including:
oPrimary induction failure (> 5% bl asts in marrow after induction)
oPersistent leukemia (>15% after first course of chemotherapy)
oComplex karyoptype, monosomy 7, or -5/-5q, FLT3 ITD-AR (>0.4) EXCEPT if also 
inv(16)/t(16;16), t(8,21)
oNormal cytogenetics or  abnormal cytogenetics EXCEPT if also inv(16)/t(16;16), t(8,21) 
are eligible for SIBLING transplant only
oBilineage or biphenotypic leukemias are high risk features and eligible. 
2.1.1.4.3 Myelodysplastic Syndrome RAEB 1 or 2; cytogenetics showing complex karyotype (3 
or more abnormalities), monosom y 7/del(7q), or inv(3)/t(3q) /del(3q); or transfusion 
dependent. 
2.1.1.4.4 Chronic Myelomonocytic Leukemia
2.1.1.4.5 Chronic Myelogenous Leukemia who have fa iled 2G- tyrosine kinase inhibitors (TKI)
25
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2.1.1.4.6 Standard pediatric indi cations for myeloablative transplantation for patients 
undergoing HSCT at Childrenâ€™s National Medical Center per institutional guidelines
2.1.1.5 Disease status 
If patients are found to not be in remission at screening, then the patient may be returned to their 
primary hematologist/oncologist or may receive ch emotherapy as per standard of care for the 
malignant disease.  Patients for whom this would be their first allogeneic transplant must be in 
remission (< 5% malignant blasts in ma rrow and peripheral blood and no evidence of 
extramedullary disease) for transplant. Patient s enrolled on this protocol for their second 
transplant do not need to have atta ined remission prior to transplant.
2.1.1.6 Performance status: Karnofsky or Lans ky performance status > 60% AND life 
expectance of greater than 3 months.
2.1.1.7 Ability to give informed consent.  For recipients and donors < 18 years of age, their 
legal guardian must give informed consent. Pediatric patients will be included in an age appropriate discussion in accordan ce with institutional guidelines. 
2.1.1.8 Hepatic function: Patients mu st have evidence of adequa te liver function prior to 
enrollment defined by total bilirubin < 2.5 mg/dL (unless doc umented Gilbertâ€™s 
syndrome) AND transaminases < 5 x the upper limit of normal for age appropriate 
indices. 
2.1.1.9 Renal function: Patients must ha ve evidence of adequate re nal function to proceed with 
stem cell transplant, creatinine clearance > 60 ml/min/1.73 m2.G F R  m a y  a l s o  
demonstrate adequate renal function.
2.1.1.10 Left ventricular ejection fraction > 50% OR  shortening fraction of >27% demonstrated 
on 2D echocardiogram or MUGA.  
2.1.1.11 Pulmonary function of DLC0 adj/VA and FEV1 > 60% of normal indices for age and 
height unless the patient has a likely acute reversible etiology of decline and then 
DLCO adj/VA > 30% of normal. Pediatric patie nts unable to complete PFTs may be 
enrolled as per enrolling institution SOP for recipient guidelines. 
2.1.1.12 Patients with prior autologous stem cell transplants will be included.  Patients with prior 
allogeneic stem cell transp lants will be eligible for 2nd BMT if not previously 
transplanted with FLT on 11-c-0136.
2.1.1.13 Prior experimental systemic therapies must have been co mpleted greater than 2 weeks 
prior to study entry.
2.1.2 Exclusion Criteria: Transplant Recipient
2.1.2.1 History of psychiatric disorder which may compromise compliance with transplant 
protocol, or which does not allow fo r appropriate informed consent. 
2.1.2.2 Active infections not responding to therapy.   All efforts should be made to clear the 
infection prior to enrollment.  
26
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2.1.2.3 Clinically significant systemic illness w ith manifestations of significant organ 
dysfunction which in the judgment PI or AI would render the patient unlikely to tolerate 
the protocol therapy or complete the study.  
2.1.2.4 Presence of active malignancy from an or gan system other than hematopoietic.
2.1.2.5 HIV infection.
2.1.2.6 Chronic active hepatitis B infection.  Patients may be hepatitis B core antibody positive 
but must be surface antigen negative and without active evidence of disease. 
2.1.2.7 Pregnant or lactating females will be ex cluded from this trial due to unknown risks to 
the developing fetus.  Patients of child-bea ring potential must use an effective form of 
contraception while on study. 
2.1.2.8 Sexually active individuals capable of becoming pregnant who are unable or unwilling 
to use effective form(s) of contraception during time enrolled on study and for 1 year 
post-transplant (see section 4.4for details). 
2.1.2.9 History of prior Lupron intolerance.  Note : patients ARE eligible if prior or current 
lupron exposure. 
2.1.3 Inclusion Criteria: Matche d Related Transplant Donor
2.1.3.1 Age Â•2 and Â” 60 years old and able to give consent or assent.  For donors < 18 years old, 
the legal guardian must be able to provide  informed consent and an evaluation by a 
LSW or psychiatric personnel will be needed to determine willingness to participate. 
Pediatric patients will be included in an age appropriate discussion in accordance with institutional guidelines.
2.1.3.2 HLA-matched related donor, excluding iden tical twins. Donors must be matched at 
least 7 loci out of 8 at the allele or an tigen level excluding antigen DRB1 mismatch.
2.1.3.3 Donor selection will be in  accordance with NIH/CC De partment of Transfusion 
Medicine criteria and must be  able to medically endure stem cell collection or as per 
local institutional guidelines. 
2.1.3.4 Donors must be HIV negative, HTLV negative, HBsAg negative.
2.1.3.5 Donors must be physically able to and willing to tolerate ma rrow harvest collection 
preferably, or in the absence of this op tion, able and willing to donate via peripheral 
blood pheresis.
2.1.4 Exclusion Criteria: Matche d Related Transplant Donor
2.1.4.1 History of medical illness that in the estimation of the PI or DTM physician precludes 
donation of marrow. 
2.1.4.2 Anemia (Hb < 10 gm/dl) or thrombocytopenia (< 100,000/ ul). 2.1.4.3 Pregnant females (due  to risk to fetus). 
2.1.4.4 Current psychiatric diagnosis that woul d compromise compliance with transplant 
protocol or precludes appr opriate informed consent. 
27
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2.1.4.5 Presence of any blood transmissible infectious  disease that cannot be cleared prior to 
stem cell collection and poses an unacceptable risk for the recipient (excludes CMV). 
2.1.4.6 Active malignancy will exclude the donor.  Any malignancy less than five years post-
remission will exclude the donor. Non-hematolo gic malignancies greater than 5 years 
ago will not exclude the donor.  Any histor y of hematologic malignancy will be 
considered on a case by case basis.  
2.1.4.7 Any medical contraindication to anesthesia or marrow donation will exclude the donor. 
2.1.4.8 Donors receiving experimental th erapy or investigational agents.
2.1.4.9 Active autoimmune disease that in the opinion of the PI or AI would compromise the 
success of the transplant.
2.1.5 Inclusion Criteria- Matched Unrelated Donor2.1.5.1 Unrelated donor matched at HLA- A, B, C, and DR loci by high resolution typing (at 8/8 
or 7/8 antigen/allele match) are acceptable donors. 
2.1.5.2 The evaluation of donors shall be in accord ance with existing National Marrow Donor 
Program (NMDP) Standard Policies and Procedures at all institutions.
2.1.6 Inclusion Criteria-
18F FLT Candidate Transplant Recipient
2.1.6.1 Meets criteria Sections 2.1.1 and 2.1.2
2.1.6.2 Age > 18 years old at NCI, and age > 4 ye ars and < 24 years at Childrenâ€™s National 
Medical Center
2.1.6.3 Donor who is willing to undergo bone  marrow or stem cell harvest. 
2.1.7 Exclusion Criteria-18F FLT Candidate Transplant Recipient
2.1.7.1 History of prior fluorothymi dine allergy or intolerance.
2.2 SCREENING EVALUATION AND CRITERIA FOR HSCT
2.2.1 RecipientThe following clinical, laboratory, radiological assessments must be performed on the recipient 
within 45 days of initiating HSCT preparative regimen with the exception of Section 2.2.2.6
which may be performed within the preceding 3 months.  These may be performed at outside 
institutions.  
2.2.1.1 Evaluations
xComplete history and physical examination. 
xCT scan of head, sinus, chest, abdomen, and pelvis.  
xAn echocardiogram (2D or MUGA) an electrocardiogram.
xPulmonary function tests (PFTs) must be performed for eligibility and FEV1, FEV1/FEV 
ratio, DLC02 recorded for adult patients; Oxygenation > 94% on RA may be used for 
pediatric patients unable to undergo PFTs at Childrenâ€™s National Medical Center.
28
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
xLaboratory studies: 
oCBC with differential, ABO blood ty pe, PT/PTT, fibrinogen, thrombin time
oComprehensive chemistry
oLipid profile with triglycerides, TSH, free T4
oUrine pregnancy test for women of childbearing potential
o24 hour creatinine clearance or GFR
oBone marrow biopsy and aspiration with studies appropriate to staging of 
malignant disease, a LP or other bi opsy may be required depending upon the 
diagnosis (to include LP for all AML and ALL) 
oInfectious disease work-up at NCI only: antibody for Hepatitis A, B, C, HIV, 
T.Cruzi, HTLV-I/II, CMV, adenovirus, varicella, EBV, HSV, Toxoplasmosis, and syphilis. Work-up at other institutions may follow their policy.
xImmunology studies: Lymphocyte phenotype panel (T, B, NK), IgG, IgA, IgM for NCI 
patients only.
xRadiation Oncology Consult (within 28 days of initiating conditioning chemotherapy for 
HSCT at NCI). At Childrenâ€™s National Medical Center and University of Oklahoma, this 
is per institutional practice.
xNutritional assessment (initial consult) and dental consult and social work consultation must be performed within 3 months of initiating preparative regimen and typing for 
HLA-A, -B, -C, and DR with PCR test of DNA mini-satellite regions for future 
determination of chimerism or as per local institutional practice. Note that when possible, the HLA and chimerism assays re quire 2 separate tubes of blood at NCI.
2.2.1.2 Criteria to proceed to HSCT
xDisease status: Remission as defined by < 5% blasts in marrow and no evidence of 
extramedullary disease for patients undergoing their first allogeneic transplant.  Patients 
undergoing their second transplant do not ha ve to have obtained a complete remission.
xPerformance status: Karnofsky or Lans ky performance status > 60% AND life 
expectance of greater than 3 months. 
xHepatic function: Patients must  have evidence of adequa te liver function prior to 
enrollment defined by total bilirubin < 2.5 mg/dL AND transaminases < 5 x the upper 
limit of normal for age appropriate indices. 
xRenal function: Patients must have evidence of adequate renal function to proceed with 
stem cell transplant, creatinine clearance > 60 ml/min/1.73 m
2.
xLeft ventricular ejection fraction > 50% dem onstrated on 2D echocardiogram or MUGA.  
xPulmonary function of DLC0/Adj/VA and FEV1 > 60% of normal indices for height and 
weight for adults and >95% oxygen ation on RA for pediatric patients.
xPatients who have received prior chemotherapy  must have had resolution of significant 
toxicities to proceed to transplant. 
xNegative pregnancy test (females)
29
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
xNo evidence of an active infection (clinical  assessment and review of CT) that is not 
currently being treated or responding to therapy.
xEither a HLA-matched related or unrelated donor, excluding identical twins. Donors must 
be matched at least 5 loci out of 6 by antigen  matching or at least 8 of 10 using allele 
matching who met criteria for entry onto this protocol. 
2.2.2 Matched Re lated Donor 
(See Section 12.3)
The following clinical, laboratory, radiologic al assessments must be performed on the donor 
within 4 weeks of initiating HSCT preparative regimen with the exception of Section 2.2.2.6 at 
NCI.  Note, where these differ from institutional practice at University of Oklahoma or 
Childrenâ€™s National Medical Center, the SOPs at those institutions may be followed.
2.2.2.1 Complete history and physical examination. 
2.2.2.2 Laboratory studies: 
oCBC with differential, ABO blood type, PT/PTT
oComprehensive chemistry
oUrinalysis 
oUrine pregnancy test for women of childbearing potential
oScreening for Hemoglobinapathy at NC I only if CBC suggests anemia due to 
hemoglobinapathy
oInfectious disease work-up: antibody for Hepatitis A, B, C, HIV, T.Cruzi, HTLV-
I/II, CMV, adenovirus, EBV, HSV, vari cella, Toxoplasmosis, and syphilis (RPR)
at NIH or as per institutional practice at Childrenâ€™s National Medical Center or University of Oklahoma.
2.2.2.3 Immunology studies: Lymphocyte phenotype panel (TBNK) at NCI only.
2.2.2.4 Electrocardiogram2.2.2.5 Chest radiograph 2.2.2.6 Typing for HLA-A, -B, -C, and DR with  PCR test of DNA mini-satellite regions for 
future determination of chimerism (may  be done at anytime prior to HSCT).
2.2.2.7 Donor Health History Screen through Dow ling Apheresis Center for those undergoing 
peripheral blood stem cell collection at Dowling Apheresis Center at NCI, or as per 
institutional guidelines at: Univ of Oklahoma, or Childrenâ€™s National Medical Center.
2.2.2.8 DTM venous assessment and health history screen through Dowling Apheresis Center 
for those undergoing PBSC collection at NCI or as per institutional practice.
2.2.2.9 For donors undergoing bone marrow harvest, pre-anesthesia evaluation at NCI or as per 
local institutional practice.
30
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
2.3 R EGISTRATION PROCEDURES
2.3.1 Protocol Entry Date
Protocol â€œentry dateâ€ is considered to be the day that the informed consent form has been signed 
by the recipient.2.3.2 RegistrationAuthorized staff must register an eligible ca ndidate with NCI Central Registration Office (CRO) 
within 24 hours of signing consent.  A registration Eligibility Checklist from the web site 
(http://intranet.cancer.gov/ccr/welcome.htm ) must be completed and sent via encrypted email to: 
NCI Central Registration Office ncicentralregi stration-l@mail.nih.gov.  After confirmation of 
eligibility at Central Registration Office, CRO staff will call pharmacy to advise them of the acceptance of the patient on the protocol prior to  the release of any investigational agents.  
Verification of Registration will be forwarded electronically via e-mail to the research team. A recorder is available during non-working hours. 
2.3.2.1 Donors at NIH will be registered on this study prior to stem cell collection. Donors at 
Childrenâ€™s National Medical Ce nter and University of Okla homa need to be identified 
and eligible but may follow local institutional practice.
2.3.2.2 Unrelated donors from NMDP Centers will be consented on an approved NMDP 
consent prior to eligibility evaluation. NIH UI D numbers will be generated on unrelated 
donors while maintaining the anonymity requi red by the NMDP. The recipient may not 
sign consent before the matched unrelated donor has been identified and cleared by 
NMDP and the patient has been determined to be eligible At other institutions, this will be done as per institutional practice.
2.3.3 University of Oklahoma Donors and Recipients
2.3.3.1 These patients will sign consent after meetin g eligibility criteria at the University of 
Oklahoma (Site PI: Dr. Holter), may receive th erapy at the National Cancer Institute or 
the University of Oklahoma.
2.3.3.2 Registration will be a two pa rt process as patients are sc reened on this protocol. A 
protocol registration form will be supplied by the CCR study coordinator and updates 
will be provided as needed. Subject eligibility and demographic information is required for registration. To initially register a subject,  after the participant has signed consent, 
complete the top portion of the form and send to CCR study coordinator.   Once eligibility is confirmed, after completion of screening studies, complete the remainder of the form which is the eligibility checklist, indicating that the patient is being registered for treatment and send to CCR study coordinator. In addition, source documents supporting the eligibility criteria must be sent to the CCR study coordinator.  
The CCR study coordinator will notify you either by e-mail or fax that the protocol registration form has been received which will include the unique patient/subject ID 
number. Questions about eligibility should be directed to the CCR study coordinator or PI.  Questions related to registration should be directed to the CCR study coordinator. 
31
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Subjects that do not meet scr eening criteria should be removed from the study following 
the procedure in section 3.10.4.
2.3.4 Childrenâ€™s National Medical Center Donors and Recipients
2.3.4.1 Patients will sign consent after meeting eligibility crite ria at Childrenâ€™s National 
Medical Center (Site PI: Dr. Williams), and will receive th erapy at Childrenâ€™s National 
Medical Center.
2.3.4.2 Registration will be a two pa rt process as patients are sc reened on this protocol. A 
protocol registration form will be supplied by the CCR study coordinator and updates 
will be provided as needed. Subject eligibility and demographic information is required for registration. To initially register a subject,  after the participant has signed consent, 
complete the top portion of the form and send to CCR study coordinator. Once eligibility is confirmed, after completion of screening studies, complete the remainder of the form which is the eligibility checklist, indicating that the patient is being registered for treatment and send to CCR study coordinator. In addition, source documents supporting the eligibility criteria must be sent to the CCR study coordinator.  The CCR study coordinator will notify you either by e-mail or fax that the protocol registration form has been received which will include the unique patient/subject ID 
number. Questions about eligibility should be directed to the CCR study coordinator or PI.  Questions related to registration should be directed to the CCR study coordinator. 
Subjects that do not meet scr eening criteria should be removed from the study following 
the procedure in section 3.10.4.
2.4 R
ANDOMIZATION PROCEDURES
2.4.1 Female Recipients2.4.1.1 All female recipients will receive Lupron2.4.2 Male Recipients2.4.2.1 The CRO will provide the randomized treatme nt assignment to the PI based on random 
assignments determined by the study statistician for first BMT. For 2
ndBMT, all 
patients will receive Lupron.
32
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
3 STUDY IMPLEMENTATION
3.1 STUDY DESIGN
3.1.1 NCI and University of Oklahoma for 1stBMT
(Note: FLT/FDG PET scans will not be performed at the University of Oklahoma)
Some of these patients are anticipated to be eval uated using FLT (to include only patients needed 
for the immunological primary endpoint, not incr easing total patient numbers). 23 adult NCI 
patients in total will undergo FLT P ET/CT imaging on day -1, at day +5 or day +9, at 4 weeks, 
and at a future point to include evidence of GVHD relapse, or immune recovery. An estimated 
50 patients (including subset of the 23 patients undergoing serial scanning) will be imaged Recipient consents
Yes
>18 yrs and
Consent to FLT?
No
FLT/FDG/CT
Imaging
Day-1 FLT Day +5 or 9 FLTDay +28 
FLT/FDG/CT
>Day +28
FLT/FDG/CT
Preparative Regimen
1) Total Body Irradiation (TBI) 1200 cGy 
fractionate twice daily (lung block) Days  -8,-7, -6, -5  (adult), -9, -8, -7, -6 (ped)
2) Cyclophosphamide IV, Days  -4, -3 (adult) 
or -5, -4, -3, -2 (ped) *refer to 3.6.3.1.3
GVHD Prophylaxis 1) Methotrexate IV Days + 1, 3, 6, 11 2
) Tacrolimus Da y -1 (Goal levels ) 
Allogeneic HSC Transplantation
1) Marrow (Day 0); Matched Related or Unrelated Donor
2) Tacrolimus 0.02 m g/kg (IBW ) continuous IV infusion from Da y -1 until toleratin g oral  
Identify Donor:
Available within 4 weeks
Females
Lupron at -1-2 wk
Males
No Lu pron
33
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
approximately at 1 year for evaluation of thymus reconstitution. The total possible numbers will 
include no more than 118 patient s to achieve the 64 evalaubl e adults for the immunological 
primary endpoint. However, as of amendment K,  all NCI patients will undergo a single 1 year 
FLT for evaluation of thymus reconstitution.
For 2ndBMT, at NCI, all 16 patients will undergo FLT imaging at day -1, and FLT and FDG 
imaging on day 28, day 60 and at relapse and response to therapy (if this occurs). 3.1.2 Childrenâ€™s National Medical CenterTen pediatric patients at CNMC will undergo F LT PET/CT imaging on Day -1, day +9, and day 
+28 (if possible). Initial images will be correlated with engraftment and other secondary 
endpoints. At Childrenâ€™s National Medical Center, the patients w ill not receive Lupron outside 
of the context of clinical care, and will receive myeloablative HSCT as per standard of care with FLT imaging for engraftment as the only primary endpoint.    
3.2 D
RUG ADMINISTRATION
3.2.1 Lupron
Lupron will be administered to all female patients a nd half of the male patients (randomized for first 
BMT) and to all patients for 2ndBMT, once optimally between day -13 and day -20 pre-HSCT but 
definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients > 18
years and as a 3 month injection (adult preparation) for patients < 18 years.  S ubsequent injections may 
be given if clinically indicated to females.  There will be no dose modifications.  Females already on 
lupron therapy will receive the 4 month injection within 2 weeks prior to the next scheduled injectionand prior to HSCT preparative regimen.
3.2.2
18F-FLT
All NCI patients will undergo PET imaging in the NCI Molecular Imaging Clinic (B3). Pediatric 
patients will undergo PET imaging in the Childre nâ€™s National Medical Center clinical imaging 
department.  Patients at University of Oklahoma will not undergo PET imaging per protocol
A low dose transmission CT scan will be perform ed for the purpose of attenuation correction.  
18F FLT PET/CT will be performed per the described schedule to include 4 imaging sessions in 
the peri-transplant at NCI and a maximum of  3 at Childrenâ€™s Nati onal Medical Center.18F FLT 
PET/CT alone will be used to assess the marrow at a pre-HSCT baseline image and an image day +5 or +9 (to evaluate for early signs of engraftment).  At both institutions, for first BMT, day + 28 (+/- 5 days) image may be performed and at NIH only, a later time point (to be obtained when clinically indicated either with evidence of thymus recovery or GVHD), 
18F FLT and FDG 
imaging will be conducted with in 48 hours.  At NIH only, all newly accrued patients will 
undergo a 18F FLT scan at 1 year post-HSCT with FDG. These will be used to distinguish 
dividing cells (18F FLT+) from cells high in glucose consumption (FDG+).  A few patients in 
relapse who are consented to this protoc ol arm will undergo imaging analysis with 18F FLT 
PET/CT alone for calculation of â€˜positiveâ€™ control for leukemia relapse.  For 2ndBMT, patients 
will undergo 18F FLT imaging on day -1, day 28, and day 60 to predict relapse.  Patients may 
also be imaged before and after therapy for relapse (to not exceed 5 scans total per patient).  
34
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
The expected dose of [18F]FLT is 0.07 mCi/kg with a maximum of 3 mCi.  Due to potential 
unpredictable delays, the total ac tivity administered may be reduced at the discretion of the PI.
18F FLT will be provided by Cardinal Health or PETnet pharmacies.  IND will be held by Dr. 
Karen Kurdziel, Molecular Imaging Program, CCR, NCI.
18F FLT and FDG uptake greater than surrounding background (T:B>1.2) will be considered 
positive.  For hypermetabolic lesions, an estimated smoothed maximum SUV will be reported.  
Analysis of uptake will be performed using current practice guidelines within the Molecular ImagingProgram, Childrenâ€™s National Medical Center and University of Oklahoma (on de-
identified scans).
3.3 O
NSTUDY PROTOCOL EVALUATION PRE-TRANSPLANT WORK-UP 
See Sections 12.2 and 12.3
3.3.1 Within 4 weeks of Transplant Date 
xHistory and Physical Examination 
xLaboratory studies must include the following: 
oComplete blood counts with differential.
oComplete chemistry panel: sodium, potassium, chloride, CO2, blood urea 
nitrogen, creatinine, calcium, phosphorus, ma gnesium, ALT, AST, total and direct 
bilirubin.
oToxoplasma IGG, Varicella IGG, CMV IGG, HSV IGG.
oImmunologic screening: Immunoglobulin levels (IgG with subclasses, IgA), 
CD4/CD8 total numbers and ratio at NCI only.
oFlow cytometry of peripheral blood fo r T/B/NK and residual disease at NCI and 
Childrenâ€™s National Medical Center only
oChest and sinus CT 
oPulmonary Function Tests for adult patients and oxygen saturation on room air for 
pediatric patients.
oEchocardiogram or MUGA
oElectrocardiogram
oBM biopsy and aspirate with flow cyto metry, and cytogenetics if previously 
positive 
oLumbar puncture with flow cytome try for patients with ALL and AML
oTestosterone and Estr ogen levels, LH, FSH f or all adult patients.
3.3.2 FLT on Study Evaluations (For patients enrolled on 18F FLT arm, Section 12.4): 
35
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
xImaging Study time points, 1stBMT:
oDay -1: 18F FLT + low dose CT 
oDay +5 or +9: 18F FLT + low dose CT 
oDay +28, 29: 18F FLT + low dose CT, 18F FDG(not required at Childrenâ€™s 
National Medical Center) + CT
oDay + (GVHD vs. thymus recovery): 18F FLT + low dose CT, 18F FDG + CT at NCI only
xImaging Study time points 2
ndBMT:
oDay -1: 18F FLT + low dose CT 
oDay +28/29: 18F FLT + FDG (not required for Childrenâ€™s National Medical Center site) +
low dose CT
oDay +60/61:18F FLT + FDG (not required for Childrenâ€™s National Medical Center site) +
low dose CT
oDay + of relapse and initia l response to immunotherapy:18F FLT + FDG + low dose CT
at NCI only
xLaboratory studies for FLT within 24 hours prior: 
oCreatinine < 2, ALT and AST within 5 x ULN
oTK1 serum measurement 
x18F FLT imaging protocol: 
oAt NCI immediately following the IV infusion of 18F FLT, a dynamic PET emission will be performed for 45 minutes followed by a whole body static image.  An additional PET emission ima ging acquisition w ill be performed 120 
minutes (+/- 15 minutes) post infusion.  A corresponding low dose transmission 
CT will be acquired immediately before each emission scan. At Childrenâ€™s National Medical Center, the dynamic image will be omitted. 
3.4 B
IOLOGIC STUDIES
The total aliquot of phlebotomy will not exceed 3 mL/kg per draw and 7 ml/kg in a 4 week period for research studies.  Should the research  requests exceed these restrictions, research 
studies will be done in the order of Sections 12.5,12.6 and12.7.
3.4.1 Immune Reconstitution
Studies to elucidate difference in immune reconstitution between Lupron treated and untreated 
groups to include multiparameter flow cytometry an alysis of relevant cell populations (B and T) 
and serum analysis of relevant cytokines.  If  available, these will be compared with donor 
lymphocyte characteristics (whereby 5 million to tal donor nucleated cells of the donor product 
will be reserved for biologic studies and go to  the clinical core of ETIB (Bldg 10, Room 12C-
216, (301- 402-3627)). At Univ of Oklahoma, these may be stored within CETI lab or Holter lab 
respectively, or sent directly to the Pre-Clini cal Core at NCI. At Ch ildrenâ€™s National Medical 
36
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Center, these may be stored within CETI lab or Bollar lab respectively, or sent directly to the 
Pre-Clinical Core at NCI. 
3.4.2 Immunologic Studies
Impaired lymphocyte reconstitution is believed to contribute to the morbidity and mortality of 
allogeneic stem cell transplantation as eviden ced by poor clearance of infections, and allo-
immunity (GVHD).[ 57] In adult HSCT recipients, T and B cell functions can be compromised 
indefinitely due to lack of thymus function and poor B cell education.  This study will use 
immunologic studies to determine if Lupron may enhance thymus reconstitution and B cell 
development.  Exploratory studies will include immunologic evaluations of HSCT complications 
to include: relapse, GVHD, inf ections, and the influence of thymus reconstitution on these 
complications. For these studies, prospective collection of infections to include: HHV6, adenovirus, EBV, CMV.  
3.4.3 Objectives/Specific Aims3.4.3.1 Determine the effect of Lupron on engraftment  and the recovery of T and B cell subsets 
following allogeneic HSCT by enumeration of cellular subsets in patients with and 
without Lupron.  Should thymus recovery be evident in subsets, secondary analysis of 
thymus function using T cell receptor excision circle analysis on peripheral T cells and 
using spectratype techniques. 
3.4.3.2 Determine whether FLT uptake demonstrates  engraftment, leukemia relapse or residual 
disease, and/or GVHD, and/or thymus re covery. FLT images will be compared as 
follows: pre-transplant image will be used for assessment of MRD (to be correlated with disease recurrence and histology at day 28), post infusion image will be used to assess homing and cellular growth at day +5 or +9 image to correlate to time to engraftment, and correlate with marrow stab ility at histological assessment day +28, 
day +28 image to be quantitatively evaluated to correlate with blast % and marrow repopulation with histology, and the final image  to be performed at a time of new-onset 
GVHD, potential relapse, or thymus recovery .  Exploratory studies to include the 
biology of HSCT.
3.4.3.3 For arm 2, exploratory analyses will include : whether FLT uptake can predict relapse or 
response to immunotherapy and whether there is  an improvement in this small number 
of patients in relapse rates (from 80% as designated in historical controls).  Immune studies will be undertaken to explore whether there is alterations in lymphocyte subsets similar to patients who remain in remission on the primary arm of the protocol.  
3.4.4 Methodology 
The following studies will be performed on peripheral blood (if available) samples.  Blood 
samples (20 cc in red/green CPT heparin and 16 cc  in EDTA tubes, age adjusted for weight in
pediatric patients) will be drawn for evaluations.  Time points are listed in section 3.8.
Complete blood counts and TBNK will be collected on the same day.  Samples should be delivered to the lab of Dr. Fran Hakim in Building 10, Room 3E-3288 (301-402-3627) at NCI 
and may be processed and froze n and shipped in batch from Ch ildrenâ€™s National Medical Center
and University of Oklahoma.
37
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
3.4.4.1 Peripheral blood: quantity (20mL).  Flow cytometry will be performed on peripheral 
blood samples. Commercially available antibodies will be used to characterize T cell, B 
cell, dendritic cell and monocyt e recovery after HSCT.  Samples will be frozen and 
thawed in batches. 
3.4.4.1.1 Research blood sample aliquot size will be minimized for patients < 18 years of age 
and the total amount restricted to a max imum of 3 ml/kg per draw and 7 ml/kg per 6-
week period (maximum 450 ml). In the event that blood draws are limited due to 
patient size, research studies will be performed in order of priority as listed in Section12.7. Small volume apheresis collections will not be included in this calculation since 
such is performed isovolumetrically with minimal red cell loss.
3.4.4.2 Plasma (>20 mL).  Plasma (EDTA and hepari n) will be spun in refrigerated centrifuge 
and frozen immediately and subsequently utilized for cytokine studies using immunofluorescent technique.
3.4.4.3 Tissue, urine, and other fluid specimens ( optional):  Any pathology or biopsy specimen 
or fluid that is obtained for clinical indications from the recipient and has remaining (or 
extra specimen) following the clinically i ndicated test may be stored and used for 
immunological characterization.  This include s any biopsies of bones obtained because 
of new onset pain, uptake of nuclear imagi ng scanning concerning for relapse or 
infection from the recipient.   Patients w ill have the opportunity to opt outin writing to 
determine if extra fluids and tissu es may be used for these studies. 
3.5 C
OLLABORATIVE RESEARCH STUDIES
Under Amendment P, coded se rum samples and human periphe ral blood will be sent to 
the Children's National Medical Center to evalua te comparisons of T and B cells between 
patients who received lupron and those who did no t in terms of relapse, GVHD, and infections
Rationale: Dr. Williams is a recognized expert in multicolor flow cytometry for the analysis of human peripheral blood from post- allogeneic-transplant patients.
Specific Aims:  To determine the effect of Lupr on on engraftment and th e recovery of T and B 
cell subsets following allogeneic HSCT by enumer ation of cellular subset s in patients with and 
without Lupron.
Design/Procedures:
The samples will be sent to laboratories at the Children's National Medical Center to perform 
multicolor flow cytometry as per section 3.4.4.1 as well as cytokine studies as per section 3.4.4.2
after an MTA is executed between the NCI and the Children's National Medical Center. All excess samples will be destroyed at the conclusion of the planned studies. The serum and human peripheral blood samples will be sent to the following address:  
Kirsten Williams MD
Center for Cancer and Immunology Research
38
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Program for Cell Enhancement and Technologies for Immunotherapy
Children's National Medical Center
5th Flr, Suite 5220 
111 Michigan Ave NWWashington, DC 20010
Coded serum samples will be se nt to Dr. Williams from patients participating in the 11-C-0136
clinical protocol led by prima ry investigator, Dr. Christopher Kanakry at NCI. Cryopreserved 
heparinized serum from up to 25 patients will be transferre d through this collaboration. 
Laboratory results will be sent back to Dr.Kanakry for data compilation and analysis. Dr. 
Williams will not have access to patient identifiers or patient information.
Only the subjectâ€™s unique identifier will be used and information about the enrolling site will be 
removed.  Authorized investigators at NCI and Dr. Williams will maintain codes linking the laboratory specimens received to clinical information; however, Dr. Williams will not have access to any other patient identif iers or patient inform ation. Sample identifie rs are not derived 
from actual identifiers and Dr. Williamsâ€™s research team will not have access to the re-identification key.
3.6 D
ONOR COLLECTION
3.6.1 Matched Unrelated Donors Matched unrelated donors will be collected as per NMDP policies and procedures.  The 
concentration of CD34+ cells w ill be determined by flow cy tometry.  The product may be 
infused fresh or stored frozen prior to infusion.  Every attempt will be made to obtain a marrow 
product for first BMT.  Should PBSC be the only alternative, these patients will be analyzed 
separately and replaced. The target dose is > 350 million total nucleated cells per kilogram. Of 
this product, 5 million total donor nuc leated cells will be reserved fo r biologic studies and go to 
the clinical core of ETIB (Bldg 10, Room 12C-216, 301 402 3627) at NCI. Ce ll selection will not 
be performed on the HSC grafts. If samples are ob tained at Childrenâ€™s National Medical Center
and University of Oklahoma, these may be proces sed, frozen, and shipped in batch, or fresh to 
Dr. Hakim (above).  MUD policies at Univ of Oklahoma and Childrenâ€™s National Medical 
Center will be followed as per SOPs of institutional practice. Please refer to Section 3.4for 
research study details. For 2ndBMT, PBSC will be preferred over marrow.  
3.6.2 Matched Re lated Donors 
Matched related donors w ill undergo marrow harvest with general anesthesia.  Subjects will 
undergo anesthesia consultation, and meet criteria for eligibility/enrollment. CD34+ fraction will be determined.  Subjects will al so undergo the Donor Health Hist ory Screen to determine donor 
eligibility using standard DTM criteria in the Dowling Apheresis Clinic by skilled staff in the Blood Services Section for adult patients and age-appr opriate questioning when indicated for 
pediatric subjects at NCI, th e Oklahoma Blood institute, and will be evaluated and exam 
performed by a member of the Oklahoma Transpla nt team for both PBSC collection and marrow 
donation, and by BMT staff at Child renâ€™s National Medical Center as per institutional protocol.
Subjects will undergo follow-up history and physical examination within 1 week of donation, at 
39
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
NCI or as per local institutional guidelines. Donor  recipient weight discrepancy with smaller 
donors placing the recipient at risk for non-engraftment will necessitate PBSC collection.  
Calculations will be performed by weight; for obese patients, an average between ideal and 
actual body weight.  PBSC collection will be done  as per standard of care and local institutional 
practice; at NCI, with donors receiving 10 ug/kg of GCSF for 5 days, with first collection 
through large bore venous catheter on the 5thday and potential second collection on day 6 (for 
insufficient sample) with a 6thdose of GCSF. Should PBSC be the only alternative, these patients 
will be analyzed separately and may be replaced .The target dose is > 350 million total 
nucleated cells per kilogram; however > 100 million total nucleated cells per kilogram will be 
sufficient for marrow collections and between 3- 4 million CD34/kg for PBSC products.  Of this 
product, 5 million total donor nucleated  cells will be reserved for biologic studies and go to the 
clinical core of ETIB (Bldg 10, Room 12C-216, 301 402 3627) at NCI, and may be processed and stored and shipped frozen from outside institutions. Cell selection will not be performed on the HSC grafts.  Note that TTV testing sample will be drawn as per institutional practice (e.g. onthe day of marrow collection at NCI). Harvested cells will be processed in DTM at NCI, within the Stem Cell laboratory at Childrenâ€™s Nationa l Medical Center and in the Oklahoma Stem cell 
processing center at Univ. of Oklahoma.  For a ll frozen samples and all fresh samples with ABO 
mismatch, the product will be deplet ed of red cells until less than 0.5 cc/kg or 50 cc total remain 
(whichever is smallest) when possible.  For fresh  harvest products, plasma pheresis may also be 
required if indicated by ABO mismatch.  DTM at NCI, the Stem Cell laboratory at Childrenâ€™s 
National Medical Center, and the Oklahoma Stem Cell processing unit  at Univ. of OK will notify the Adjunct PI and/or NIH PI and /or site PI and research RN of any problems in regard to 
cell number or red cell volume prior to freezing product. Note: for 2
ndBMT, PBSC products 
will be preferred.  
3.7 P REPARATIVE REGIMEN FOR HSCTAND GVHDP ROPHYLAXIS
(Refer to Sections 12.5 and 12.6)
3.7.1 Central AccessAn appropriate form of central access will be obtained prior to HSCT procedure. Tunneled triple 
lumen catheter is preferred in thorax at NCI.  Other institutions will follow institutional 
standards.
3.7.2 Remission StatusPatients undergoing first HSCT must be in remi ssion prior to HSCT; this may include patients 
without evidence of disease in aplasia.   3.7.3 Conditioning Regimen 3.7.3.1 Adults (>22 years and on ETIB service at NCI, on adult BMT at Univ of Oklahoma): 
3.7.3.1.1 TBI will be delivered to a total midplane dose of 12Gy and median lung dose of 6Gy.  
Radiation will be frac tionated twice daily over 4 days (days -8, -7, -6, -5).  Opposed 
lateral fields with lung compensation will be treated to 1.5 Gy for each fraction to a 
total cumulative dose of 12Gy.  Mediastinal fields will be treated AP-PA concurrently with the opposed lateral fields at a dose of 75cGy twice daily to bring the mediastinal 
dose to 12Gy with a median lung dose of 6 Gy.  Fractions will be delivered with at 
40
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
least a 6 hour interfraction interval.  Gona dal shielding will not be used.  Head and 
neck compensation and other technical modifications may be made at the discretion of 
the treating radiation oncologist.  For patients with CNS positive disease at any timeafter diagnosis, CNS boost may be delivered unless contraindicated by PI or AI. 
The CNS boost will be delivered as a 6 Gy boost in once daily 2 Gy fractions.  The boost will be delivered prior to  TBI.  Patients with sites identified by nuclear imaging 
or other clinically accepted diagnostic te sts may receive a boost to these areas as 
clinically indicated at any time point pre- or post transplantation.
3.7.3.1.2 Cyclophosphamide:  cyclophosphamide 60 mg/kg IV, Days -4, -3 with forced diureses 
with IV hydration to maintain urine output at 2-3ml/kg/hr and mesna 60mg/kg/dose IV at continuous intravenous infusion equa l to the dose of cyclophosphamide. For 
patients with BMI > 35, the cyclophosphamid e and mesna dosing will be based on a 
modified weight half way between the ideal and actual body weights.
3.7.3.1.3 Modifications: For adult patients with MDS who are aplastic after induction therapy, 
a modified regimen may be used as the pr eparative regimen including: Fludarabine 30 
mg/m2 for 3 days (day -4, -3, -2) and TBI 200cGy day -1.
For patients who have already received TBI, or exceeded the radiation maximum tolerated dose to preclude TBI for first or  second BMT, preferred second choice is 
busulfan (with goal steady state of 800-1000)  with fludarabine or cyclophosphamide at 
myeloablative dosing or non-myeloablative dosing if recommended for 2
ndBMT.
3.7.3.2 Pediatric (<22 years and on POB service a t NCI or at Childrenâ€™s National Medical 
Center):
3.7.3.2.1 At NCI: TBI will be delivered to a total midplane dose of 12Gy and median lung dose 
of 6Gy. Radiation will be fractionated twice daily over 4 days (days -9, -8, -7, -6). Opposed lateral fields with lung compensa tion will be treated to 1.5 Gy for each 
fraction to a total cumulative dose of 12Gy.  Mediastinal fields will be treated AP-PA concurrently with the opposed lateral fields at  a dose of 75cGy twice daily to bring the 
mediastinal dose to 12Gy with a median lung dose of 6Gy.  Fractions will be delivered with at least a 6 hour interfraction interval.  Gonadal shielding w ill not be used.  Head
and neck compensation and other technica l modifications may be made at the 
discretion of the treating radi ation oncologist.  For patient s with CNS positive disease 
at any time after diagnosis without definitive prior cranial radiation, CNS boost may
be delivered unless contraindicated by PI or AI. Adjustments to the boost dose in 
pediatric patients may be made if contraindicated at the disc retion of the PI or AI.  The 
CNS boost will be delivered as a 6 Gy boost in once daily 2 Gy fractions.  The boost 
will be delivered prior to TBI.  Patients with sites identified by nuclear imaging may receive a boost to these areas as clinically  indicated at any time point pre- or post 
transplantation.
3.7.3.2.2 At NCI: Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2 with 
forced diureses with IV hydration to maintain urine output at 2-3ml/kg/hr and mesna 
41
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
as 24 hour continuous intravenous infusion equal to the dose of cyclophoshamide.  For 
patients with BMI > 35, the cyclophosphamid e and mesna dosing will be based on a 
modified weight half way between the ideal and actual body weights. 
3.6.3.2.3 For patients who have already received TBI, or exceeded the radiation maximum 
tolerated dose to preclude TBI for first or  second BMT, preferred second choice is 
busulfan (with goal steady state of 800-1000)  with fludarabine or cyclophosphamide at 
myeloablative dosing or non-myeloablative dosing if 2ndBMT.
3.6.3.2.4At Childrenâ€™s National Medical  Center, myeloablative tran splantation for FLT imaging 
may be according to current standard practice including the regimens of: TBI   
3.7.4 GVHD Prophylaxis 
GVHD prophylaxis at NCI and Univ of Oklahom a will include: methotrexate 10 mg/m2 IV on 
day +1, and 5 mg/m2 IV Days + 3, 6, 11 and tacrolimus  starting Day -1 at dose of 0.02 
mg/kg/day continuous infusion  (with target  level between 5 and 10 ng/ml though up to 15 
acceptable).  Note, methotrexate dose should be discussed with pharmacy and adjusted for renal or liver dysfunction.  Should either agent not be  tolerated (for exampl e, posterior reversible 
encephalopathy from tacrolimus) or other risks put patients at added risk, these may be substituted with standard alternatives (e.g. cyclosporine, sirolimus, cellcept). When the patient is tolerating orals, tacrolimus may be converted to oral administration.  Taper of tacrolimus may be 
initiated on day +100 if there is no evidence of GVHD.  Patients should be evaluated weekly 
after the initiation of tacrolimus taper and tacrolimus taper held or increased for evidence of GVHD (to include diarrhea, mouth sores, unexplained elevation of liver enzymes).  If taper is not 
able to be initiated at day +100, by day +180, a new evaluation should occur to attempt taper.  
Patients are at high risk of relapse and every a ttempt should be made in this protocol to permit 
graft-versus-leukemia effects. For patients after 2
ndBMT, taper may be initiated as early as day 
45 and the plan will be to taper as rapidly as possible. 
3.7.5 Growth Factors (GCSF)
GCSF will not be administered unless clinically indicated such as life threatening infection and 
neutropenia or significantly delayed engraftment (greater than day 18) during the initial 
transplant phase (less than day 30).  A PI or AI must be involved in this clinical decision.  While 
there are data that GCSF acceler ates neutrophil engraftment by several days without effects on 
GVHD and relapse in two randomize d, placebo controlled studies [ 58,59], there are also data 
from larger historical cohorts that suggest high er rates of GVHD and relapse without significant 
differences in neutrophil recovery times. [ 17,60] In addition, GCSF has the potential to induce 
leukemic expansion in AML patients [ 60] and to alter the imaging evaluation by FLT studies.  
Notably, GCSF is not standard practice for pedi atric patients receiving marrow grafts which are 
the primary source for pediatric transplantations  currently. Given the lack of clear benefit from 
these studies and the likelihood that patients will recover neutrophils prior to life-threatening 
infections with matched marrow products, GCSF will not be pa rt of the planned BMT support
but rather an option for the few patients who may benefit from its administration (due to delayed 
engraftment or infections ). GCSF may be used after engraf tment in the setting of secondary 
42
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
neutropenia (often associated with medi cations administered post-transplant (e.g. 
antimicrobials).  
3.8 T RANSPLANT PROCEDURE FOR 1STAND 2NDBMT
3.8.1 Day 0
On day 0, the patient will receive the donor product from the selected donor intravenously per 
DTM standard operating procedures or local institutional guidelines. 
.3.8.2 Transplant Outcome Determinations
xNeutrophil Recovery: Designated by the first of 3 consecutive days with an ANC 
above 500/mm
3.
xPlatelet Recovery: Designated by the first of 7 days where the platelet count remains 
above 20,000/mm3 without transfusion support.
xSustained Donor Engraftment: Neutrophil recovery associated with complete donor 
chimerism at day 100.  Any patient who dies before day 28 will not be evaluated for 
engraftment but will be evaluable by FLT.
xPrimary Graft Failure: Failure to achieve sustained donor engraftment
xSecondary Graft Failure: Documented sustained donor engraftment as defined above 
followed by:  1) severe neutropenia (ANC < 500/mm3) and bone marrow biopsy 
revealing a cellularity of less than 25% or 2) absence of donor cells in the marrow or blood as demonstrated by a chimerism assay without subsequent improvement occurring 
either spontaneously or after growth factor  treatment.  Improvement is defined as ANC 
> 500/mm
3consistently.  Severe neutropenia with marrow cellularity > 25% is not 
secondary graft failure.
xAplasia : Less than 5% marrow cellularity as measured on bone marrow biopsy. 
3.9 P OST-TRANSPLANT MONITORING (1STAND 2NDBMT)
(See Sections 12.5 and 12.6)
At NCI, patients will be admitted during the pr eparative regimen and throughout the peri-
transplant period until engraftment has occurred and the patient is deemed stable for discharge.  After discharge, the patient will be monito red as clinically indicated until day +100.  
3.9.1 Day 0 to day +100
xHistory and physical evaluation
xCMV, Adenovirus, EBV PCR
xCBC with differential 
xAcute, Hepatic and Mineral Pa nels, CK , Uric acid and LDH
xLipid panel ( days +28, +60, and +100(+/-10 days ))
xTacrolimus level as long as on tacrolimus
xMonitoring for aGVHD (documented day + 28, +60, +100) (see Section 12.10)
43
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
xMonitoring for HHV6 in peripheral blood (all patients) and CSF (for those with leukemia 
diagnosis) at day +28, +60, +100 +/- 10 days for patients at NCI only
xResearch blood (day +5, +7, +14, +21, +28, +60, +100)
o+/- Allowances for the drawing of research blood is +/-1 day for day +5 and +7, +/- 2
days for day +14, +/- 3 days for day +28, +/- 7 days for day +60, +/- 14 days for day 
+100, and +/- 30 days for later time points.
3.9.2 Specific evaluation time points (1stand 2ndBMT)
Patients will be followed as clinically indicated.  These eval uations should occur within 10 days 
of anticipated date for time points less than day 100 and within 1 month for time points after day 100.
xHistory and physical evaluation on day +180, +270, +365
xBone marrow aspirate with studies appropriate to staging of malignant disease, a LP or 
other biopsy may be required depending upon the diagnosis (to include LP for all AML 
and ALL) with chimerism on day +28, +60, +100, +365
xBone marrow biopsy on day +28, +60, +100, +365
xLymphocyte phenotyping (T,B,NK) on day +28, +60, +100, +180, +270, +365 ( to be 
performed at NCI including those from outside institutions)
xPulmonary function tests on day + 100, +180, +270, +365
xChimerism of peripheral blood on day +28, +100, +180, +270, +365 for all adult 
patients
xImmunoglobulins (IgG, IgM, IgA) on day +28, +100, +180, +270, +365
xAcute, Hepatic and Minera l Panels, CK , Uric acid and LDH and lipid on day +28, +100, 
+180, +270, +365
xcGVHD evaluations on day +100, +180, +270, +365 (see Sections 12.11, 12.12 and 
12.13)
xResearch blood on day +180, +270, +365, and when clinically significant events such as 
cGVHD, laboratory suspicion of relaps e, or thymus recovery occur. 
xChest CT +100, +365
3.9.3 Long term follow-up guidelines (1
stand 2ndBMT)
Ref: recommendations [ 61]
These guidelines are for all NIH patients.  All patients may obtain these studies within 1 month of desired date and these may be done in other institutions than NIH with documentation.  Please note that 
these should be performed yearly for 5 years after transp lantation either as part of this protocol or in 
another setting for abnormal resu lts. Pediatric follow-up for CNMC  patients will be done as per 
Childrenâ€™s National Medical Center guidelines.  
xDental evaluations day +180, +365
xFerritin and iron studies on day +180, +270, +365
44
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
xThyroid studies on day +180, +270, +365
xFSH, LH on day +180, +270, +365
xOphthalomological evaluation on day +180, +365
xDEXA scan on day +365
xEchocardiogram on day +365
xPulmonary Function Te styearly for 5 years
xGYN examination (female patients) day +365
xUrinalysis/protein screening day +180, +365
3.9.4 FLT on study evaluations 
(For patients enrolled on FLT arm at NCI or Childrenâ€™s National Medical Center)
xImaging Study time points 1stBMT:
oDay -1: 18F FLT + low dose CT 
oDay +5 or +9:18F FLT + low dose CT 
oDay +28/29: 18F FLT + FDG (not required for Childrenâ€™s National Medical Center site) +
low dose CT
oDay + (GVHD vs. thymus recovery):18F FLT + FDG + low dose CT at NCI only
xImaging Study time points 2ndBMT:
oDay -1: 18F FLT + low dose CT 
oDay +28/29: 18F FLT + FDG (not required for Childrenâ€™s National Medical Center site) +
low dose CT
oDay +60/61:18F FLT + FDG (not required for Childrenâ€™s National Medical Center site) +
low dose CT
oDay + of relapse and initia l response to immunotherapy:18F FLT + FDG + low dose CT
at NCI only
xLaboratory studies for FLT within 24 hours prior : 
oCreatinine < 2, ALT and AST within 5 x ULN
oTK1 serum measurement 
x18F FLT imaging protocol: 
oAt NCI, Immediately following the IV infusion of 18F FLT, a dynamic PET emission 
imaging will be performed for 60 minutes, immediately followed by a whole body static 
image.  An additional PET emission imaging acquisition will be performed 120 minutes 
(+/- 15 minutes) post infusion.  A corresponding transmission CT will be acquired immediately before each emission scan. Child renâ€™s National Medical  Center will omit the 
dynamic protocol.
3.10 C
RITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA
3.10.1 Criteria for Removal from Protocol Therapy 
x Completion of 1year protocol therapy
x Participant requests to be withdrawn from active therapy 
x The option to treat the patient after protocol therapy with alternative therapies.
x Investigator discretion
45
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Please note: The AEs as outlined in the treatment protocol will not be collected from that point 
forward .
3.10.2 Off-Study Criteria
x Failure to meet pre-transplant eligibility criteria as defined in section 3.3.1 and 3.7.2.
x Patients who do not have a suitable donor or patients for whom the collection product is 
deemed insufficient without oppor tunity for further collection of the donor (via PBSC). 
Patients may proceed on standard of care if this is deemed to be the best medical 
management by the PI or AI. 
x The donor or recipient refuses to continue therapy
x Patients for whom a suitable donor cannot be found
x Donor subjects who become decisionally impaired 
x Lost to follow-up
x PI decision to end this study
x Death 
x Completed post-transplant follow up period (5 years)
In all cases, the reason(s) for withdrawal will be documented.
In addition, a patient may at anytime be removed from protocol at the pr incipal investigatorâ€™s 
discretion, if the P.I. deems the subject to be at unacceptable risk to remain on study. Reasons for 
this action may include (but are not limited to disease progression with declining organ 
function/performance status before transplant ation; inadequate fa mily/caregiver support; 
noncompliance.
Note: Minors should remain on study until they re ach the age of 18 and have an opportunity to 
be consented for the future us e of their data and specimens. 
3.10.3 Off Protocol Therapy and Off Study Procedure at NCIAuthorized staff must notify Central Registrati on Office (CRO) when a subject is taken off-
protocol therapy and when a subject is taken off-study. A Participant Status Update Form from 
the web site ( http://camp.nci.nih.gov/ccr/welcome.htm ) main page must be completed and sent 
via encrypted email to: NCI Central Registration Office<ncicentralregistration-l@mail.nih.gov.3.10.4 Participating Site Off-Study Notification
The Participant Status Update Form will be s upplied by the CCR study coordinator. Send the 
completed form to the CCR study coordinator.
46
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
4 SUPPORTIVE CARE
4.1 INFECTION PROPHYLAXIS
For a full description of infection prophylaxis  for NCI patients please refer to the NIH BMT 
Consortium Supportive Care Guidelines at 
http://intranet.cc.nih.gov/bmt/clinicalcare/guidelines.shtml ) which are recommended.  Infection 
prophylaxis for pediatric patients at NCI s hould follow the NIH BMT Consortium Supportive 
Care Guidelines found at http://intranet.cc.nih.gov/bmt/clinicalcare/guidelines.shtml or as per 
local institutional practice .
Below is a table summarizing adult recommendati ons at NCI.  Please note that the numbers 
correspond to the order in which the agents shoul d be attempted (i.e. first choice for PJP is 
trimethoprim/sulfamethoxazole a nd the second choice is atovaquone). Whenever possible, these 
should be followed at University of Oklahoma.  Childrenâ€™s National Me dical Center pediatric 
patients should follow Childrenâ€™s National Medical Center guide lines (SOP). Also, please note 
that these should be followed for patients receiving chemotherapy on this protocol as well. 
Table 1
Organism Prophylaxis Recommendations Timing
Pneumocystis jiroveci pneumonia 1) Trimethoprim/sulfamethoxazole 
DS (or pediatric dose equivalent) once a day three times weekly
2) Atovaquone 1500 mg daily 3) Inhaled Pentamidine monthlyStart after immune reconstitution or by day 28. Stop > 6 months after immunosuppression withdrawal without evidence of GVHD and greater than 1 year after HSCT.
Fungus 1) Caspofungin 
2) Voriconazole or Posaconazole 
(Check levels and target dose to Vori > 2 for prophylaxis, >4 for treatment; posa > 1000)
3) Liposmal amphotericin BStart caspofungin with preparative regimen for mold prophylaxis and continued until neutrophil recovery and not on prednisone equivalent exceeding 0.8mg/kg/qod.  Plan to switch to or add azole for evidence of invasive mold.  Note: azoles will need to modify tacrolimus dosing.  History of presumed or proven invasive fungal infection necessitates continuous antifungal coverage throughout HSCT until off immunosuppression unless there is a significant complication of therapy.
47
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Organism Prophylaxis Recommendations Timing
Virus 1) Acyclovir 800 mg po BID or 
250mg/m2 IV q12. Positive HSVI/II serology, 
history of Herpes Simplex or varicella infection, or CMV infection.  Starting on day -4.
Bacteria 1) Ceftazidime 2 gm IV q 8 hrs 
2) Levofloxacin 500 mg PO or IV Start at neutropenia, discontinue after resolution of neutropenia.  Note: patients should remain on PCN (encapsulated organism prophylaxis) until off immunosuppression > 6 months and without ongoing or cGVHD.
This study will also monitor for viral infections  to include adenovirus, EBV, CMV, and HHV6.  
If the patient develops chronic GVHD, he/she w ill receive penicillin V for prophylaxis against 
bacterial infections.  He/she will undergo vaccination against S. pneumoniae and H. influenzae ,
beginning 12 months after transplantation as  per the NIH BMT Consortium Supportive Care 
Guidelines.
Administration of live vaccines will be avoided during the first 2 ye ars after transplantation or in 
patients with ongoing chronic GVHD or imm unosuppression. Immunizations with inactive 
vaccines will be administered starting 6 months  after withdrawal of immunosuppression or one 
year whichever comes first with the exception of influenza vaccine and prevnar.  Response to 
vaccines is an exploratory endpoint on this trial.  Vaccine response is one of the best markers of 
T and B cell function (requiring CD4+ T cells to convert B cells to IgG).  
4.1.1 Infectious Disease Surveillance:  Adenovirus PCR will be sent weekly during engraftment. For patients wh o have Toxoplasmosis 
titer positive (at any point prior to HSCT), toxoplasmosis will be monitored weekly during 
engraftment at NCI only. HHV6 will be monitore d in blood and CSF at day +28, +60, +100 +/-
10 days (for those undergoing CSF evaluation at these time points at NCI only).
4.2 M
ANAGEMENT OF ENGRAFTMENT SYNDROME
Engraftment syndrome is characterized by noninfec tious fever, rash, and vascular leak causing 
non-cardiogenic pulmonary edema, weight gain, and renal.  Diagnostic criteria and a treatment 
schema for engraftment syndro me are included in Section 12.9.
4.3 T REATMENT OF GRAFT-VERSUS-HOST DISEASE
In patients in whom GVHD is suspected, standard  clinical criteria and biopsy findings (when 
clinically indicated) will be used to esta blish the diagnosis. Acute GVHD will be assessed 
according to 1994 Consensus Conference on Acute GVHD Grading criteria [62].  Chronic GVHD will be assessed according to 2005 Chronic GVHD Consensus Project [ 62]. See Section 
12.12 for details concerning the asse ssment of acute and chronic GVHD.
48
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Patients with clinical Stage 1 or 2 (Grade I) GVHD of the skin without any other organ 
involvement will be treated with a topical corticosteroid cream.
In general, patients with tGrade II acute GVHD will be treated with high-dose, systemic 
corticosteroids.
Patients who fail to respond to corticosteroids within 3 days w ill be considered for second-line 
immunosuppressive therapy.   Given that the patients in this protocol are young adults with the 
potential for rapid response to immunosuppressive agents, every ef fort will be made for rapid 
taper of high dose steroids and rescue with other, less immunosuppressive agents. 
As standard treatment of steroid-refractory acute GVHD and of chronic GVHD is often unsuccessful, treatment of either can include standard systemic or local therapies. This can specifically include autologous serum eye dr ops when recommended by ophthalmology for 
ocular GVHD per NIH Consensus Guidelines.
4.4 M
ENSES SUPPRESSION AND CONTRACEPTION
For a full description of menses  suppression and contraception gui delines for NCI please refer to 
the NIH BMT Consortium Supportive Care Guidelines at: http://intranet.cc.nih.gov/bmt/clinicalcare/guidelines.shtml
Pre-menopausal women who have  not undergone hysterectomy will receive Lupron within 2 
weeks of preparative regimen. Adult women will receive the 4 month (30 mg) preparation and 
females < 18 years old will receive the 3 month (11.25 mg) preparation.  Subsequent therapy will 
continue until platelet recovery  after transplantation (> 50,000/ Î¼l without transfusion) and may 
include repeat Lupron dosing or Lo-Ovral (300 Î¼g norgestrol and 30 Î¼g ethinyl estradiol) 1 tablet 
daily without placebo tablets. If Lo-Ovral is st arted when the patient is bleeding and bleeding 
persists for more than 2-3 days, increase the dose to 1 tablet twice daily. If bleeding persists for 
more than an additional 2-3 days (total 5 to 6 days after starting hormones), consult the NIH 
Gynecology Consult Service.  However, Lo-O vral will be stopped as soon as possible and 
patients who receive it may be analyzed separately from the lupron-treated female cohort.Female transplant recipients will be advised to use an effective fo rm of contraception for at least 
1 year after transplantation, and to ha ve their male partners use condoms.  
Male transplant recipients will be advised to use contraception, preferably condoms, for 1 year 
after transplantation.
4.5 B
LOOD PRODUCT SUPPORT
Patientâ€™s blood counts will be mon itored daily during the transplant  hospitalization. Patients will 
receive packed red blood cells and platelets as needed to maintain Hb > 8.0 gm/dl at NCI and 
CNMC and Hb> 7.0 gm/dl at Univ. of OK as per institutional practice, and plts > 10,000/mm3
(or higher, if clinically indicated) unless the patient is not group 0 blood type and the donor 
is, then Hb> 9.4 until after day 15 at  NCI and per inst itutional practice . All blood products, 
with the exception of the stem cell product and Do nor Cell Infusion (DCI), will be irradiated and 
leukoreduced as per DTM protocol at NIH, and per the Blood Bank at Childrenâ€™s National 
Medical Center or the University of Oklahoma. The patient, who is seronegative for CMV and 
whose donor is seronegative, should receive CMV-negative blood products whenever possible.
49
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Notably, all future transplant recipients shoul d receive transfusion only of irradiated blood and 
cellular blood products. Transfusi on of irradiated blood and cellu lar blood products will continue 
to at least one year after transplantation. Patients receiving immunosuppr essive medication will 
continue to have all blood and cellular blood products irra diated until discontinuation of 
immunosuppressive treatment.
Patients sensitized to HLA or platelet specific  antigens should receive HLA matched apheresis 
platelet collections.4.6 N
UTRITIONAL SUPPORT
If mucositis or GVHD prevent adequate PO inta ke, nasogastric tube feeds or parenteral 
hyperalimentation will be ins tituted and discontinued with input from the Pharmacy and 
Nutrition Departments at NCI. Oral intake will resume when c linically appropriate under the 
supervision of the dietary service of the Clin ical Center. At Childrenâ€™ s National Medical Center
and University of Oklahoma, this should be done as per institutional practice.4.7 A
NTI-EMETIC USAGE
Anti-emetic usage will follow recommendations from the NIH CC Pharmacy or as per 
institutional practice.
4.8 INTRAVENOUS IMMUNE GLOBULIN (IVIG)
IVIG administration will follow Guidelines for Infection Management in pediatric standard 
practices due to the difficulties of avoidance of viral exposures in pediatric patients.  For an IgG values less than 400 mg/dl, 500 mg/kg IVIG will be administered intravenously as per 
institutional guidelines.  Administration of IVIG may also occur if clinically indicated (e.g. setting of severe viral infection and vascular leak). 
4.9 H
EPATIC FUNCTION SUPPORT
All patients will receive  ursodeoxycholic acid (Ursodiol ) for the prevention of hepatic 
complications after allogeneic stem cell transplantation.  Ursodiol will start by day -4 prior to the 
transplant and will continue un til day +100 post-transplant (or longer if clinically indicated).
Patients weighing less than 90 kg will receive 300mg orally twice daily (600mg total dose each 
day). Those patients weighing more than 90 kg will receive 300 mg orally each morning and 600 mg orally each evening (900 mg total dose each day). CNMC pediatric patients will be dosed as per Childrenâ€™s National Medical Center guidelines.
The primary hepatic complication after transpla ntation is sinusoidal obstructive syndrome (also 
known as veno-occlusive disease or VOD).  This  has been defined using Seattle criteria as: 
unexplained weight gain, hepatic  tenderness, and jaundice; these criteria have been refined by 
Baltimore to include: total bilirubin > 2, and 2 of the following: hepatomegaly, weight gain 5%, 
and ascites.  Because no drugs are approved to treat VOD, and access to defibrotide, the only 
drug that has demonstrated promise, is limited, every effort will be made to optimize management to minimize the severity of VOD.  Throughout the first 30 days of transplantation, 
management should include equal ins and outs without weight gain.  Salt loads should not occur 
in the absence of clear benefit to the patient (e.g . sepsis).  Close monitoring for this condition and 
immediate fluid restriction, use of oncotics and lasix (see Section 4.11), and salt removal from 
infusions should be instituted.  
50
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
4.10 C ENTRAL NERVOUS SYSTEM PROPHYLAXIS
Patients with history of CNS positiv e disease will receive CNS boost.  
4.11 F LUID MANAGEMENT DURING FIRST 30DAYS FOLLOWING TRANSPLANTATION
Patients should be well-hydrated prior to stem cell infusion (within 12 hours prior).  Following 
stem cell infusion, weights and abdominal girths should be followed closely.  Patients should be 
kept EVEN in fluid status with every attempt to minimize salt and fluid loading.  High salt and 
fluid loads have been implicated in the physiolo gy that leads to severe engraftment syndrome 
and VOD.  Lasix may be used to maintain th is.  In addition, an oncotic (e.g. blood, IVIG, 
platelets, albumin) may be used followed by lasix to preserve renal function while optimizing fluid management. 
4.12 A
NCILLARY SUPPORT
Other supportive care to include: physical therapy,  occupational therapy, psychosocial therapy as 
deemed clinically appropriate. 
4.13 SUPPORTIVE CARE FOR RELAPSE
Patients who experience relapse on this  protocol may receive therapy for relapse to include intrathecal or 
systemic chemotherapy, donor lymphoc yte infusions or other treatments.
4.14 A DDITIONAL CELL INFUSIONS FOR GRAFT FAILURE ,IMPENDING GRAFT FAILURE ,OR 
POOR GRAFT FUNCTION .
Patients who experience graft failure  (primary or secondary), impe nding graft failure (falling counts 
and/or donor chimerism afte r initial engraftment in the absence of relapse), or poor graft function 
posttransplant (hypoplastic bone marrow, complete  or near-complete donor chimerism, absence of 
relapse or cytopenias clinically thought to be caused  by medication or infection, severe cytopenias in at 
least two lines [Hb < 10 g/dL, platelet count < 30 x 109/L, neutrophil count < 1.0 x 109/L] lasting at least 
2 weeks beyond day +14 and with transfusion requirement) will be eligible to receive a CD34+-selected 
cell boost.  The same donor for the most recent BM T must be used.  The donor will have a GCSF-
mobilized peripheral blood stem cell product collected and CD34+-selected using the Miltenyi 
CliniMACSÂ® system prior to infusion into the patient.  A fresh product will be preferred although a 
cryopreserved product will be acceptable.
5 DATA COLLECTION AND EVALUATION 
5.1 D ATA COLLECTION
Data will be prospectively and en tered into an NCI, CCR C3D Database from each institution.  After 
obtaining Informed Consent, a file will be created in the database with standardized forms.  The 
database will ma intain complete records on each patient  including any pertinent supplementary 
information obtained from outside la boratories, outside hospitals, radiology reports, laboratory reports, 
or other patient records. Patient records will be summarized at key time points in protocol visit notes at:pre-transplant, day 28, 60, 100, 6 month, 9 month, 12 months, and yearly post-transplant. These 
protocol notes will serve as the primary source materi al from which data will be collected and research 
51
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
analyses will be performed.  These will be reviewed by the Adjunct PI or site PI and research 
nurse/coordinator for accuracy and include interpretation of the events prior to this note.  This is done to 
minimize the day to day confusion that may occur (e .g. patient has diarrhea, thought initially to be 
GVHD but later determined to be CMV).  The follo wing will be used for source data and wherever 
possible will use the interpretations from the protocol visit notes as detailed below:
xEligibility Checklist: To be completed at study entry and forwarded to the protocol research nurse. 
xPatient history and physical examinati ons while on study (protocol visit notes)
xPatient flow sheets (protocol visit notes)
xPatient pathology, radiology, chimerism da ta, laboratory evaluations. (interpreted in 
protocol visit notes)
xRelevant data will also be sent to the Center for International Bone Marrow Transplant 
Registry (CIBMTR). This will include outcome data and patient characteristics, but do 
not include adverse events.
xProtocol Deviations/Una nticipated problems (UPs): Any protocol deviations or UPs 
should be directly reported to the PI, PC, or AI. These will be submitted to each siteâ€™s respective IRB. Outside institutions are required to send all protocol deviations and UPsto the Adjunct PI to be submitted to NCI IRB.
xConfidentiality Protection: Prior to analysis, all identifiers will be  removed and a random 
number ascribed to protec t patient confidentiality. 
The PI will be responsible for overseeing entry of da ta into an in-house password protected electronic 
system and ensuring data accuracy, consistency an d timeliness. The principal investigator, associate 
investigators/research nurses and/or a contracted data manager will assist with the data management efforts. All data obtained during the conduct of the protoc ol will be kept in secure  network drives or in 
approved alternative sites that comply with NIH security standards. Primary and final analyzed data will have identifiers so that research data can be a ttributed to an individual human subject participant.
All adverse events, including clinically significant abnormal findings on laboratory evaluations, regardless of severity, will be followed until return to baseline or stabilization of event. Patients will be followed for adverse events for at least 30 days after removal from study treatment or until off-study, whichever comes first.
An abnormal laboratory value w ill be considered an AE if the laboratory abnormality is 
characterized by any of the following:
xResults in discontinuation from the study
xIs associated with clinical signs or symptoms 
xRequires treatment or any other therapeutic intervention
xIs associated with death or another seri ous adverse event, including hospitalization. 
xIs judged by the Investigator to be of significant clinical impact
52
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
xIf any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test drug and about the patientâ€™s outcome.
End of study procedures : Data will be stored according to HHS, FDA regulations, and NIH Intramural 
Records Retention Sche dule as applicable. 
Loss or destruction of data : Should we become aware that a major breach in our plan to protect subject 
confidentiality and trial data has occurred, the IRB will be notified.
5.1.1 Adverse event recording
xGrade 1 adverse events will not be recorded
xAll serious adverse events regardless of the attribution will be recorded
xIf adverse events are not serious and possibly, pr obably, or definitely attributable to either 
Lupron or FLT imaging then they will be recorded.
5.2 R
ESPONSE CRITERIA
5.2.1 Primary Endpoints5.2.1.1 To determine whether Lupron leads to accel erated B cell recovery after allogeneic 
hematopoietic stem ce ll transplantation.
5.2.1.2 To determine if FLT imaging can be used  safely to evaluate for engraftment of 
transplanted cells. 
5.2.1.3 B cell recovery will be assessed on day 180 for comparison between two groups: those 
who have received Lupron and those who have not.  
5.2.1.4 Patients will be evaluated for complete clinical response to  primary malignancy at day 
+28, day +100, and day +365; those with and without Lupron will be compared.  
Complete response will include M1 marrow and no evidence of disease by flow 
cytometry, cytogenetics or FI SH testing in all sites ev aluated (lumbar puncture, bone 
marrow).  Minimal residual disease will be used to denote < 5 % blasts in marrow but detection of disease by one of these measures.  
5.2.2 Secondary Endpoints 
5.2.2.1 Thymus studies with CT scan thymic index, flow cytometry measurements of naÃ¯ve T cells.
5.2.2.2 Assess feasibility and tolerability of Lupron in male HSCT recipients. Assess recovery of testicular and ovar ian function after HSCT.
5.2.2.3 Rates and details of acute and chronic GVHD in Lupron vs. no-Lupron HSCT recipients. 
5.2.2.4 Rates and details of infectious episodes in Lupron vs. no-Lupron HSCT recipients.
5.2.2.5 Recovery of other populations to include: neutrophils, red blood cells, platelets, and 
other cell subsets (e.g. monocytes) will be  assessed and compared between groups.
53
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
5.2.2.6 Transplant related mortality, incidence of  graft rejection, disease-free and overall 
survival will also be collected.
5.2.2.7 The FLT images will be used in exploratory fashion to determine if the day +5 or day 
+9 image can be used to predict engraftment  of donor cells by comparing the uptake of 
FLT at day -1 with day +5 or day +9 and day +28 (post-engraftment) and correlating 
this will leukocyte recovery for first BMT. Difference between patients who receive bone marrow or peripheral blood stem cell products will also be explored. For 2
nd
BMT, exploratory analyses will compare day -1 FLT image with relapse rates, and day 
+28 and +60 image abnormalities suggestive of relapse with relapse rates.
5.2.2.8 Evaluate thymic reconstitution by FLT (1stBMT).
5.2.2.9 Evaluate whether FLT vs. FDG could dis tinguish GVHD vs. infection and relapse vs. 
healthy donor engraftment (1stand 2ndBMT).
5.2.2.10 Evaluate the safety of FLT imaging  in the peritransplant period (1stand 2ndBMT).
5.3 T OXICITY CRITERIA
Adverse events on this study will be reported using the NIH mechanism of NCI Common Terminology Criteria for Adverse Events.  This study will utilize the CTCAE version 4.0 for toxicity and adverse event reporting.  A copy of the CTCAE version 4.0 can be downloaded from the CTEP home page (http://ctep.info.nih.gov ) under reporting guidelines.  All appropr iate treatment areas should have access 
to a copy of the CTCAE version 4.0.
An adverse event will be defined as any novel, concerning medical condition or worsening of a 
previously existing medical condition. Please refer to  section 8 for details on adverse event collection. 
6 STATISTICAL SECTION 6.1 S
UBJECT ACCRUAL
Non-pregnant female and male subject s from all racial and ethnic groups ar e eligible for this trial if they 
meet entry criteria.  Although every effort will be made to incorporate individuals representative of the 
national population with the eligible  malignant diseases, issues of limited accrual may not permit this 
study to explore the impact of race or gender.  Shou ld the analysis suggest that there is a difference 
observed across race or gender, accrual may be expa nded or additional studie s will be designed to 
address these questions. 
6.1.1 Statistics and FeasibilityThe primary objectives of this study are:
1) To determine if there is a difference in th e percentage of B cells which recover at 12 
months between males who are randomized to receive Lupron or not, and to estimate the 
fraction of females, a ll of whom will receive Lupron, who have B cells which recover at 
12 months.
2) To evaluate engraftment kinetics to estimate the relationship between level of uptake of 
FLT at a day +5 scan and the day at whic h neutrophils recover to >500, statistical 
analyses were performed for this secondary endpoint. 
6.1.1.1 Statistics on FLT
54
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
This subset of the total male  and female patients receiving marrow transplants will undergo pre-
transplant conditioning and FLT imaging agent.  The patients will have their level of FLT uptake 
evaluated at a day +5 scan, and will be followe d until they recover their neutrophils to >500. A 
Spearman correlation coefficient will be used to estimate the degree of association between these two parameters. With 13 evaluabl e patients, who have both a day +5 scan level of uptake and a 
known number of days to recovery of neutrophils, a correlation co efficient will be estimated in a 
pilot fashion; a 0.10 one-sided Fisherâ€™s test of wh ether the correlation coefficient has a value of 
0.85 rather than a null value of 0.50 can be performed with 80% power  if 13 patients are 
included in the evaluation.  Fifteen patients will be studied in this cohort to obtain 13 fully 
evaluable images given that 2 may have early ev ents that preclude day 28 evaluation.  Patients 
enrolled on this arm of the protocol who do not complete a day 28 evaluation may be substituted to achieve 13 evaluable patients unless the patients are not evaluable due to toxicities attributed 
to FLT.  Interim safety analysis of AEs attributed to FLT imaging will be performed on the first 7 patients.  Should greater than 1 of these 7 pa tients not engraft and re quire a back-up product, 
the FLT arm of this protocol will be halted. Notably, patients who experience early relapse may be analyzed separately for some statistical ev aluations as leukemia cells upregulate TK1 and may 
alter images obtained around the time  of relapse.  An additiona l eight evaluable patients will 
permit us to evaluate the day +9 scan rather than a day +5 scan and correlate this with engraftment and explore differences between pe ripheral blood stem cell source and bone marrow 
stem cell source.  These demonstrate different ki netics of marrow recovery (with engraftment of 
neutrophils typically 14 days earlier with periphe ral blood stem cells).  Finally, not only will 
these kinetics help us to understand the biology of  stem cell transplantation, they will also serve 
as a critical piece of information fo r a future study with cord blood as the stem cell source (which 
has even greater delay in neutrophil recovery, typically engrafting 2 weeks later than a marrow product).  
Because the interim analysis confirmed safety in adults, up to 10 pediatric patients will now be 
enrolled at Childrenâ€™s National Medical Center.  These patients will be imaged on day -1, day +9, and if possible, day +28.  Analyses will mirro r the adult statistics and also permit exploratory 
comparisons between pediatric a nd adult patients.  The same sa fety stopping rules will apply: 
should greater than 1 of these 7 patients not engr aft and require a back-up  product, the FLT arm 
of this protocol will be halted.  
In addition, because there is a suggestion that FL T may predict relapse (showing relapse in 4/4 
imaged patients to date, and prediting relapse in Â¾), FLT will be incorporated into the evaluation 
of all patients in arm 2 (who are undergoing 2
ndHSCT for relapse after 1stHSCT).  This will be 
exploratory analyses to use FLT to try to predict response of therapy (in the day -1 image) and relapse in subsequent images in this population at high risk for relapse (80% historically).  For 
patients who do relapse after this 2
ndHSCT, a scan may be performed pre- and after therapies to 
treat this relapse to explore the effect of immunotherapy on FLT uptake.
6.1.1.2 Statistics on Lupron
For 1stBMT the larger cohort of patients (of whic h some of these patients may undergo FLT 
imaging as well) will be eligible  male subjects who will be rando mized in a 1:1 ratio to receive 
55
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Lupron vs. no Lupron prior to receiving their pre- transplant preparative regimen.  The objective 
will be to determine if there is a difference in the percentage of these subjects who recover their 
B cells by 12 months according to whether th ey receive Lupron or not. With 17 evaluable 
patients per arm (34 total evaluable patients), there is 80% power  to detect a difference equal to 
one standard deviation (one SD effect size) between the two arms using a 0.05 two-sided two-
sample t-test (that is, that the difference in the means of the two groups differs by one SD, 
assumed to be the same in both groups).  In pr actice, if the data from the two groups are not 
normally distributed (p<0.05 by a Shapiro-Wilks te st in either group), then a Wilcoxon rank sum 
test will be used.  Since only patients who have not relapsed by 12 months would be eligible for this definitive evaluation, up to 68 patients may ne ed to be enrolled in order to obtain this 
definitive evaluation. 
For 1
stBMT, a second cohort of patients (which ma y include FLT exposed patients) will be 
eligible female subjects who will each receive Lu pron prior to receiving their pre-transplant 
preparative regimen. The objective in this cohort will be to estimate the fraction of patients who 
recover their B cells by 12 months. If there are 30 eligible female patient s who have this value 
determined at 12 months, then a two-sided 95%  confidence interval could have width of 
approximately +/- 4 if the standa rd deviation was equal to 10.  Si nce the female patients may also 
relapse prior to 12 months and not provide a definitive value for evaluation, up to 50 females will 
be enrolled into this cohort to try to ensure that at least 30 are evaluable.
For 1stBMT, for the female and male cohorts, all enrolled pa tients will be evalua ted at the latest 
time point possible for a variety of immune reconstitution parameters.  Thus, even if they are 
unable to ultimately contribute information to the definitive evaluation at 12 months, the values that are obtained at any time point will be used to estimate the recovery at various time points prior to 12 months.
In order to complete accrual to these cohorts, up to 68+50=118 patients ma y need to be enrolled. 
If 2-3 patients per month are able to be accrue d onto this trial, accrual should be completed 
within 3 to 5 years.  Patients who do not underg o allogeneic transplantation may be substituted. 
Toxicity of FLT and Lupron in this population wi ll be evaluated in all exposed patients.  
For 1
stBMT, exploratory analyses will evaluate othe r leukocyte subsets of immune reconstitution with 
and without Lupron (including tran sitional B cells, dendritic  cells, recent thymus emigrants, naÃ¯ve and 
memory T cells), disease control by treatments pr e- and peri-transplant, whether FLT can identify 
relapse disease, or GVHD.  The effect of cell dose and age on lymphoid engraftment will also be 
explored.  In addition, evidence of  functional immune recovery as pe r vaccine response will also be 
explored.  For patients to receive  benefit from vaccines after myel oablative HSCT, the immune system 
must mount a durable response.  If the patient receive s a vaccine without evidence of a rise in antibody 
titers, it is possible or even likely that the patient does  not receive benefit from this vaccine.  In pediatric 
HSCT recipients in many institutions, it is standard practice to test for a vaccine response and repeat 
vaccinations when one is achieved to maximize the pot ential for long-lasting immunity to this pathogen.  
In adult HSCT recipients, this is not standard of  care because both there is less likelihood that older 
adults can achieve this after myeloablative transpla ntation and high likelihood th at residual plasma cells 
(of host origin) will respond after non-myeloablative tr ansplantation which may not be meaningful for 
long-lasting immunity.  Because the immune modulati on of lupron may improve the immune system of 
these young adults similar to those often achieved in pediatric patients, the optimal approach for long 
56
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
lasting immunity is to attempt to determine a functional benefit to the vaccines, to give the vaccine to 
the patient when they can respond and develop dur able benefit (prophylaxis from infections). 
Interim analyses will be conducte d on FLT treated patients after 7 patients have completed day 28 
imaging and on the lupron treated vs. untreated male subjects after 15 have been enrolled to each arm to evaluate for safety (lupron and FLT) and efficacy (lupron). 
Using the CIBMTR (international registry data), the expected survival is < 30% for acute myelogenous 
leukemia and 30% for acute lymphoid leukemia at 2 years.   Because 10% of these patients die of non-
relapse causes, this means that the expected relapse rate is 60% for similar patients, suggesting that our 
relapse rate of less than half this is considerably better.  The relapse rate for patients after 2
ndBMT is 
even higher, so these patients will need to be analyzed separately from patients who have only undergone 1 BMT.  These patients will be added via amendment L, which will have the following 
characteristics: males and females who have previously failed a transplant will be enrolled onto the trial and receive Lupron. The patients w ill be followed for progression and for survival. With 16 patients, 
there would be 82% power to detect an improveme nt from 60% who relapse by one year to 30% who 
relapse by one year (using data for 2
ndBMT where the relapse rates exceed 60%), using an exact 
binomial test with a 0.10 one-sided significance leve l. In practice, the fraction of the 16 evaluable 
patients who survive without relapse to one year will be es timated; this fraction will be reported along 
with appropriate confidence intervals, such as a one- sided 90% interval to show if the fraction is below 
60%, as well as a two-sided 95% confidence interval to help describe the obse rved fraction of patients 
who are relapse free at one year. In addition, a Kapl an-Meier curve of relapse free survival will be 
constructed to estimate the relapse free probabilities at various time points. 
To ensure that patients are not continued to enroll onto this arm in the event that results are not adequate, 
the following early stopping rule will apply: if among the first 8 patients enrolled, 0 of 8 are able to 
survive to one year, then no further patients will be  enrolled onto this trial as soon as this can be 
determined, as this will indicate worse than expected results: the upper one sided 90% Confidence interval on 0/8 is 0.25, which would indicate that this result would not be cons istent with tolerable 
results.
7 HUMAN SUBJECTS PROTECTIONS 
7.1 R
ATIONALE FOR SUBJECT SELECTION
All patients with eligible malignant diseases who may benefit from allogeneic stem cell 
transplantation are eligible for this trial. All ethnic groups and both sexes may be enrolled.  Ethnic 
enrollment may vary as ethnic groups afflicted by these diseases may vary.  Pregnant females will 
be excluded from this trial.  It is unlikely that our patient numbers will permit statistics of individual ethnic or age groups, however this will be attempted s hould numbers permit. 
7.2 P
ARTICIPATION OF CHILDREN
In addition, this trial is open to pediatric as we ll as adult patients; howev er, at Univ of Oklahoma
only adult patients will be enrolled and at Childrenâ€™s National Medical Center only pediatric 
patients will be enrolled.  Patients > 15 years old and/or > 9 years and after Tanner stage 2 are 
57
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
eligible at NCI, because these; patients who are pre-pubertal are unlikely to receive benefit (and 
may be harmed) by exposure to Lupron. At Child renâ€™s National Medical Ce nter pediatric patients 
> 4 years of age will be eligib le. Donors less than 2 years of age will not be included on this 
protocol.  Physicians, nurses, and multidisciplinary support teams of the POB, NCI, and CC at 
NIH, and Oklahoma Transplant Team, Childrenâ€™s Hospital, Stephenson Ca ncer Center, and HCA 
at Univ of Oklahoma, and the BMT team, Blood Bank at Childrenâ€™s Natio nal Medical Center will 
provide patient care.  The staff of the POB has expertise in the management of children with complex oncologic disorders a nd complications of therapy.  Full pediatric support and 
subspecialty services are available at the NIH CC.  Note: arm 2 is for adults only at NIH.
7.3 P
ARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT
.Re-consent may be necessary and there is a possibility, though unlikely, that subjects could 
become decisionally impaired. For this reason and be cause there is a prospect of direct benefit
from research participation (section 7.4), all recipients VXEMHFWVÂ•DJHZLOOEHRIIHUHGWKH
opportunity to fill in their wishes for research an d care, and assign a substitute decision maker on 
the â€œNIH Advance Directive for Health Care and Medical Research Participationâ€ form so that another person can make decisions about their medical care in the event that they become incapacitated or cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment T eam for evaluation.  For those subjects that 
become incapacitated and do not have pre-determined substitute decision maker, the proceduresdescribed in MAS Policy 87-4 for appointing a su rrogate decision maker for adult subjects who
are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of 
attorney, will be followed.
Donor subjects who become incapacitated or cognitiv ely impaired during the course of the study
will come off study since there are no direct benefit to the donor subjects.
7.4 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS
7.4.1 Recipient
Patients are likely to obtain direct benefit from the HSCT as the eligible diseases for this protocol 
are aggressive and likely to lead to death w ithout HSCT.  The transplantation preparative 
regimen and GVHD prophylaxis are standard of care for patients of these ages with these 
diseases.  These regimens carry an acceptable risk of direct toxicities including: organ toxicity (lung, heart, kidney, endocrinological, ne urological, and liver), immunosuppression with 
increased risk of infections, potential for graft versus host disease.  The patients will be monitored for toxicities using the current best practice guidelines and will receive prophylaxis for those complications that we can prevent (e.g. infectious, mesna for cyclophosphamide to minimize kidney toxicity).   See section 10for details.  The greatest risk to mortality remains 
relapse in this population.  Thus, a myeloablative regimen has been chosen that confers the greatest potential for disease control.  Lupron may not impact on disease control, or it may 
improve disease control by decreasing androgen levels (leukemias often have androgen receptor 
and may respond to this substrate) and th rough enhanced post-transplant lymphocyte 
reconstitution (with potential to improve GVL).  
7.4.1.1 FLT risks to exposed recipient
58
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
The greatest risks of clinical FLT scans to pa tients enrolled on imaging studies to date have 
included bruising at the injection site; no significant adverse events were reported in the 
literature.  Please see section 1.2.7 for details and toxicities at much higher doses of FLT than 
patients on this protocol will recei ve, none of which are expected.  The one theoretical risk to 
patients undergoing HSCT is that the newly dividi ng hematopoietic stem cells could be affected 
by FLT delaying engraftment or contributing to failu re to engraft.  However, the actual radiation 
dose to which the bone marrow is exposed is equivalent to the dose received in an abdominal CT with contrast, a test routinely performed for clinical indications w ithout adverse effects on 
engraftment.  Stopping rules ar e in place for nonengraftment. 
7.4.2 Risks in relation to benefit for Donor
Healthy HLA-matched donors will be co-enrolled onto this study. The collection aspect of this 
protocol is not investigationa l. There is potential benefit for donors, as they may derive 
psychological benefit from participating in a clinical trial designed to improve the health of the recipient of the prior transplant donation. Other potential benefits include the diagnosis of 
previously unknown illnesses (such as viral hepatitis) at the time of donor screening. 
7.4.3 Pediatric Patients
Pediatric patients are eligible to participate in this trial if they meet criteria including a disease 
for which BMT is the recommended therapy. The diseases addressed in this protocol are the 
current diseases recommended for transplantatio n by the national cooperative groups (Childrenâ€™s 
Oncology Group). The preparative regimen is one of the standard recommended regimens. Pediatric patients at Childrenâ€™s Nati onal Medical Center are now eligible for FLT,
because this testing did not increase the risk to recipients in the adult study (14 adult patients have undergone FLT without attr ibutable toxicities at NCI). F emale patients who have begun 
puberty will receive the standard of care for me nses prophylaxis, lupron at the dose of 11.25 mg 
for patients < 18 years. Thus, the only additive risk to pediatric patients beyond standard of care is the exposure of male patients to lupron. Given that female child ren have tolerated this agent 
well, the risks of lupron in male subjects are expected to be mild and reversible (the drug will clear in 3 months and not redosed in this study in male subjects). The potential benefits include: 
1) improved immune reconstitution, 2) potential anti-tumor effects,  and 3) possible benefit for 
preservation of fertility. 
7.5 C
ONSENT AND ASSENT PROCESS AND DOCUMENTATION
Informed consent will be obtained from all patients, and/or the patientâ€™s parents or legal guardian 
(if he/she is < 18 years of age) and matched rela ted donors prior to entry..  The procedures and 
treatments involved in this  protocol, with their attendant risks and discomforts, potential benefits, 
and potential alternative therapies will be carefully explained to the recipient and/or parent/guardian.  Where deemed appropriate by  the clinician and the childâ€™s parent(s) or 
guardian, the child will also be included in all discussions about the tr ial and age-appropriate 
language will be used to describe the procedures and tests involved in this study, along with the 
risks, discomforts and benefits of  participation.  Verbal assent w ill be obtained as appropriate for 
children ages (12 years and older) and the parent or guardian will sign the designated line on the informed consent attesting to the fact that the child has given assent.  Children under the age of 
12 years will not be required to provide assent as they typically do not have the cognitive ability to fully understand the nature of research. The consent/assent process w ill be documented in the 
59
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
childâ€™s medical record, including the assessment of the childâ€™s ability to provide verbal assent. 
All children will be contacted after they have reached the age of 18 to determine whether they wish to continue on the trial and informed consent will be obtained from them at that time. Note that NMDP consents will be used for unrelated donor patients. 
The investigators are requesting a waiver from the IRB to allow only one parent to sign the 
informed consent to enter a child on the protocol . Because many patients must travel to the NIH 
from long distances at substantial expense, requi ring both parents to be present for the consent 
process could be a financial hardship for many families. When guardianship status of the child is uncertain, a social worker will be asked to investigate and, if necessary, seek documentation of custody status. In situations where there is jo int custody of a child, both parents must sign 
consent. If only one parent can be present at NI H, the other parentâ€™s consent can be obtained by 
telephone via the procedur e described in section 7.5.1 Similarly, the procedures and treatments 
involved in this protocol, with their attendant risks and discomforts, will be carefully explained 
to the matched unrelated donors at the respec tive donor center as required by NMDP.  The 
original signed informed consent goes to Medical Records; a copy will be kept for the research record.  The Central Registration Office (CRO), Data Management Section will also retain a copy of the informed consent document.  A copy of the signed informed consent document will also be given to the recipient (and matched re lated donor, when applicab le).  b) The Central 
Registration Office (CRO) will ascertain the date of IRB approval before registering the first patient.
The Principal Investigator and/or an authorized designee will consent the patient and matched 
related donor (when applicable) and will be available to an swer all patient questions.
If any new information becomes available relating to risks, adverse events, or toxicities, while patients are participating in this protocol, this information will be provided orally and/or in writing to all enrolled and prospective patient participants.  Documentation will be provided to the IRB and if necessary the informed consen t amended to reflect relevant information.
The possible risks and benefits of this trial will be explained in laymanâ€™s terms for patients and 
guardians.  For patients who elect to enroll, consent will be obtained.  A signed consent must be obtained by patient or legal guardian prior to stud y entry.  The PI, an Associate investigator, or 
an appropriate designee will answer all questions regarding this medication and the purpose of the trial prior to obtaining consent
7.5.1 Consent for minors when they reach the age of majority When a pediatric subject reaches  age 18, continued participation (including ongoing interactions 
with the subject or continued analysis of identifiable data) will require consenting of the now 
adult with the standard protocol consent document to ensure legally effective informed consent has been obtained. We request waiver of inform ed consent for those individuals who have 
completed their participation in the research study and subjects who have been lost to follow-upRequirements for Waiver of Consent consistent with 45 CFR 46.116 (d): 
1)The research involves no more than minimal risk  to the subjects. a. Analysis of samples 
and data from this study involves no additional risks to subjects. 
2)The waiver or alteration will not adversely affect the rights and welfare of the subjects. a. Retention of these samples or data does not affect the welfare of subjects. 
60
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
3)The research could not practicably be carried  out without the waiver or alteration. a. 
Considering the length of time between the minorâ€™s last contact with the research team 
and their age of majority, it will likely be very difficult to locate them again. A significant reduction in the number of samples analyzed is likely to impact the quality of the research. 
4)Whenever appropriate, the subjects will be provided with additional pertinent information after participation. a. We only plan to requ est a waiver of reconsent for those subjects 
who have been lost to follow-up or prior to amendment T, have been taken off study prior 
to reaching the age of majority. 
7.5.2 Telephone consent and re-consent procedure
The following procedure may be used in cases of  re-consent or for intial consent in cases where 
the consent of both parents of a minor partic ipant is required as discussed in section 7.5. the 
informed consent document will be sent to the subject.  An explanation of the study will be provided over the telephone after the subject has had the opportunity to read the consent form.  
The subject will sign and date the informed consent. A witness to the subjectâ€™s signaturewill sign and date the consent.  The original informed consent document will be sent back to the consenting investigator who will sign and date the consent form with the date the consent wasobtained via telephone.  A fully executed copy will be returned via mail for the subjectâ€™s records.  The informed consent process will be documented on a progress note by the consenting investigator.
7.5.3 Informed consent of Spanish speaking subjectsWe anticipate the enrollment of Spanish speaking research participants into our study. The IRB 
approved full consent document will be translated into that language in accordance with the Clinical MAS Policy M77-2.
7.5.4 Short form consent process for other non-English speaking patients
If there is an unexpected enrollment of a research participant for whom there is no translated extant 
IRB approved consent document, the principal i nvestigator and/or those authorized to obtain 
informed consent will use the Short Form Oral Consent Process as described in MAS Policy M77-2, OHSRP SOP 12, 45 CFR 46.117 (b) (2).  The summary that will be used is the English version of the extant IRB approved consent document.  Si gned copies of both the English version of the 
consent and the translated short form will be given to the subject or their legally authorized representative and the signed original will be filed in the medical record.
Unless the PI is fluent in the prospective subjectâ€™s language, an interpreter will be present to 
facilitate the conversation. Preferably someone who is  independent of the subject (i.e., not a family 
member) will assist in presenting information and obtaining consent. Whenever possible, interpreters will be provided copies of the relevant consent documents well before the consent conversation with the subject (24 to 48 hours if possible). 
We request prospective IRB approval of the use of the short form process and will notify the IRB 
at the time of continuing review of the frequency of the use of the Short Form.
61
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
8 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN
8.1 D EFINITIONS
8.1.1 Adverse Event
Any untoward medical occurrence in a human  subject, including any abnormal sign (for 
example, abnormal physical exam or laboratory finding), symptom, or disease, temporally 
associated with the subjectâ€™s participation in re search, whether or not considered related to the 
subjectâ€™s participation in the research.8.1.2 This study incorporates a standard myeloa blative bone marrow tran splantation platform 
that has been in use for ~50 years and has ma ny expected adverse events.  As the purpose 
of this study is to assess the integration of lupron and FLT imaging with this 
transplantation platform, only 1) serious a dverse events and 2) adverse events not 
attributable to the standard BMT platform a nd either possibly, probably, or definitely 
attributable to either lupron or FLT imaging will be reportedSuspected adverse reaction
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of IND safety reporting, â€˜reasonable possibilityâ€™ means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.
8.1.3 Unexpected adverse reactionAn adverse event or suspected adverse reaction is considered â€œunexpectedâ€ if it is not listed in 
the investigator brochure or is not listed at the sp ecificity or severity that has been observed; or, 
if an investigator brochure is not  required or available, is not cons istent with the risk information 
described in the general inve stigational plan or elsewhere in the current application. 
"Unexpectedâ€, also refers to adverse events or suspected adverse reactions that are mentioned in 
the investigator brochure as occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but are no t specifically mentioned as occurring with the 
particular drug und er investigation.
8.1.4 SeriousAn Unanticipated Problem or Prot ocol Deviation is serious if it meets the definition of a Serious 
Adverse Event or if it compromises the safety , welfare or rights of subjects or others.
8.1.5 Serious Adverse EventAn adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following:
xDeath,
xA life-threatening adverse drug experience
xInpatient hospitalization or prolongation of existing hospitalization
xA significant disability/incapacity
62
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
xA congenital anomaly/birth defect.
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious  adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.
8.1.6 Disability
A substantial disruption of a personâ€™s  ability to conduct normal life functions.
8.1.7 Life-threatening adverse drug experienceAny adverse event or suspected adverse reaction that places the patient or subject, in the view of 
the investigator or sponsor, at immediate risk of  death from the reaction as it occurred, i.e., it 
does not include a reaction that had it occurred in  a more severe form, might have caused death.
8.1.8 Protocol Deviation (NIH Definition)
Any change, divergence, or departure from the IRB approved research protocol8.1.9 Non-compliance (NIH Definition)The failure to comply with applicable NIH Human Research Protections Program (HRPP) 
policies, IRB requirements, or regulatory requirements for the protection of human research 
subject.
8.1.10 Unanticipated ProblemAny incident, experience, or outcome that:
xIs unexpected in terms of nature, severity, or frequency in relation to 
(a) the research risks that are described in the IRB-approved research protocol and 
informed consent document; Investigatorâ€™s Brochure or other study documents, and
(b) the characteristics of the subject population being studied; AND
xIs related or possibly related to participation in the research; AND
xSuggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social  harm) than was previously known or 
recognized.
8.2 NCI-IRB
AND CLINICAL DIRECTOR REPORTING
8.2.1 NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths
The Protocol PI will report in the NIH Problem Form to the NCI-IRB and NCI Clinical Director:
xAll deaths, except deaths due to progressive disease
xAll Protocol Deviations
xAll Unanticipated Problems
xAll non-compliance
63
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Reports must be received within 7 days of PI awareness via iRIS.
8.2.2 NCI-IRB Requirements for PI Reporting at Continuing Review
The protocol PI will report to the NCI-IRB: 
1. A summary of all protocol deviations in a ta bular format to include the date the deviation 
occurred, a brief description of the deviation and any corrective action.
2. A summary of any instances of non-compliance
3. A tabular summary of the following adverse events:
x All Grade 2 unexpected events that are possibly, probably, or definitely related to 
lupron or the IND;
x All Grade 3 and 4 events that are possibly,  probably, or definitely related to the 
lupron or the IND;
x All Grade 5 events regardless of attribution; 
x All Serious Events regardless of attribution. 
NOTE : Grade 1 events are not required to be collected or reported. 
Note : With the exception of severe adverse events, AE that occur prior to the initiation of 
protocol directed therapy (to include standard of care chemotherapy that could be given 
due to delay in donor availability or for ot her reasons) will not be collected or reported.
NOTE: Expected AE of transplantation that will be exempt from reporting (because they will not be related to research) include: 
- Leukopenia, anemia, and thrombocytopeni a until engraftment of these cellular 
populations.  Should a patient not engraft, this will be captured as an AE.
- Coagulation abnormalities- Electrolyte abnormalities including sodi um, potassium, chloride, magnesium, 
calcium, phosphorus, bicarb, blood urea nitrogen, lactate dehydrogenase, 
creatinine kinase.
- Endocrine abnormalities, bone miner alization abnorma lities, avascular 
necrosis, delay in growth/development, and nutritional data (to include lipid 
levels, prealbumin, albumin).  
- Dermatology abnormalities (to include  changes in nails, pigmentation)
- Mucositis
8.2.3 NCI-IRB Reporting of IND Safety Reports
Only IND Safety Reports that meet the definition of an unanticipated problem will need to be 
reported to the NCI IRB.
64
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
8.3 NCIG UIDANCE FOR REPORTING EXPEDITED ADVERSE EVENTS FOR MULTI-CENTER 
TRIALS
The site PI must immediately report to the coordinating center PI any serious adverse event, 
whether or not considered drug related, including those listed in the protocol or investigator 
brochure and must include an assessment of whether there is a reasonable possibility that the drug caused the event within 24 hours of PI awarenes s of the event. The Site PI must also report 
any protocol deviations to the coordinating center PI  within 7 days of PI awareness. Participating 
centers must also submit the report to their IRB in accordance with their institutional policies. 
A participating site problem form (available in section 12.16) is to be filled out and sent to the 
Coordinating Centerâ€™s PI.
8.4 INDS
PONSOR REPORTING CRITERIA
During the first 30 days after the subject re ceives investigational agent/intervention, the
investigator must immediately report to the s ponsor using the mandatory MedWatch form 3500a,
or equivalent any serious adverse event, whether or not considered drug related, including those 
listed in the protocol or investigat or brochure and must include an assessment of whether there is 
a reasonable possibility that the drug caused the event. For serious adverse events that occur 
more than 30 days after the last administration of investigational agen t/intervention, only report 
those that have an attribution of at least possibly related to the agent/intervention.
Required timing for reporting per the above guideline:
xDeaths (except death due to progressive dis ease) must be reported via email within 
24 hours.  A complete report must be  submitted within one business day. 
xOther serious adverse events as well as de aths due to progressive disease must be 
reported within one business day
.Events will be submitted to the Center for Cancer Research (CCR) at: CCRsafety@mail.nih.gov
and to the CCR PI and study coordinator.8.5 D
ATA RECORDING OF UNRELATED DONORS FROM NMDP
Per NMDP regulations, and to maintain donor confidentiality, unrel ated donor source documents 
will notbe sent to the NIH. The NMDP will maintain  all required source documents in accordance 
with NMDP policies and procedures. The NMDP will confirm donor eligib ility and will notify the 
NIH of any deviations in regard to protocol requirements.
The National Marrow Donor Program (NMDP) IRB will be responsible for the review and
continuing oversight of protocol procedures that relate only to NMDP unrelated donors.
8.6 D ATA AND SAFETY MONITORING PLAN
8.6.1 Principal Investigator/Research Team The clinical research team will meet on a regular basis weekly when patients are being actively 
treated on the trial to discuss each patient. 
65
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
All data will be collected in a timely manner and reviewed by the principal investigator or a lead 
associate investigator. Pertinent data includes: GVHD acute or chronic and characterization as per appendices and medications to treat th is documented at day 30, 60, 100, 180, 270, 365, and 
yearly after this, infections and medications and disease response and therapies for recurrent 
disease also collected at these key time points.  Ancillary medications taken at the time of these time points needs to be collected, however, ancillary medications not associated with the aforementioned that are started and stopped between key time points need not to be 
collected/recorded unless associated with adverse events.  Adverse events will be reported as 
required above. Any safety concerns, new informati on that might affect either the ethical and or 
scientific conduct of  the trial, or protocol deviations will be immediately reported to the IRB 
using iRIS.
The site principal investigator  will review adverse event and response data on each patient to 
ensure safety and data accuracy. The site prin cipal investigator will personally conduct or 
supervise the investigation and provide appr opriate delegation of responsibilities to other 
members of the research staff. 8.6.2 Sponsor Monitoring PlanAs a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring 
program. The CCRâ€™s program allows for confirmation of: study data, specifically data that could affect the interpretation of prima ry study endpoints; adherence to  the protocol, regulations, and 
SOPs; and human subjects protection. This is done through independent veri fication of study data 
with source documentation focusing on:
â€¢ Informed consent processâ€¢ Eligibility confirmationâ€¢ Drug administration and accountabilityâ€¢ Adverse events monitoringâ€¢ Response assessment.The monitoring program also extends to multi-site research when the CCR is the coordinating 
center.
8.6.3 This trial will be monitored by personnel em ployed by an NCI contractor. Monitors are 
qualified by training and experience to monito r the progress of clinical trials. Personnel 
monitoring this study will not be affiliate d in any way with the trial conductSafety 
Monitoring Committee (SMC)
This protocol will require oversight from the Safety Monitoring Committee (SMC).  Initial 
review will occur as soon as possible after the annual NCI-IRB continuing review date.   Subsequently, each protocol will be reviewed as close to annually as the quarterly meeting 
schedule permits or more frequently as may be required by the SMC.   For initial and subsequent reviews, protocols will not be reviewed if ther e is no accrual within the review period. Written 
outcome letters will be generated in response to the monito ring activities and submitted to the 
Principal investigator and Clinical Director or Deputy Clinical Director, CCR, NCI.
66
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
9 MULTI-INSTITUTIONAL GUIDELINES
This is a multi-institutional trial with University of Oklahoma and National Institutes of Health, 
National Cancer Institute, and Childrenâ€™s National Medical Center.
Childrenâ€™s National Medical Center will enroll only children and open only the FLT arm of the 
study.  Univ. of Oklahoma will enroll only adults and open only the Lupron arm.  
9.1.1 IRB Approvals 
The PI will provide the NCI IRB and Central Registration Office with a copy of the participating 
institutionâ€™s approved yearly continuing review.  Registration will be halted at any participating institution in which a current continuing approval is not on file at the NCI IRB.
9.1.2 Amendments and ConsentsThe PI will provide NIH IRB with any and all documentation of amendments, consents, and approvals 
from IRB reviews at all participating institutions.  All amendments to the protocol or the NCI consent are to be approved by the NCI PI and the NCI IRB and then submitted to the participating institutionâ€™s IRB for approval.  
9.1.3 Data and Specimen Collection Procedures
The NCI C3D data base will be utilized; data will only be collected at the time points specified in 
this trial.  Participating sites will be trained in the use of C3D and directly enter data at these sites into C3D.  Any questions or concerns should e licit immediate contact of the NCI PI or AI.  .
9.1.4 Data Center Audits
All participating sites will be monitored as per section 8.7.2. Scans and data may also be reviewed of 
primary NIH or Childrenâ€™s National Medical Center patie nts at Univ of Oklahoma after de-identification
for exploratory analyses. The NCI PI or AI will oversee the implementation of any necessary quality 
improvement measures that may be indicated as a result of these quality assurance activities.
9.1.5 Protocol Monitoring CommitteesThe NCI PI or AI will have either a meeting or ph one conversation with all IRB-approved participating 
institution PIs to discuss protocol progress at leas t monthly after the outside site as begun accrual.
10 PHARMACEUTICAL INFORMATION  10.1 L
UPRON DEPOT
10.1.1 Chemical name5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-Larginyl-N-ethyl-L-
prolinamide acetate
Lupron is a synthetic nonapeptide analog of naturally produced gonadotropin-releasing hormone 
(GnRH).
67
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10.1.2 Chemical structure 
Figure 8: Chemical Structure of Lu pron Depot
10.1.3 Commercial Formulation
Supplied either daily or extende d release injections.  Daily formulation is a 2.8 mL multi-dose 
vial with 5 mg/mL Lupron, administered as 1 mg (0.2 mL) subcutaneously per day.  Lupron also 
is supplied as Lupron Depot in either a 1, 3, or  4 month preparation with 3.75, 22.5 mg, or 30 mg
leuprolide acetate respectively for adults and as 11.25 mg 3 month preparation for children.
Lupron Depot is given as an intramuscular inje ction in a dual chamber syringe system that 
contains sterile lyophilized mic rospheres which become suspended in the carrier solution upon 
injection and continue drug release for the recommended timeframe. 
10.1.4 StorageRoom temperature 10.1.5 StabilityLupron remains stable when stored at 15-30 deg. Celsius.  The product should be stored in the 
original container and away from light sources. 10.1.6 Route of administrationIntramuscular injection.  Emla may be given pr ior to injection to minimize discomfort at 
injection site. 10.1.7 DoseLupron will be administered as 30 mg intramuscular injection once prior to stem cell transplant
for adult patients and as an a dult preparation 3 month extended release 11.25 mg intramusclular 
injection once prior to stem cell transplant for patients <18 years.
10.1.8 Drug InteractionsThere are no reported drug interactions with Lupr on.  It is metabolized by peptidases and does 
not involve the P450 enzyme system.  However, given the mechanism of action of sex hormone 
suppression, all sex hormones are contraindicated (including: te stosterone, progesterone, and 
estrogen) in all preparations. 10.1.9 Known toxicities for patients >18(see table below)

68
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Please utilize the table for the most accurate asse ssment of Lupron toxicities.  The most common 
side effects in large trials include headache and fa tigue.  A toxicity table from the Lupron insert 
is included here: 
Table 2: Adverse Events in â‰¥5% of Patients Regardless of Causality
10.1.10Known toxicities for patients <18
(see table below)In two studies of children with central precoci ous puberty, in 2% or more of the patients 
receiving the drug, the following adverse reactions were reported to have a possible or probable 
relationship to drug as ascribed by the treating physician. Reactions which are not considered drug related are excluded.

69
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
Table 3
10.2 C YCLOPHOSPHAMIDE
10.2.1 Chemical name
2-[bis(2-chloroethyl)amino] tetrahydro-2 H-1,3,2-orxazaphosphorine 2-oxide monohydrate.
Cyclophosphamide is a chemotherapy metabolized in the liver to an active alkylator that 
interferes with cell division through cross-linking of DNA.
10.2.2 Chemical structure 
Figure 9: Chemical Structure of C yclophosphamide

70
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10.2.3 Commercial Formulation
Supplied as lyophilized powder that will be recons tituted with normal saline prior to intravenous 
administration.  Oral tablets are availabl e but not relevant to this trial.  
10.2.4 StorageRoom temperature 10.2.5 StabilityCyclophosphamide reconstituted is stable for 24 hours at room temperature or for 6 days in the 
refrigerator.    
10.2.6 Route of administrationIntravenous injection 10.2.7 DoseCyclophosphamide will be administered as per Section 12.4.
10.2.8 Drug InteractionsThe rate of metabolism and the activity of cyclophosphamide are increased with concomitant 
administration of Phenobarbita l.  Cyclophosphamide also increases the activity of 
succinylcholine chloride.  If the patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.  
10.2.9 Known toxicities (see table below)
Table 4: Toxicity
Common Occasional Rare
Immediate:
Within 1-2 days of receiving drugAnorexia (L), nausea (L), vomiting(L)Metallic taste (L), Inappropriate ADH
1Transient blurred vision1cardiac 
toxicity with arrhythmias1
myocardial necrosis 2(L)
Prompt:
Within 2-3 weeks, prior to the next courseMyelosuppression (L), alopecia (L)Hemorrhagic cystitis (L)
Delayed:
Any time later during therapy, 
excluding the above conditionsImmunosuppression, 
gonadal dysfunction 
/sterility (L)Pulmonary fibrosis3(L)
Late:Any time after completion of treatmentSecondary malignancy, bladder fibrosis
Unknown Frequency and Timing :  **Fetal and teratogenic toxicities and toxicities in breast-fed children
1Less common with lower doses.
2Only with very high doses.
3Risk increased with chest radiation.
(L) Toxicity may also occur later.
71
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
**Fetal toxicities and teratogenic effects of  cyclophosphamide (alone or in combination 
with other antineoplastic agents) have been noted in humans.  Toxicities include: 
chromosome abnormalities, multip le anomalies, pancytopeni a, and low birth weight.
**Cyclophosphamide is excreted into breast milk.  Neutropenia has been reported in 
breast-fed infants. Cyclophosphamide is consid ered to be contraindicated during breast 
feeding because of the reported cases of neut ropenia and because of the potential adverse 
effects relating to immune suppre ssion, growth, and carcinogenesis.
10.3 T OTAL BODY IRRADIATION
10.3.1 Chemical name
Not applicable10.3.2 Known toxicitiesThe side effects of radiation have been well described. The most common include nausea and 
mucositis. There also exists a risk of hypothyroidism, cataracts, interstitial pneumonitis, 
nephropathy, and an unspecified long-term ri sk of developing s econdary malignancies [ 63].
Importantly, the majority of the non-neoplastic effects were subclinical and/or reversible [ 64].
Studies attempting to evaluate the risk attributed  to radiation within a preparative regimen have 
implicated secondary malignancies, however th is is difficult to ascribe since secondary 
malignancies are also increased with cGVHD and other post-transplant complications [ 65][66].
Pediatric patients who require seda tion in order to undergo TBI will be asked to sign a separate 
consent outlining the risk of the selected anesthesia.
10.4 FLT10.4.1 Chemical Name3â€™-deoxy-3
18F-fluorothymidine
10.4.2 Commercial FormulationFLT is supplied as a unit dose by intravenous injection.10.4.3 StorageRoom Temperature10.4.4 Chemical Structure
Figure 10: Chemical Structure of FLTO
FNNH
HOO
Me
O
FLT
72
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10.4.5 Method of Administration
[18F]FLT is administered by intravenous injec tion over 15 seconds with a saline flush.  
Appropriate shielding will meet the Radiation Safety Guidelines of NIH. 10.4.6 Availability[
18F] FLT will be synthesized and delivered to Building 21 by Cardinal Health, or PETnet 
Pharmacies. [18F] FLT will be synthesized and delivered Radiology Department located on 2nd
floor of hospital at Childrenâ€™s National Medical Center by Ca rdinal Health or PETnet 
Pharmacies.10.4.7 Known ToxicitesNo AEs attributable to 
18F FLT administered at tracer levels have been reported in the published 
literature. While no related AEs are expected, patients will be monitored very closely with 
regards to hepatic, neurologic , and hematologic parameters fo llowing radiotracer injection.
10.5 F LUDARABINE (FLUDARA,BERLEX LABORATORIES )
10.5.1 Chemical Name
Fludarabine monophosphate 10.5.2 SupplyFludarabine monophosphate will be pur chased by the NIH Clinical Center Pharmacy Department 
from commercial sources and is supplied as a white, lyophilized powder.  Each vial contains 50 
mg of fludarabine phosphate, 50 mg of mannitol, a nd sodium hydroxide to adjust pH.  Fludara is 
stored at room temperature.
10.5.3 PreparationFLUDARA IV should be prepared for parenteral use by aseptically adding Sterile Water for 
Injection, USP.  When reconstitu ted with 2 ml of Sterile Wate r for Injection, each ml of the 
resulting solution will contain 25 mg of Fludarabine Phosphate, 25 mg of mannitol, and sodium 
hydroxide to adjust the pH to 7â€“8.5.  Fludarabine will be diluted in 100 to  125ml of either 5% 
dextrose in water or 0.9% sodium chloride, and infused IV over 30 minutes.
10.5.4 Storage and StabilityReconstituted FLUDARA IV is chemically and physically stable for 24 hours at room 
temperature or for 48 hours if refrigerated.  Because reconstituted FLUDARA IV contains no 
antimicrobial preservative, care must be taken to assure the sterility of the prepared solution; for this reason, reconstituted FLUDARA IV should be used or discarded within 8 hours.
10.5.5 Administration 
Parenteral drug products should be inspected vi sually for particulate matter and discoloration 
prior to administration.10.5.6 Toxicities Fludarabine toxicities include myelosuppression (dose limiting toxicity), fever, nausea, vomiting, 
stomatitis, diarrhea, gastrointestinal bleeding, anorexia, edema, skin rashes, myalgia, headache, 
73
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
agitation, hearing loss, transient episodes of so mnolence and fatigue, auto-immune hemolytic 
anemia, auto-immune thrombocytopenia, paresthesias, peripheral neur opathy, renal, and 
pulmonary toxicity (interstitial pneumonitis).  Seve re fatal CNS toxicity presenting with loss of 
vision and progressive dete rioration of mental status were en countered almost exclusively after 
very high doses of fludarabine monophosphate.  Such toxicity has only rarely been demonstrated 
at the 25-30 mg/m2/day dosage of fludarabine.  Very ra rely described complications include 
transfusion-associated graft-versus-host disease,  thrombotic thrombocytopenic purpura, and liver 
failure.  Tumor lysis syndrome following fludarabine administration has been observed, 
especially in patients with advanced bulky disease.  Opportunistic infec tions (protozoan, viral, 
fungal, and bacterial) have b een observed post-fludarabine, esp ecially in heavily pre-treated 
individuals, and in individuals receiving fludarabine combined with other agents.
10.6 B USULFAN (BUSULFEX)
Busulfan is a bifunctional alkylating agent appr oved for use as a conditioning agent prior to 
allogeneic hematopoieitc stem  cell transplantation at NCI on protocol 10-c-0174 amendment
M.The IV formulation is administered as Busulfan (Busulfex, Otsuka America Pharmaceutical, Inc.)
10.6.1 Source
For patient administration, IV Busulfan is purchased by the NIH Clinical Center Pharmacy 
Department from commercial sources. The drug is supplied as a clear, colorless sterile solution in 
10ml single use vials. Each vial of Busulfan contains 60 mg (6mg/ml) of busulfan.
10.6.2 Storage and Stability
Unopened vials of Busulfan are stable until the da te indicated on the pack age when stored under 
refrigeration at 2-6 degrees C (36-46 degrees F).10.6.3 Administration
Busulfan must be diluted prior to use with either 0.9% Sodium chloride or 5% Dextrose   Injection. 
The diluent quantity should be 10 times the volume of Busulfan so that the final concentration of 
busulfan is approximately 0.5 mg/ml.  Busulfan should be administere d intravenously via a central 
venous catheter as a two-hour infusion every 24 h ours for a total of 4 doses over four days.  
10.6.4 Toxicities
At the indicated dose and schedule Busulfan i nduces profound myelosuppression; 2) All patients 
should be given a seizure prophylaxis regime n (e.g. Clonazepam plus levetiracetam) since 
busulfan is known to cross the blood brain barrier and induce seizures; 3) Nausea, vomiting, and stomatitis are common side effects of busulfan.  
10.6.5 Drug Interactions Itraconazole increases the clearance of busulfan by up to 25%. Phenytoin increases the clearance 
of busulfan by 15%.
74
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
11 REFERENCES 
1. Hakim, F.T., et al., Constraints on CD4 recovery postch emotherapy in adults: thymic 
insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood, 1997. 
90(9): p. 3789-98.
2. Hazenberg, M.D., et al., T-cell receptor excision circle and T-cell dynamics after 
allogeneic stem cell transplantation are related to clinical events. Blood, 2002. 99(9): p. 
3449-53.
3. Storek, J., et al., Infectious morbidity in long-term  survivors of allogeneic marrow 
transplantation is associated with low CD4 T cell counts. Am J Hematol, 1997. 54(2): p. 
131-8.
4. Roux, E., et al., Recovery of immune reactivity after T-cell-depleted bone marrow 
transplantation depends on thymic activity. Blood, 2000. 96(6): p. 2299-303.
5. Dumont-Girard, F., et al., Reconstitution of the T-cell compartment after bone marrow 
transplantation: restoration of the repertoire by th ymic emigrants. Blood, 1998. 92(11): 
p. 4464-71.
6. Lewin, S.R., et al., Direct evidence for new T-cell gene ration by patients after either T-
cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood, 
2002.100(6): p. 2235-42.
7. Novitzky, N., et al., Immune reconstitution at 6 months following T-cell depleted 
hematopoietic stem cell transplantation is predictive for treatment outcome.
Transplantation, 2002. 74(11): p. 1551-9.
8. Koehl, U., et al., Immune recovery in children undergoing allogeneic stem cell 
transplantation: absolute CD8+ CD3+ count re constitution is associated with survival.
Bone Marrow Transplant, 2007. 39(5): p. 269-78.
9. Parkman, R., et al., Successful immune reconstitution decreases leukemic relapse and 
improves survival in recipients of  unrelated cord blood transplantation. Biol Blood 
Marrow Transplant, 2006. 12(9): p. 919-27.
10. Weinberg, K., et al., Factors affecting thymic function after allogeneic  hematopoietic 
stem cell transplantation. Blood, 2001. 97(5): p. 1458-66.
11. Fallen, P.R., et al., Factors affecting reconstitution of the T cell compartment in 
allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant, 2003. 
32(10): p. 1001-14.
12. Jimenez, M., et al., Clinical factors influencing T-cell receptor excision circle (TRECs) 
counts following allogeneic stem cell transplantation in adults. Transpl Immunol, 2006. 
16(1): p. 52-9.
13. Omazic, B., et al., Memory B lymphocytes determine repe rtoire oligoclonality early after 
haematopoietic stem cell transplantation. Clin Exp Immunol, 2003. 134(1): p. 159-66.
75
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
14. Marie-Cardine, A., et al., Transitional B cells in humans: characterization and insight 
from B lymphocyte reconstitution after he matopoietic stem cell transplantation. Clin 
Immunol, 2008. 127(1): p. 14-25.
15. Omazic, B., et al., Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic 
haematopoietic stem cell transplantation w ith myeloablative or reduced-intensity 
conditioning regimens. Scand J Immunol, 2005. 61(1): p. 72-81.
16. Parsons, R.F., et al., Acquisition of Humoral Transplantation Tolerance upon De Novo 
Emergence of B Lymphocytes. J Immunol, 2010.
17. Chu, R., et al., Comparison of Outcomes after Transplantation of G-CSF Stimulated 
Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-
Matched Sibling Donors for Patients with Severe Aplastic Anemia. Biol Blood Marrow 
Transplant, 2010.
18. Anderson, D., et al., A comparison of related donor peripheral blood and bone marrow 
transplants: importance of late-onset chroni c graft-versus-host disease and infections.
Biol Blood Marrow Transplant, 2003. 9(1): p. 52-9.
19. Goldberg, G.L., et al., Enhanced Immune Reconstitution by Sex Steroid Ablation 
following Allogeneic Hemopoie tic Stem Cell Transplantation. J Immunol, 2007. 178(11): 
p. 7473-84.
20. Leposavic, G., et al., Differential effects of gonadectom y on the thymocyte phenotypic 
profile in male and female rats. Pharmacol Biochem Behav, 1996. 54(1): p. 269-76.
21. Olsen, N.J. and W.J. Kovacs, Effects of androgens on T and B lymphocyte development.
Immunol Res, 2001. 23(2-3): p. 281-8.
22. Olsen, N.J., et al., Induction of immature thymocyte proliferation after castration of 
normal male mice. Endocrinology, 1994. 134(1): p. 107-13.
23. Sutherland, J.S., et al., Activation of thymic regeneration in mice and humans following 
androgen blockade. J Immunol, 2005. 175(4): p. 2741-53.
24. Ellis, T.M., et al., Alterations in peripheral B cells  and B cell progenitors following 
androgen ablation in mice. Int Immunol, 2001. 13(4): p. 553-8.
25. Williams, K.M., et al., CCL25 increases thymopoiesis after androgen withdrawal. Blood, 
2008.112(8): p. 3255-63.
26. Aragon-Ching, J.B., K.M. Williams, and J.L. Gulley, Impact of androgen-deprivation 
therapy on the immune system: implications fo r combination therapy of prostate cancer.
Front Biosci, 2007. 12: p. 4957-71.
27. Ghalie, R., et al., Prevention of hypermenorrhea with leuprolide in premenopausal 
women undergoing bone marrow transplantation. Am J Hematol, 1993. 42(4): p. 350-3.
28. Vermeulen, A. and Oddens, Androgens and the Aging Male , in Declining Androgens with 
age: an overview , A. Vermeulen, Editor. 1996, Parthenon Publishing: New York. p. 3-14.
29. Huang, C.X., L.Z. Chen, and J.G. Zhao, [Influence of chemotherapy with FOLFOX 
protocol on sex hormones of male patients and the protective effect of herbal medicines 
76
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
for reinforcing Shen and supplementing qi on it]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 
2008.28(11): p. 986-9.
30. Isasi, C.R., P. Lu, and M.D. Blaufox, A metaanalysis of 18F-2-d eoxy-2-fluoro-D-glucose 
positron emission tomography in the staging and restaging of patients with lymphoma.
Cancer, 2005. 104(5): p. 1066-74.
31. Spaepen, K., et al., Prognostic value of pretransplantation positron emission tomography 
using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with 
high-dose chemotherapy and stem cell transplantation. Blood, 2003. 102(1): p. 53-9.
32. Spaepen, K., et al., Can positron emission tomography with [(18)F]-fluorodeoxyglucose 
after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J 
Haematol, 2001. 115(2): p. 272-8.
33. Spaepen, K., et al., [(18)F]FDG PET monitoring of tum our response to chemotherapy: 
does [(18)F]FDG uptake correlate with  the viable tumour cell fraction? Eur J Nucl Med 
Mol Imaging, 2003. 30(5): p. 682-8.
34. Schwartz, J.L., et al., Monitoring tumor cell proliferati on by targeting DNA synthetic 
processes with thymidine and thymidine analogs. J Nucl Med, 2003. 44(12): p. 2027-32.
35. Kasper, B., et al., Functional diagnosis of residual ly mphomas after radiochemotherapy 
with positron emission tomography comparing FDG-and FLT-PET. Leuk Lymphoma, 
2007.48(4): p. 746-53.
36. Buchmann, I., et al., [18F]3'-deoxy-3'-fluorothymidine- PET in NHL patients: whole-body 
biodistribution and imaging of lymphoma manifestations--a pilot study. Cancer Biother 
Radiopharm, 2004. 19(4): p. 436-42.
37. Herrmann, K., et al., Early response assessment using 3' -deoxy-3'-[18F]fluorothymidine-
positron emission tomography in hi gh-grade non-Hodgkin's lymphoma. Clin Cancer Res, 
2007.13(12): p. 3552-8.
38. Buck, A.K., et al., Molecular imaging of proliferation in malignant lymphoma. Cancer 
Res, 2006. 66(22): p. 11055-61.
39. Been, L.B., et al., Positron emission tomography in patients with breast cancer using 
(18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol, 2006. 
32(1): p. 39-43.
40. Kenny, L., et al., Imaging early changes in proliferation at 1 week post chemotherapy: a 
pilot study in breast cancer patients with  3'-deoxy-3'-[18F]fluorothymidine positron 
emission tomography. Eur J Nucl Med Mol Imaging, 2007. 34(9): p. 1339-47.
41. Pio, B.S., et al., Usefulness of 3'-[F-18]fluoro-3'-deo xythymidine with positron emission 
tomography in predicting breast cancer response to therapy. Mol Imaging Biol, 2006. 
8(1): p. 36-42.
42. Cobben, D.C., et al., Detection and grading of soft tissue sa rcomas of the extremities with 
(1
8)F-3'-fluoro-3'-deoxy-L-thymidine. Clin Cancer Res, 2004. 10(5): p. 1685-90.
77
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
43. Buck, A.K., et al., First demonstration of leukemia imaging with the proliferation marker 
18F-fluorodeoxythymidine. J Nucl Med, 2008. 49(11): p. 1756-62.
44. Agool, A., et al., 18F-FLT PET in hematologic disord ers: a novel technique to analyze 
the bone marrow compartment. J Nucl Med, 2006. 47(10): p. 1592-8.
45. Agool, A., et al., Effect of radiotherapy and chemot herapy on bone marrow activity: a 
18F-FLT-PET study. Nucl Med Commun, 2011. 32(1): p. 17-22.
46. Awasthi, V., et al., F-18-fluorothymidine-PET evaluation of bone marrow transplant in a 
rat model. Nucl Med Commun. 31(2): p. 152-8.
47. Flexner, C., et al., Relationship between plasma c oncentrations of 3'-deoxy-3'-
fluorothymidine (alovudine) and antiretrovira l activity in two con centration-controlled
trials. J Infect Dis, 1994. 170(6): p. 1394-403.
48. Shields, A.F., et al., Imaging proliferation in vivo with [F-18]FLT and positron emission 
tomography. Nat Med, 1998. 4(11): p. 1334-6.
49. Kong, X.B., et al., Comparisons of anti-human imm unodeficiencyvirus  activities, 
cellular transport, and plasma and intrace llular pharmacokinetics of 3'-fluoro-3'-
deoxythymidine and 3'-a zido-3'-deoxythymidine. Antimicrob Agents Chemother, 1992. 
36(4): p. 808-18.
50. Goldstone, A.H., et al., In adults with standard-risk ac ute lymphoblastic leukemia, the 
greatest benefit is achieved from a matched sibling allogeneic transplantation in first 
complete remission, and an autologous transplanta tion is less effec tive than conventional 
consolidation/maintenance chemotherapy in all pa tients: final results of the International 
ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008. 111(4): p. 1827-33.
51. Stock, W., Adolescents and young adults with acute lymphoblastic leukemia. Hematology 
Am Soc Hematol Educ Program, 2010. 2010: p. 21-9.
52. Foran, J.M., New prognostic markers in acute myeloid leukemia: perspective from the 
clinic. Hematology Am Soc Hema tol Educ Program, 2010. 2010: p. 47-55.
53. Byrd, J.C., et al., Pretreatment cytogenetic abnormalitie s are predictive of induction 
success, cumulative incidence of relapse, and overall survival in adult patients with de 
novo acute myeloid leukemia: results fr om Cancer and Leukemia Group B (CALGB 
8461). Blood, 2002. 100(13): p. 4325-36.
54. Bornhauser, M., et al., Improved outcome after stem-cell transplantation in FLT3/ITD-
positive AML. Blood, 2007. 109(5): p. 2264-5; author reply 2265.
55. Scholl, S., et al., Clinical impact of nucleophosmin mu tations and Flt3 internal tandem 
duplications in patients older than 60 yr with acute myeloid leuk aemia. Eur  J Haematol, 
2008.80(3): p. 208-15.
56. Thiede, C., et al., Analysis of FLT3-activating mutations in 979 patients with acute 
myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 2002. 99(12): p. 4326-35.
78
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
57. Williams, K.M. and R.E. Gress, Immune reconstitution and implications for 
immunotherapy following haematopoi etic stem cell transplantation. Best Pract Res Clin 
Haematol, 2008. 21(3): p. 579-96.
58. Bishop, M.R., et al., A randomized, double-blind trial of filgrastim (granulocyte colony-
stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
Blood, 2000. 96(1): p. 80-5.
59. Ernst, P., et al., A Phase 3, Randomized, Placebo-cont rolled Trial of Filgrastim in 
Patients with Haematological Malignancies Undergoing Matched-re lated Allogeneic 
Bone Marrow Transplantation. Arch Drug Inf, 2008. 1(3): p. 89-96.
60. Battiwalla, M. and P.L. McCarthy, Filgrastim support in allogeneic HSCT for myeloid 
malignancies: a review of the role of G-CSF and the implications for current practice.
Bone Marrow Transplant, 2009. 43(5): p. 351-6.
61. Rizzo, J.D., et al., Recommended screening and preventive practices for long-term 
survivors after hematopoietic cell trans plantation:joint recommendations of the 
European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow 
Transplantation. Biol Blood Marrow Transplant, 2006. 12(2): p. 138-51.
62. Filipovich, A.H., et al., National Institutes of Health consensus development project on 
criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 2005. 11(12): p. 945-56.
63. Buchali, A., et al., Immediate toxicity during fractionated total body irradiation as 
conditioning for bone marrow transplantation. Radiother Oncol, 2000. 54(2): p. 157-62.
64. Thomas, O., et al., Long-term complications of total body irradiation in adults. Int J 
Radiat Oncol Biol Phys, 2001. 49(1): p. 125-31.
65. Curtis, R.E., et al., Solid cancers after bone marrow transplantation. N Engl J Med, 
1997.336(13): p. 897-904.
66. Kolb, H.J., et al., Malignant neoplasms in long-te rm survivors of bone marrow 
transplantation. Late Effects Working Pa rty of the European Cooperative Group for 
Blood and Marrow Transplantation and the European Late Effect Project Group. Ann 
Intern Med, 1999. 131(10): p. 738-44.
12 APPENDICES
12.1 A
PPENDIX 1:PERFORMANCE SCALES
%Karnofskyâ€ Status Lansky Scale#
100Normal; no complaints/ no 
evidence of disease100 Fully Active
90Able to carry on normal 
activity; minor signs or 
symptoms of disease90Minor restrictions in 
physically strenuous play
79
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
â€      Karnofsky =  D.A., et al., Cancer 1: 634 -656, 1948
#Lansky Scale = Lansky, et. al., Cancer Oct 1; 60(7): 1651-1656, 198780Normal activity with effort; 
some signs or symptoms of 
disease80Restricted in strenuous 
play, tires more easily, 
otherwise active
70Cares for self; unable to 
carry on normal activity or 
do active work70Both greater restrictions of 
and less time spent in 
active play
60Requires occasional 
assistance but is able to care 
for most of his needs60Ambulatory up to 50% of 
time, limited active play 
with assistance / 
supervision
50Requires considerable 
assistance and frequent 
medical care50Considerable assistance 
required for any active 
play; fully able to engage 
in quiet play
40Disabled, requires special 
care and assistance40Able to initiate quiet 
activities
30Severely disabled; 
hospitalization is indicated 
though death not imminent30Needs considerable 
assistance for quiet activity
20Very sick; hospitalization is 
necessary20Limited to very passive 
activity initiated by others 
e.g. TV
10Moribund; fatal process 
progressing rapidly10Completely disabled, not 
even passive play
0 Unresponsive, coma
80
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
12.2 A PPENDIX 2A:RECIPIENT (ARM 1AND 2)
Name: ______________ Donor: _______________
DOB: ___/___/______ MR#______________
Tentative Transplant Date ___/___/______
Pre-Tx W/u: Scheduled   Date Done    CommentsH/P:   __/__/__     __/__/__CT Scans: 
Head __/__/__     __/__/__Sinus __/__/__     __/__/__
Chest __/__/__     __/__/__Abd/Pel __/__/__     __/__/__
Echo __/__/__     __/__/__
EKG __/__/__     __/__/__
PFT
DLCO __/__/__     __/__/__FEV1 __/__/__     __/__/__
Dental Ex __/__/__      __/__/__
Broviac p. __/__/__      __/__/__
Radiation __/__/__ __/__/__BM/LP __/__/__      __/__/__Nutrition __/__/__      __/__/__
Date Done     Result
CBC __/__/__ABO Type __/__/__ _______PT/PTT             __/__/__
Acute care panel __/__/__ _______
Hepatic panel    __/__/__      _______
Mineral Panel   __/__/__ _______
CK and LDH __/__/__            _______
Uric Acid _/__/__             _______
Lipid/TRI __/__/__ _______U Preg (F) __/__/__ _______
Hep A Ab __/__/__ _______
Hep B Ab __/__/__ _______Hep C Ab __/__/__ _______HIV Ab __/__/__ _______Toxo IgG/IgM  __/__/__ _______
CMV IgG/IgM  __/__/__ _______
HTLV I/II IgG  __/__/__ _______HSV1,2 IgG/IgM  __/__/__ _______ Testosterone and Estrogen level 
Adenovirus IgG __/__/__ _______ Pre-Lupron for females and males. 
EBV IgM/IgG  __/__/__ _______
Syphilis __/__/__ _______ Radiation records (prior)? 
Varicella IgG  __/__/__ _______
T/B/NK __/__/__ _______Disease diagnosis:
CNS+ ever? ______________Cytogenetics:Flow:
Extra evaluations based on hx:
Social work?Ophtho?ID?Should be completed within 45 days of BMT.
May need to repeated if chemo required.
81
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
24 hr CCL/GFR__/__/__ _______
NMDP sample __/__/__
IgG, IgA, IgM__/__/__RFLP __/__/__TSH/FreeT4 __/__/__ _______Urinalysis __/__/__ _______
82
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
12.3 A PPENDIX 2B:DONOR(ARM 1AND 2)
Name: ______________ Recipient: _______________
DOB: ___/___/______ MR#______________
Diagnosis: ___________
Tentative Transplant Date ___/___/______
Pre-Tx W/u: Scheduled   Date Done    Comments
H/P:   __/__/__     __/__/__EKG __/__/__     __/__/__CXR __/__/__     __/__/__
Anesthesia __/__/__      __/__/__
Date Done     Result
CBC __/__/__ _______
ABO Type __/__/__ _______PT/PTT __/__/__Acute care, hepatic, and miner al panel plus LDH __/__/__ _______
Lipid/TRI __/__/__ _______U Preg (F) __/__/__ _______Hep A Ab __/__/__ _______Hep B Ab __/__/__ _______Hep C Ab __/__/__ _______HIV Ab __/__/__ _______Toxo IgG/IgM  __/__/__ _______CMV IgG/IgM  __/__/__ _______HTLV I/II IgG  __/__/__ _______HSV1,2 IgG/IgM  __/__/__ _______Adenovirus IgG __/__/__ _______EBV IgM/IgG  __/__/__ _______Syphilis __/__/__ _______Varicella IgG  __/__/__ _______T/B/NK __/__/__ _______NMDP sample __/__/__ _______RFLP __/__/__ _______Urinalysis __/__/__ _______Should be completed within 30 days of BMT.
May need to repeated if chemo required.
83
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
8312.4 A PPENDIX 3A:FLT(1STBMT)
PATIENT Name _______________ MR#________________ DOB_________________
Date 
DueDate 
GivenWeek Day18F 
FLT18F 
FDGPre-Eval Post-Eval Comments
-1 Cr, ALT, AST, TK F18 1,2hr
0
1 1
2
3
4
5/9 CR, ALT, AST, TK F18 1,2hr
6
7
2 8
3 15
4 28 CR, ALT, AST, TK F18 1,2hr
29
+ CR, ALT, AST, TK F18 1,2hr To occur with GVHD, or thymus recovery
84
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
84Appendix 3B: FLT (2ndBMT)
Patient Name_____________ MR#____________________   DOB ____________________      
Date 
DueDate 
GivenWeek Day 18F FLT18F 
FDGPre-Eval Post-Eval Comments
-1 Cr, ALT, AST, TK F18 1,2hr
0
1 1
2
3
4 28 _______ CR, ALT, AST, TK F18 1,2hr
29 _______
5-7
8 60 _______ CR, ALT, AST, TK F18 1,2hr
61 _______
+ PD CR, ALT, AST, TK F18 1,2hr
P+1
+ TX CR, ALT, AST, TK F18 1,2hr To occur with progressive disease
T+1 To occur with immunotherapy 
85
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
8512.5 A PPENDIX 4A:ADULT (>22YEARS)BMTR OADMAP
Bone Marrow Transplant with Total Bo dy Irradiation and Cyclophosphamide
This roadmap represents the general plan of care for this patient during the bone marrow transplant 
process. This is not an order sheet. Transplant Date:____________
Patient/Diagnosis Basis for Dose 
CalculationsTransplant Donor
Name: Ht (cm): Type of 
Match:Name:
MR#: Wt (kg): Prep 
Regimen:TBI, Cytoxan NMDP/MR#:
Sex: BSA(m2): Product: Marrow Sex:
DOB: // IBW 
(kg):GVH 
Regimen:Methotrexate
, TacrolimusAge:
Age: y/o Allergies: Day 0: /    / Relationship:
ABO/Rh: Wt (kg):
CMV IgG: ABO/Rh:
HSV (I/II): CMV IgG:
Toxo IgG: HLA: A (     ,      
), Cw (     ,  
), B (      ,
), Bw (  ,    
), DRB1 (    
,     ), 
DRB3 (     
), DQB1 (    
,      )HLA:A (        ,      ), Cw (     ,        ), 
B (      ,      ), Bw (   ,   ), 
DRB1 (      ,      ), 
DRB3 (    ), 
DQB1 (     ,       )
Diagnosis:
Status:
Cytogenetics:
Risk Factors:
Performance 
Score:
Chemotherapy started on: (write in date) ______Was dose of prep regimen modified? If yes, explain:
___________________________
86
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
86Ht (cm): Dx:                 Prep Regimen: TBI/Cytoxan Type of Match: 
Wt (kg): Status:                 Product: Marrow Donor CMV: 
IBW (kg): Risk Factors: GVH Regimen: MTX/tacro Donor ABO/Rh: 
BSA (m2): Day 0:   /  /
Age: ABO/Rh: 
Day#: Date: Re gimen: Medications/Interventions: Notes:
-14 to day -7 /   / +/-male LUPRON (+females) One injection of 4 month 
preparation. 
-8 TBI Start Pneumocystis carinii (PCP) 
and Caspofungin prophylaxisWeekly Fungitall, Asp ag, Adeno 
+/- Toxo (for positive patients).  
-7 TBI
-6 TBI
-5 TBI
-4 CY
MesnaForced diuresis with IV hydration 
to maintain UOP volume of 2-3ml/kg/hr
-3 CY
MesnaDiscontinue PCP prophylaxis Forced diuresis with IV hydration 
to maintain UOP volume of 2-
3ml/kg/hr
-1 +/- FLT (1stor 
2ndBMT)Tacro 0.02mg/kg/day IBW continuous infusion TAC trough at least weekly, adjust to goal of 5-10ng/ml.
0 TX Start prophylactic antibiotics TAC trough at least weekly, adjust 
to goal of 5-10ng/ml.
+1 Methotrexate 10mg/m2 IV
+3 Methotrexate 5mg/m2 IV TAC trough at least weekly, adjust to goal  of 5-10ng/ml.
+5 +/- FLT  (1st
BMT)FLT can be on either day 5 or day 9 (BMT# 1 only)
+6 Methotrexate 5mg/m2 IV 
+11 Methotrexate 5mg/m2 IV TAC trough at least weekly, 
adjust to goal of 5-10ng/ml.
+14 -Research Blood
87
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
87+28 +/- FLT (1stor 
2ndBMT)Restart PCP prophylaxis -BMB, BMA morphology, RFLP, 
-BMA FISH, flow 
-diagnostic LP, Research Pl/BM
-Chimerism Bl/BM,
-H/P aGVHD, IgGs, TBNK
+29 +/-FDG(1st
or 2ndBMT)
+30 +/- FLT When 
GVHD or 
thymus 
+60 +/- FLT &
FDG (2ndBMT 
only)-BMB, BMA morphology, RFLP, 
-BMA cytogenetics, FISH, flow 
-diagnostic LP
-Chimerism Bl/BM,  
- Research blood/BM 
-TBNK, H/p w/ AGVHD eval. 
+100 Taper Tacrolimus if no signs of 
GVHD-H/P w/a or cGVHD, 
-BMB, BMA morphology, RFLP -BMA cytogenetics, FISH, flow 
- diagnostic LP
- Chimerism Bl/BM,- Research blood/BM, TBNK
- LDH,  IGs,- PFTs, CHEST CT.  
+180 Taper Tacrolimus if no signs of 
GVHD-H/P w/ cGVHD, -C h i m e r i s m  B l ,
- Research blood, TBNK
- Ferritin, Fe, LDH,  IGs,-P F T s .- Ophthalmology-D e n t a l- LH/FSH, TSH/T4, U/A, Chem20
+270 -H/P w/ cGVHD, 
-C h i m e r i s m  B l ,
- Research blood, TBNK- Ferritin, Fe, LDH,  IGs,-P F T s .- LH/FSH, TSH/T4, Chem20
+365 Consider Immunizations 6 months 
after withdrawal of immunosuppression.  -H/P w/a or cGVHD, 
-BMB, BMA morphology, RFLP 
-BMA cytogenetics, FISH, flow 
- diagnostic LP
88
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
88TBI twice daily fractionated with lung block on days -7, -6, -5, and -4. Cumulative dose = 1200 
cGy/course. CNS boost if CNS positive at any time prior to HSCT. 
Cyclophosphamide 60mg/kg IV over 1 hour on days -3, -2.  Cumulative dose =120mg/kg.
***Note: Use a modified dose in obese patients that is defined as BMI > 35 and modified weight is half way 
between  actual and ideal body weight for Cyclophosphamide and Mesna dosing
Mesna IV 24 hour infusion = to total Cyclophosphamide dose on days -3, -2.- Chimerism Bl/BM,
- Research blood/BM, TBNK
- Ferritin, LDH,  IGs,
- PFTs, CHEST CT.
- Ophthalmology-D e n t a l- LH/FSH, TSH/T4, U/A, Chem20
-E c h o
-D e x a
- GYN (female)
89
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
8912.6 A PPENDIX 4B:PEDIATRIC (<22YEARS)BMTR OADMAP
Bone Marrow Transplant with Total Bo dy Irradiation and Cyclophosphamide
This roadmap represents the general plan of  care for this patient during the bone marrow 
transplant process. This is not an order sheet. 
Transplant Date:____________
Patient/Diagnosis Basis for Dose 
CalculationsTransplant Donor
Name: Ht (cm): Type of 
Match:Name:
MR#: Wt (kg): Prep 
Regimen:TBI, 
CytoxanNMDP/MR#
:
Sex: BSA(m2)
:Product: Marrow Sex:
DOB: /    / IBW 
(kg):GVH 
Regimen:Methotrexate, TacrolimusAge:
Age: y/o Allergies: Day 0: /    / Relationship
:
ABO/Rh: Wt (kg):
CMV IgG: ABO/Rh:
HSV (I/II): CMV IgG:
Toxo IgG: HLA: A (     ,      ), 
Cw (     ,     ), 
B (       ,        ), Bw (  ,    ), 
DRB1 (     ,     
), DRB3 (     
), DQB1 (     ,  
)HLA: A (        ,      ), Cw (     ,        
), B (      ,      
), Bw (   ,   ), 
DRB1 (      ,      
), DRB3 (    ), 
DQB1 (     ,       
)
Diagnosis:
Status:
Cytogenetics:
Risk Factors:
Performance 
Score:
Chemotherapy started on: (write in date) _________________________________________
Was dose of prep regimen modified? If yes, explain:
____________________________________________________________________
90
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
90Ht (cm): Dx:                 Prep Regimen: TBI/Cytoxan Type of Match: 
Wt (kg): Status:                 Product: Marrow Donor CMV: 
IBW (kg): Risk Factors: GVH Regimen: MTX/tacro Donor ABO/Rh: 
BSA (m2): Day 0:   /  /
Age: ABO/Rh: 
91
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
91Day#: Date: Re gimen: Medications/Interventions: Notes:
-14 to day -7 /   / +/-male 
LUPRON (+females ) One injection of 4 month preparation. 
-9 TBI Start Pneumocystis carinii (PCP) and Caspofungin prophylaxisWeekly Fungitall, Asp ag, Adeno +/-
Toxo (for positive patients).  
-8 TBI
-7 TBI
-6 TBI
-5 CYMesna Forced diuresis with IV hydration to maintain 
UOP volume of 2-3ml/kg/hr
-4 CY
MesnaForced diuresis with IV hydration to maintain 
UOP volume of 2-3ml/kg/hr
-3 CY
MesnaForced diuresis with IV hydration to maintain 
UOP volume of 2-3ml/kg/hr
-2 CY
MesnaDiscontinue PCP prophylaxis Forced diuresis with IV hydration to maintain 
UOP volume of 2-3ml/kg/hr
-1 +/- FLT* Tacro 0.02mg/kg/day IBW 
continuous infusion TAC trough at least weekly, adjust to goal of 5-10ng/ml.
0 TX Start prophylactic antibiotics TAC trough at least weekly, adjust to goal 
of 5-10ng/ml.
+1 Methotrexate 10mg/m2 IV
+3 Methotrexate 5mg/m2 IV TAC trough at least weekly, adjust to 
goal  of 5-10ng/ml.
+5 +/- FLT  
+6 Methotrexate 5mg/m2 IV 
+11 Methotrexate 5mg/m2 IV TAC trough at least weekly, adjust to 
goal of 5-10ng/ml.
+14 -Research Blood
+28 +/- FLT Restart PCP prophylaxis -BMB, BMA morphology, RFLP, 
-BMA cytogenetics, FISH, flow 
-diagnostic LP, Research Pl/BM
-Chimerism Bl/BM,
-H/P aGVHD, IgGs, TBNK
+29 +/-FDG
+30 +/- FLT When 
GVHD or thymus 
+60 -BMB, BMA morphology, RFLP, -BMA cytogenetics, FISH, flow 
-diagnostic LP
-Chimerism Bl/BM,  
- Research blood/BM 
-TBNK, H/p w/ AGVHD eval. 
+100 Taper Tacrolimus if no signs of 
GVHD-H/P w/a or cGVHD, -BMB, BMA morphology, RFLP -BMA cytogenetics, FISH, flow 
- diagnostic LP
- Chimerism Bl/BM,
- Research blood/BM, TBNK
92
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
92TBI twice daily fractionated with lung block on days -8, -7, -6, -5.  Cumulative dose = 1200 cGy/course. CNS boost if 
CNS positive at any time prior to HSCT. 
Cyclophosphamide 50mg/kg IV over 1 hour on days -5, -4,-3, -2.  Cumulative dose =200mg/kg.
***Note: Use a modified dose in obese patients that is  defined as BMI > 35 and modified weight is half way 
between actual and ideal body weight for Cyclophosphamide and Mesna dosing
Mesna IV 24 hour infusion = to total Cyclophosphamide dose on days -5,-4, -3, -2.- Ferritin, LDH,  IGs,
- PFTs, CHEST CT.  
+180 Taper Tacrolimus if no signs of GVHD-H/P w/ cGVHD, -C h i m e r i s m  B l ,- Research blood, TBNK- Ferritin, Fe, LDH,  IGs,-P F T s .
- Ophthalmology
-D e n t a l
- LH/FSH, TSH/T4, U/A, Chem20
+270 -H/P w/ cGVHD, 
-C h i m e r i s m  B l ,
- Research blood, TBNK- Ferritin, Fe, LDH,  IGs,
-P F T s .
- LH/FSH, TSH/T4, Chem20
+365 Consider Immunizations 6 
months after withdrawal of immunosuppression.  -H/P w/a or cGVHD, -BMB, BMA morphology, RFLP -BMA cytogenetics, FISH, flow 
- diagnostic LP
- Chimerism Bl/BM,- Research blood/BM, TBNK
- Ferritin, LDH,  IGs,- PFTs, CHEST CT.
- Ophthalmology-D e n t a l
- LH/FSH, TSH/T4, U/A, Chem20
-E c h o
-D e x a
- GYN (female)
93
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
9312.7 A PPENDIX 5:RESEARCH SPECIMENS
Please note that any extra clinical specimen taken from the patient on protocol may become a research specimen if the patient has agreed to this, to include: BAL, biopsies of lung, bone, or liver etc. 
Note total aliquot will not exceed 3 ml/kg/draw nor 7 ml/kg in 4 week period for research.
Day#: From: Source: Notes:
- DONOR Donor marrow product  5 million total nucleated donor cells 
(of marrow product) 
-1 HOST Peripheral Blood â€“ FLT patients TK for FLT 1stor 2ndBMT
patients. 3 cc EDTA PB
+5 HOST Peripheral Blood â€“ FLT patients
Peripheral Blood â€“ cells, EDTA, 
HEP pl, TBNKTK 3 cc EDTA PB for FLT 1stBMT 
only patients.
20cc in red/green CPT PB
16 cc in EDTA PB
+7, 14, 21 HOST Peripheral Blood â€“ cells, EDTA, 
HEP pl, TBNK20cc in red/green CPT PB
16 cc in EDTA PB
+28 HOST Peripheral Blood â€“ cells, EDTA, 
HEP plBone marrow aspirateBone marrow biopsy 
Peripheral Blood â€“ FLT patients20cc in red/green CPT PB
16 cc in EDTA PB
+ TK 3 cc EDTA PB for FLT 1
stor 
2ndBMT patients 
+45 HOST Peripheral Blood â€“ cells, EDTA, 
HEP pl, TBNK
+ 60 HOST Peripheral Blood â€“ cells, EDTA, 
HEP plBone marrow aspirateBone marrow biopsy20cc in red/green CPT PB
16 cc in EDTA PB+ TK 3 cc EDTA PB for FLT 2
nd
BMT patients 
+ONSET AGVHD  HOST Peripheral Blood â€“ cells, EDTA, 
HEP pl20cc in red/green CPT PB16 cc in EDTA PB
+100 HOST Peripheral Blood â€“ cells, EDTA, 
HEP plBone marrow aspirateBone marrow biopsy20cc in red/green CPT PB16 cc in EDTA PB
+ONSET 
cGVHDHOST Peripheral Blood â€“ cells, EDTA, 
HEP pl20cc in red/green CPT PB16 cc in EDTA PB
+180 HOST Peripheral Blood â€“ cells, EDTA, 
HEP pl20cc in red/green CPT PB
16 cc in EDTA PB
+270 HOST Peripheral Blood â€“ cells, EDTA, 
HEP pl
+365 HOST Peripheral Blood â€“ cells, EDTA, 
HEP pl
Bone marrow aspirateBone marrow biopsy
+yearly on 
study until 5 
yearsHOST Peripheral Blood â€“ cells, EDTA, 
HEP pl
94
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
9412.8 A PPENDIX 6:IMMUNIZATION POST-TRANSPLANT
Immunizations:  All recipients will receive immu nizations after transplant, according to the BMT 
consortium guidelines 
(https://cccasper.cc.nih.gov/cvpn/aHR0cDovL2 ludHJhbmV0LmNjLm5paC5nb3Y/bmt/clinicalc
are/pdf/Table_II.pdf)
95
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
9512.9 A PPENDIX 7:MANAGEMENT OF ENGRAFTMENT SYNDROME
Clinical Definition of Engraftment Syndrome
A constellation of clinical symptoms and signs has been observed during neutrophil recovery 
following HSCT, most commonly termed â€œe ngraftment syndromeâ€ (ES), sometimes 
â€œhyperacuteâ€ graft-versus-host reaction.  Be low are guidelines for diagnosis and treatment.
Major criteria:xFever > 38.3 qwith no identifiable infectious etiology
xErythrodermatous rash involving more than 25% of body 
surface area and not attributable to a medication
xNoncardiogenic pulmonary edema, manifested by diffuse 
pulmonary infiltrates and hypoxia
Minor criteriaxHepatic dysfunction with either total bilirubin > 2 mg/dl or 
transaminases levels > two times normalxRenal insufficiency (serum creatinine > two times 
baseline)xWeight gain > 2.5% of baseline body weight
xTransient encephalopathy unexp lainable by other causes
A diagnosis of ES is established by the presence of all three major criteria, or two major criteria 
and one or more minor criteria;  the clinical signs and symptoms should appear within 96 hours 
of neutrophil recovery, according to the above proposed definition.
Â‰Neutrophil recovery after transplantation may result in â€œengraftment syndromeâ€ (which may include fever, rash, edema, hypoxia)
Â‰The following criteria will be utilized to diagnose engraftment syndrome (must have 3 major criteria or 2 major + 1 minor criteria):
Â‰To promote consistency of our clinical practice, the following will be the recommended therapy for engraftment syndrome.  However, th is schedule may be modified (taper either 
accelerated or delayed) for individual patient s as clinical circumstances warrant.  In 
particular, every attempt should be made to rapidly wean steroids due to infection and 
disease control issues in our patient population. 
Treatment of Engraftment Syndro me without pulmonary edema: 
- attempt to use diuretics first.- If progression of edema, consider me thylprednisolone at 0.5mg/kg/day x 3 
days.
Treatment of Engraftment Syndrome if pulmonary edema is present
Day 1: Methylprednisolone 250 mg IV Q6 hours x 4 dosesDay 2: Methylprednisolone 250 mg IV Q8 hours x 3 dosesDay 3: Methylprednisolone 250 mg IV Q12 hours x 2 dosesDay 4: Methylprednisolone 125 mg IV Q12 hours x 2 dosesDay 5: Methylprednisolone 60 mg IV Q12 hours x 2 dosesDay 6: Methylprednisolone 30 mg IV Q12 hours x 2 dosesDays 7-8: Prednisone 60 mg PO QD x 2 daysDays 9-10: Prednisone 50 mg PO QD x 2 days
96
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
96Days 11-12: Prednisone 40 mg PO QD x 2 days
Days 13-14: Prednisone 30 mg PO QD x 2 daysDays 15-16: Prednisone 20 mg PO QD x 2 daysDays 17-18: Prednisone 10 mg PO QD x 2 daysDay 19: Discontinue prednisone
In the event that symptoms or clinical signs of ES recur during the steroid taper, patients should 
be retreated with methylprednisolone  at a minimum dose of 60 mg IV QD. This schema is 
intended to serve as a guideline and to promote consistency in our clinical practice; it may be 
modified for individual patients as  clinical circumstances warrant. In particular, steroid dosing 
for pediatric patients (< 18) will be determined on a case-by-case basis.
97
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
9712.10A PPENDIX 8A:GRADING AND MANAGEMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE
Clinical Staging of Acute GVHD to be done/documented day +28, +60, +100 at minimum
Stage Skin Liver Gut
1 Rash < 25% BSA Total bilirubin 2-3 mg/dl Diarrhea 500-999ml/d
2 Rash 25-50% BSA Total bilirubin 3-6 mg/dl Diarrhea 1000-
1499ml/d
3 Rash > 50% BSA Total bilirubin 6-15 mg/dl Diarrhea Â•1500ml/d
4 Generalized 
erythoderma with 
desquamation and bullaeTotal bilirubin > 15 mg/dl Severe abdominal pain 
+/- ileus
BSA = body surface area; use â€œrule of ninesâ€ or burn chart to determine extent of rash.
Clinical Grading of Acute GVHD 
Stage
Grade Skin Liver Gut
0 (none ) 000
I1 -2 0 0
II 3 or 1 or 1
III 2-3 or 2-4
IV 4 or 4
Grade IV may also include le sser organ involvement but with  an extreme decrease in 
performance status.
Treatment of Acute GVHD
This schema is intended to serve as a guidelin e and to promote consistency in our clinical 
practice; it may be modified for individual patients as clinical circumstances warrant.
Grade I GVHD: 
1) Supportive care or topical corticosteroids (usu ally 0.1% triamcinolone; 1% hydrocortisone to 
face) applied to rash BID.
Grade II GVHD
1)   Supportive care or topical corticosteroids or oral/IV corticosteroids as deemed necessary by the clinical 
providers.
Grade III-IV GVHD:
1) Methylprednisolone (MP) 1 mg/kg per dose IV, BID for 3 consecutive days.2) If no response after 4 days, continue until re sponse (7-day maximum trial) add second line 
therapy which could include: MMF, ECP, rituximab, sirolimus, and will be directed based on 
98
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
98organ and severity and patient co-morbidities. 3)Regardless of response within 7 days, taper 
as follows (note add other agents prior to taper for non-responders):
a) 0.75 mg/kg per dose IV BID for 7 days.
b) 0.5 mg/kg per dose IV BID for 7 days.c) 0.375 mg/kg per dose IV BID for 7 days.d) If clinically appropriate, change MP to oral prednisone to equivalent of IV dose) daily for 
2 days.  MP may be converted to prednisone  later in the taper at the investigatorsâ€™ 
discretion.
e) After this, steroids will be reduced by 10% of  starting oral dose each week until a dose of 
10 mg/day is reached.  Subsequent reductions w ill be made at the investigatorsâ€™ discretion.
f) If GVHD worsens during taper, steroids should be increased to previous dose.g) During steroid taper, maintain tacrolimus at therapeutic levels.
5)Antifungal prophylaxis with agents effective against muld will be started when it is anticipated that the patient will be receiving steroids at >1 mg /kg/day of methylprednisolone 
(or equivalent) for >2 weeks. Voriconazol e, caspofungin, liposomal amphotericin B 
(Ambisome), posaconazole, or amphotericin B lipid complex (Abelcet) are valid alternatives.  
During prophylaxis with any of the above agen ts, fluconazole should be discontinued.  In 
patients with therapeutic cyclosporine levels at the initiation of voriconazole therapy, the cyclosporine or tacrolimus dose should be decrea sed by approximately 50%. In patients with 
therapeutic sirolimus levels at the initiation of voriconazole therapy, the sirolimus dose 
should be decreased by approximately 90%.
6) Determination of GVHD treatment response should be made  within 96 hours of starting the 
treatment.  The following are crite ria to determine definitions of response to GVHD treatment:
a) Complete response:  Complete  resolution of all clinical signs and symptoms of acute 
GVHD.
b) Partial Response: 50% reduction in skin rash, stool volum e or frequency, and/or total 
bilirubin.  Maintenance of adequate performance status (Karnofsky Score > 70%).
c) Non-responder: < 50% reduction in skin rash , stool volume or frequency, and/or total 
bilirubin.  Failure to maintain adequate performance status (Karnofsky Score d70%).
d) Progressive disease:  Further progression of  signs and symptoms of acute GVHD, and/or 
decline in performance status after the initiation of therapy.
Treatment 
This schema is intended to serve as a guidelin e and to promote consistency in our clinical 
practice; it may be modified for individual patients as clinical circumstances warrant.
99
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
9912.11 A PPENDIX 8B
Please complete for new diagnosis and fo llow-up with cGVHD (and/or day +100, 180, 270, 365)
Current Patien t Weight: ___________________ Todayâ€™s Date: ________________________ MR#/Name: ____________________   
CHRONIC GVHD ACTIVITY ASSESSMENT- CLINICIAN
Component Findings Scoring (see skin score worksheet)
Skin Erythematous rash of any sort                         % BSA (max 100%)
Moveable sclerosis                         % BSA (max 100%)
Non-moveable sclerosis (hidebound/non-pinchable) or subcutaneous sclerosis/fasciitis                         % BSA (max 100%)
Ulcer(s): select the largest ulcerative lesion, and measure its largest dimension in cm and mark 
location of ulcerLocation: ___________________
Largest dimension: __________cm
Eyes
Bilateral Schirmerâ€™s Tear Test(without anesthesia) 
in persons 9 years or olderRight Eye:                                        mm of wetting Left Eye:                                                      m m of wetting
Mouth Mucosal 
changeNo evidence 
of cGvHDMild Moderate Severe
Erythema None0Mild erythema or 
moderate erythema 
(<25%)1Ëœ oËœerate (â‰¥25%) or 
Severe erythema 
(<25Ëœ )2Severe erythema 
(â‰¥25%) 3
Lichenoid None0Hyperkeratotic 
changes(<25%) 1Hyper Ëœeratotic 
chanËœ es(ËœËœËœ 50%) 2Hyperkeratotic cha Ëœges 
(>5Ëœ%) 3
UËœ cers Ëœone0Non Ulcers involving (â‰¤20%)3Seve Ëœe Ëœlcerations 
(>20
Mucoceles* None01-5 mucoceles16-10 scattered 
mucoceles 2Over 10 mucoceles3
           
*Mucoceles score Ëœ for lower 
laËœialËœËœËœ d sof Ëœ palate onlyTotalËœscore for all 
mËœcosalËœchange
s

100
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
100Blood Counts Platelet Count                               
                                         K/uLULN    
                             K/uLTotal WBC
                                                   K/uLULN
                                          K/uL% Eosinophils
                                                  %
Liver Function Tests Total serum bilirubin
                           mg/dLULN                                                   mg/dL ALT
                           U/LULN                                                         U/L Alkaline Phosphatase        
                            U/LULN
                           U/L
Gastrointestinal-Upper GI 
x Early satiety  OR
x Anorexia     OR
x Nausea & Vomiting0= no symptoms
1=mild, occasional symptoms, with little reduction in oral intake during the past week
2=moderate, intermittent symptoms, with some reduction in oral intake during the past week
3=more severe or persistent symptoms throughout the day, with marked reduction in oral intake, on almost every day of the past week
Gastrointestinal-Esophageal
x Dysphagia     OR
x Odynophagia0= no esophageal symptoms1=Occasional dysphagia or odynophagia with solid food or pills during the past week
2=Intermittent dysphagia or odynophagia with solid foods or pills, but not for liquids or soft foods, during the past week
3=Dysphagia or odynophagia for almost all oral intake, on almost every day of the past week
Gastrointestinal-Lower GI
x Diarrhea0= no loose or liquid stools during the past week
1= occasional  loose or liquid stools, on some days during the past week
2=intermittent loose or liquid stools throughout the day, on almost every day of the past week, without requiring intervention to prevent or correct 
volume depletion3=voluminous diarrhea on almost every day of the past week, requiring intervention to prevent or correct volume depletion
Lungs
x Bronchiolitis ObliteransPulmonary Function Tests with Diffusing Capacity   (attach report for person> 5 yrs old)FEV-1
% PredictedSingle Breath DLCO 
(adjusted for hemoglobin)
                                                     % Predicted
Health Care Provider 
Global Ratings:
In your opinion, do you 
think that this patientâ€™s chronic GvHD is mild, 
moderate or severe?
0=none1= mild
2=moderate
3=severeWhere would you rate the severity  of this patientâ€™s chronic GvHD symptoms on the following 
scale, where 0 is cGVHD symptoms that are not at all severe and 10 is the most severe cGVHD symptoms possible:
             0       1         2         3         4         5         6    7         8          9         10
cGvHD symptoms                                                                                                                      Most severe cGvHD
not at all severe                                                                                                                                     symptoms
                                                                                                                                                                 possibleOver the past month would you say that this patientâ€™s cGvHD is
+3= Very much better +2= Moderately better
+1= A little better
0= About the same
-1=A little worse-2=Moderately worse 
-3=Very much worse
Functional Performance (in 
persons >4 years old)
x Walk Time
x Grip StrengthTotal Distance Walked in 2 Minutes :
Number of laps: _______ (x 50 feet) + final partial 
lap: _____ feet  = ______ feet walked in 2 minutes ,
6min                                          Grip Strength (Dominant Hand) Range of Motion: 
o Not performed
o Physical Therapy Report AttachedTrial #1
            psiTrial #2           psiTrial #3            psi
             Score Lansky Performance Status Scale Definitions (circle from 0-100) (persons < 16 years 
old)Karnofsky Performance Status Scale Definitions (circle 
from 0-100) (persons 16 years or older)
100 Fully active, normal Normal no complaints; no evidence of disease
90 Minor restrictions in physically strenuous activity Able to carry on normal activity; minor signs or symptoms of disease
80 Active, but tires more quickly Normal activity with effort; some signs or symptoms of disease
101
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10170 Both greater restriction of and less time spent in play activity Cares for self; unable to carry on normal activity or to do act ive work
60 Up and around, but minimal active play; keeps busy with quieter activities Requires occasional assistance but is able to care fo r most personal needs
50 Gets dressed but lies around much of the day, no active play but able to participate in all quiet play and activities Requires c onsiderable assistance and frequent medical care
40 Mostly in bed; participates in quiet activities Disabled; requires special care and assistance
30 In bed; needs assistance even for quiet play Severely disabled; hospital admission is indicated although death not 
imminent
20 Often sleeping; play entirely limited to very passive activities Very sick; hospital admission necessary; active supportive treatment 
necessar y
10 No play; does not get out of bed Moribund; fatal processes progressing rapidly
0 Unresponsive Dead
102
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10212.12A PPENDIX 8C:SIGNSAND SYMPTOMS OF C GVHD
ORGAN OR SITEDIAGNOSTIC (Sufficient to 
establish the 
diagnosis of chronic 
GVHD)DISTINCTIVE 
(Seen in chronic GVHD, but 
insufficient alone to establish a 
diagnosis of chronic GVHD)OTHER 
FEATURES*COMMON
(Seen with both 
acute and 
chronic GVHD)
Skin Æ”Poikiloderma 
Æ”Lichen planus-like features 
Æ”Sclerotic features
Æ”Morphea-like features
Æ”Lichen sclerosus-like featuresÆ”Depigmentation Æ”Sweat impairment
Æ”Ichthyosis
Æ”Keratosis pilaris
Æ”Hypopigmentation
Æ”HyperpigmentationÆ”Erythema
Æ”Maculopapular 
rash
Æ”Pruritus
Nails Æ”Dystrophy
Æ”Longitudinal ridging, 
splitting or brittle features
Æ”Onycholysis
Æ”Pterygium unguis
Æ”Nail loss** (usually 
symmetric, affects most nails)
Scalp and Body Hair Æ”New onset of scarring or non-scarring scalp alopecia, (after 
recovery from 
chemoradiotherapy)
Æ”6FDOLQJSDSXORVTXDPRXV
lesionsÆ”Thinning scalp hair, typically 
patchy, coarse or 
dull (not explained by endocrine or other causes), 
Æ”Premature gray hair
Mouth Æ”Lichen-type features
Æ”Hyperkeratotic plaques
Æ”Restriction of mouth opening
from sclerosisÆ”Xerostomia
Æ”Mucocele
Æ”Mucosal Atrophy
Æ”Pseudomembranes**
Æ”Ulcers**Æ”Gingivitis
Æ”Mucositis
Æ”Erythema
Æ”Pain
Eyes Æ”New onset dry, gritty, or 
painful eyesâ€ 
Æ”Cicatricial conjunctivitis
Æ”Keratoconjunctivitis siccaâ€ 
xConfluent areas of punctate 
keratopathyÆ”Photophobia
Æ”Periorbital hyperpigmentation
Æ”Blepharitis (erythema of the eye lids with 
edema)
Genitalia Æ”Lichen planus-like 
features
Æ”Vaginal scarring 
or stenosisxErosions**
xFissures**
xUlcers**
GI Tract xEsophageal web
xStrictures or stenosis 
in the upper to midthird of the esophagus**xExocrine 
pancreatic 
insufficiencyxAnorexia
xNausea
xVomiting
xDiarrhea
xWeight loss
103
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
103ORGAN OR SITEDIAGNOSTIC (Sufficient to establish the diagnosis of chronic 
GVHD) DISTINCTIVE 
(Seen in chronic GVHD, but 
insufficient alone to establish a diagnosis of chronic GVHD)OTHER 
FEATURES*COMMON
(Seen with both acute and chronic GVHD)
xFailure to thrive (infants 
and children
Liver xTotal bilirubin, 
alkaline phosphatase > 2 x upper limit of normalâ€ 
Æ”ALT or AST > 
2x upper limit of 
normalâ€ 
Lung Æ”Bronchiolitis 
obliterans diagnosed 
with lung biopsyxBronchiolitis obliterans 
diagnosed with PFTs and radiologyâ€ xBOOP
Muscles, Fascia, Joints xFasciitis
xJoint stiffness or 
contractures secondary to sclerosisxMyositis or 
polymyositis â€ xEdema
xMuscle cramps
xArthralgia or 
arthritis
Hematopoieticand ImmunexThrombocytopenia
xEosinophilia
xLymphopenia
xHypo- or hyper-gammaglobulinemia
xAutoantibodies (AIHA, ITP)
Other xPericardial or pleural effusions
xAscites
xPeripheral neuropathy
xNephrotic syndrome
xMyasthenia gravis
xCardiac conduction abnormality or cardiomyopathy
*Can be acknowledged as part of the chronic GVHD symptomatology if diagnosis is confirmed**In all cases, infection, drug effect, malignancy or other causes must be excluded.
â€ Diagnosis of chronic GVHD requires biopsy or radi ology confirmation (or Schirmerâ€™s test foreyes). 
GVHD (graft versus host disease); ALT (alanine aminotransferase); AST (aspartate aminotransferase); 
BOOP (bronchiolitis obliterans organizing pneumon ia); PFTs (pulmonary function tests); AIHA 
(autoimmune hemolytic anemia)
1 0 4 
A b b r e v i a t e d  T i t l e :  L u p r o n  &  1 8 F  F L T  i n  a l l o -H S C T 
V e r s i o n  D a t e :  D e c em b e r  2 8 ,  2 0 1 7 
1 0 4 1 2 . 1 3  A P P E N D I X  8 D : CG VH D  S CO R E  SH E E T 
P l e a s e  c om p l e t e  f o r  n e w  d i a g n o s i s  a n d  f o l l o w - u p  w i t h  c G V H D  ( a n d / o r  d a y  + 1 0 0 ,  1 8 0 ,  2 7 0 ,  3 6 5 ) 
S CO R E  0 S CO R E  1  S CO R E  2 S CO R E  3 
PE R FO RM A N C E  
SCO R E :
K P S    E COG    L P S A s ym p t om a t i c  
a n d  f u l l y  a c t i v e  
( E C O G  0 ;  K P S  o r  
L P S  1 0 0% ) S ym p t om a t i c ,  
f u l l y  am b u l a t o r y ,  
r e s t r i c t e d  o n l y  i n  
p h y s i c a l l y  s t r e n u o u s  
a c t i v i t y  ( E C O G  1 ,  
K P S  o r  L P S  8 0 - 
9 0% ) S ym p t om a t i c ,  
am b u l a t o r y ,  
c a p a b l e  o f  s e l f - 
c a r e ,  > 5 0%  o f  
w a k i n g  h o u r s  o u t  
o f  b e d  ( E C O G  2 ,  
K P S  o r  L P S  6 0 - 
7 0% )  S ym p t om a t i c ,  
l im i t e d  s e l f - c a r e ,  
> 5 0%  o f  w a k i n g  
h o u r s  i n  b e d  ( E C O G  
3 - 4 ,  K P S  o r  L P S  
< 6 0% ) 
SK I N 
C l i n i c a l  f e a t u r e s : 
M a c u l o p a p u l a r  
r a s h 
L i c h e n  p l a n u s - l i k e  
f e a t u r e s 
P a p u l o s q u am o u s  
l e s i o n s  o r  i c h t h y o s i s 
H y p e r p i gm e n t a t i o n 
H y p o p i gm e n t a t i o n 
K e r a t o s i s  p i l a r i s 
E r y t h em a 
E r y t h r o d e rm a  
P o i k i l o d e rm a 
S c l e r o t i c  f e a t u r e s  
P r u r i t u s 
H a i r  i n v o l v em e n t 
N a i l  i n v o l v em e n t 
%  B S A  
i n v o l v e d N o  S ym p t om s  <1 8%  B S A  w i t h  
d i s e a s e  s i g n s  b u t  
NO s c l e r o t i c  
f e a t u r e s 1 9 - 5 0%  B S A  
O R  i n v o l v em e n t  
w i t h  s u p e r f i c i a l  
s c l e r o t i c  f e a t u r e s  
â€œ n o t  h i d e b o u n d â€  
( a b l e  t o  p i n c h ) > 5 0%  B S A  O R 
d e e p  s c l e r o t i c  
f e a t u r e s  â€œ h i d e b o u n d â€  
( u n a b l e  t o  p i n c h )  O R 
im p a i r e d  m o b i l i t y ,  
u l c e r a t i o n  o r  s e v e r e  
p r u r i t u s  
MO U TH N o  s ym p t om s  M i l d  s ym p t om s  
w i t h  d i s e a s e  s i g n s  
b u t  n o t  l im i t i n g  o r a l  
i n t a k e  s i g n i f i c a n t l y M o d e r a t e  
s ym p t om s  w i t h  
d i s e a s e  s i g n s  w i t h 
p a r t i a l  l im i t a t i o n  
o f  o r a l  i n t a k e S e v e r e  s ym p t om s  
w i t h  d i s e a s e  s i g n s  o n  
e x am i n a t i o n  w i t h 
m a j o r  l im i t a t i o n  o f  
o r a l  i n t a k e 
EY E S 
M e a n  t e a r  t e s t  (mm ) : 
> 1 0 
6 - 1 0 
< 5 
N o t  d o n e N o  s ym p t om s  M i l d  d r y  e y e  
s ym p t om s  n o t  
a f f e c t i n g  A D L  
( r e q u i r i n g  e y e d r o p s  
<  3  x  p e r  d a y )  O R 
a s ym p t om a t i c  s i g n s  
o f   
k e r a t o c o n j u n c t i v i t i s  
s i c c a M o d e r a t e  d r y  
e y e  s ym p t om s  
p a r t i a l l y  a f f e c t i n g  
A D L  ( r e q u i r i n g  
d r o p s  >  3  x  p e r  
d a y  o r  p u n c t a l  
p l u g s ) ,  
W I THO U T 
v i s i o n  im p a i rm e n t S e v e r e  d r y  e y e  
s ym p t om s  
s i g n i f i c a n t l y  
a f f e c t i n g  A D L  
( s p e c i a l  e y e w a r e  t o  
r e l i e v e  p a i n )  O R 
u n a b l e  t o  w o r k  
b e c a u s e  o f  o c u l a r  
s ym p t om s  O R l o s s  
o f  v i s i o n  c a u s e d  b y  
k e r a t o c o n j u n c t i v i t i s  
s i c c a 
1 0 5 
A b b r e v i a t e d  T i t l e :  L u p r o n  &  1 8 F  F L T  i n  a l l o -H S C T 
V e r s i o n  D a t e :  D e c em b e r  2 8 ,  2 0 1 7 
1 0 5 S CO R E  0 S CO R E  1  S CO R E  2 S CO R E  3 
G I  T R A C T N o  s ym p t om s S ym p t om s  s u c h  
a s  d y s p h a g i a ,  
a n o r e x i a ,  n a u s e a ,  
v om i t i n g ,  a b d om i n a l  
p a i n  o r  d i a r r h e a  
w i t h o u t  s i g n i f i c a n t  
w e i g h t  l o s s  ( < 5% ) S ym p t om s  
a s s o c i a t e d  w i t h  
m i l d  t o  m o d e r a t e  
w e i g h t  l o s s  ( 5 - 
1 5% ) S ym p t om s  
a s s o c i a t e d  w i t h  
s i g n i f i c a n t  w e i g h t  
l o s s  > 1 5% ,  r e q u i r e s  
n u t r i t i o n a l  
s u p p l em e n t  f o r  m o s t  
c a l o r i e  n e e d s  O R 
e s o p h a g e a l  d i l a t i o n 
LI V E R N o rm a l  L F T E l e v a t e d  
B i l i r u b i n ,  A P * ,  A S T  
o r  A L T  < 2  x  U L N B i l i r u b i n  > 3  
m g / d l  o r  B i l i r u b i n ,  
e n z ym e s  2 - 5  x  
U L N  B i l i r u b i n  o r  
e n z ym e s  >  5  x  U L N 
LU NG S *
F E V 1 
D L CO N o  s ym p t om s 
F E V 1  >  8 0%  
O R L F S = 2 M i l d  s ym p t om s  
( s h o r t n e s s  o f  b r e a t h  
a f t e r  c l im b i n g  o n e  
f l i g h t  o f  s t e p s ) 
F E V 1  6 0 - 7 9%  
O R L F S  3 - 5 M o d e r a t e  
s ym p t om s  
( s h o r t n e s s  o f  
b r e a t h  a f t e r  
w a l k i n g  o n  f l a t  
g r o u n d ) 
F E V 1  4 0 - 5 9%  
O R L F S  6 - 9 S e v e r e  s ym p t om s  
( s h o r t n e s s  o f  b r e a t h   
a t  r e s t ;  r e q u i r i n g  0 2)
F E V 1  < 3 9%  O R 
L F S  1 0 - 1 2 
JO I N T S  A N D  FA S C I A N o  s ym p t om s M i l d  t i g h t n e s s  o f  
a rm s  o r  l e g s ,  n o rm a l  
o r  m i l d  d e c r e a s e d  
r a n g e  o f  m o t i o n  
( R OM )  A N D n o t  
a f f e c t i n g  A D L T i g h t n e s s  o f  
a rm s  o r  l e g s  O R 
j o i n t  c o n t r a c t u r e s ,  
e r y t h em a  d u e  t o  
f a s c i i t i s ,  m o d e r a t e  
d e c r e a s e  R OM  
A N D m i l d  t o  
m o d e r a t e  
l im i t a t i o n  o f  A D L C o n t r a c t u r e s  
W I TH s i g n i f i c a n t  
d e c r e a s e  o f  R OM 
A N D  s i g n i f i c a n t  
l im i t a t i o n  o f  A D L  
( u n a b l e  t o  t i e  s h o e s ,  
b u t t o n  s h i r t s ,  d r e s s  
s e l f  e t c . )  
GE N I T A L  TR A C T N o  s ym p t om s  S ym p t om a t i c  w i t h  
m i l d  s i g n s  o n  e x am  
A N D n o  e f f e c t  o n  
c o i t u s  a n d  m i n im a l  
d i s c om f o r t  w i t h  
g y n e c o l o g i c  e x am S ym p t om a t i c  
w i t h  m o d e r a t e  
s i g n s  o n  e x am  
A N D w i t h  m i l d  
d y s p a r e u n i a  o r  
d i s c om f o r t  w i t h  
g y n e c o l o g i c  e x am S ym p t om a t i c  
W I TH a d v a n c e d  
s i g n s  ( s t r i c t u r e ,  
l a b i a l  a g g l u t i n a t i o n  
o r  s e v e r e  u l c e r a t i o n )  
A N D s e v e r e  p a i n  
w i t h  c o i t u s  o r  
i n a b i l i t y  t o  i n s e r t  
v a g i n a l  s p e c u l um 
*A P  m a y  b e  e l e v a t e d  i n  g r o w i n g  c h i l d r e n ,  a n d  n o t  r e f l e c t i v e  o f  l i v e r  d y s f u n c t i o n 
O t h e r  i n d i c a t o r s ,  c l i n i c a l  m a n i f e s t a t i o n s  o r  c om p l i c a t i o n s  r e l a t e d  t o  cG VH D  ( c h e c k  a l l  t h a t  a p p l y  a n d  a s s i g n  
a  s c o r e  t o  i t s  s e v e r i t y  ( 0 - 3 )  b a s e d  o n  i t s  f u n c t i o n a l  im p a c t  ( n o n e  â€“  0 ,m i l d  - 1 ,  m o d e r a t e  - 2 ,  s e v e r e  â€“  3 ) 
E s o p h a g e a l  s t r i c t u r e  o r  w e b _ _ _ P e r i c a r d i a l  E f f u s i o n _ _ _ P l e u r a l  E f f u s i o n ( s ) _ _ _ 
A s c i t e s  ( s e r o s i t i s ) _ _ _ N e p h r o t i c  s y n d r om e _ _ _ P e r i p h e r a l  N e u r o p a t h y _ _ _ 
M y a s t h e n i a  G r a v i s _ _ _ C a r d i om y o p a t h y _ _ _ E o s i n o p h i l i a  >  l _ _ _ 
P o l ym y o s i t i s _ _ _                C a r d i a c  c o n d u c t i o n  d e f e c t s _ _ _ C o r o n a r y  a r t e r y  i n v o l v em e n t _ _ _ 
P l a t e l e t s  < 1 0 0 , 0 0 0 / l  _ _ _ P r o g r e s s i v e  o n s e t 
106
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
106Ô¼OTHERS:___________
107
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
10712.14A PPENDIX 9:ETIBP OLICY FOR SAMPLE HANDLING
Experimental Transplanta tion and Immunology Branch 
Preclinical Service Policy for Sample Handling
12.14.1Sample Processing EDTA plasma:Spin down cells at 1500 rpm, 10 min, 10Â°C. Draw off plasma. Store >6 ml of plasma in 1ml 
conical tubes, labeled as EDTA plasma. Store at -80Â°C.Heparinized Blood:Heparinized whole blood is coll ected for analysis of relevant  cytokine/chemokines content. 
Separate plasma by centrifugation and freeze > 6ml samples in 1ml conical tubes, labeled as 
heparinized plasma. Store at   â€“80Â°C.
If whole blood is being processed for flow cytometry:Place 1 ml of well mixed whole blood in a 15ml t ube. Add 10ml ACK. Mix well by repeatedly 
inverting tube. Hold 5 min RT. Spin down ( 1500 rpm, 10 min, 10Â°C), Resuspend in 0.5ml FACS 
buffer. Distribute to staining tubes.If whole blood is cryopreservedFicoll blood and cryopreserve cells, divide d into two 1ml aliquots. Store in LN2.
Our freezing protocol is attached, but any commercial cryopreserve media will suffice.
12.14.2Labeling
All samples are to be labeled with an anonymized Patient identifier such as the patient # in the 
protocol#), date, content (EDT A or heparinized plasma, PB MC with cell number,) and 
preferably stage (pre, 3m, 6m).  We need to be able to link all timepoints collected on a single patient but not an identity.
12.14.3Storage/Tracking in the Preclinical Devel opment and Clinical Monitoring Facility 
(PDCMF)
Samples will be ordered in CRIS and tracked through a Clinical Trial Data Management system.
Should a CRIS screen not be available, the CRIS downtime procedur es will be followed.
Samples will not be sent outside  NIH without IRB notification a nd an executed MTA. Normal 
donor and patient blood and tissue samples, collected for the purpose of research under IRB approved protocols of the Expe rimental Transplantation a nd Immunology Branch, may be 
archived by the ETIB Preclinical Service. All da ta associated with archived clinical research 
samples is entered into the ETIB Preclinical Servicesâ€™s Microsoft Excel databases on frozen cells and plasma. These databases are stored on the NC I group drive in the ETIB Preclinical Service 
folder. Access to this folder is limited to ETIB clinical staff, requiring individual login and password. All staff in the Prec linical Service laboratory have received annually updated 
108
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
108NIH/CIT training and maintain standards of co mputer security. Only NIH PI and Adjunct PI 
may appropriate samples for use and interpret data in the context of  the endpoints of this trial.  
The data recorded for each sample includes the patient ID, name, trial name/protocol number, 
date drawn, treatment cycle/pos t transplant time point, cell source (e. g. peripheral blood, 
lymphapheresis, mobilized periphe ral blood stem cells, marrow, pleural fluid) as well as box and 
freezer location. Patient demographics that corre late treatment outcomes and therapies with the 
samples can be obtained only through the NCI/ETIB clinical records or NCI C3D. As of January 2007, all newly received samples w ill receive a unique bar code number, which will be added to 
the sample Preclinical Service database. Only this bar code will be recorded on the sample vial and the vials will not be traceable back to patients without authorized access to the Preclinical Service database. All non-coded samples previously archived will be stripped of identifiers prior to distribution for any use othe r than as a primary objective of the protocol under which they 
were collected.
Samples are stored in locked freezers. All samples will be labeled solely with a bar code (which 
includes the date, and serially determined individual sample identifier). The key will be available to a restricted number of ETIB investigators and associate inve stigators on the protocol. Coded 
samples will be stored frozen at -20Â°, -80Â° or liquid nitrogen vapor phase according to the stability requirements under the restricted control of the PDCM Facility of ETIB..
Access to samples from a protocol for research purposes will be by permission of the Principal Investigator of that protocol in order to be used (1) for research purposes associated with 
protocol objectives for which th e samples were collected, or (2) for a new research activity 
following submission and IRB approval of a new protocol and consent, or (3) for use only as 
unlinked or coded samples under the OHSRP Exemption Form guidelines stipulating that the 
activity is exempt from IRB review. Unused samples must be returned to the PDCMF laboratory.
Samples, and associated data, will be stored permanently unless the patient withdraws consent. If 
researchers have samples remaining once they have completed all studies associated with the protocol, they must be returned to the PDCMF laboratory.
These freezers are located onsite at the PDCMF laboratory (12C216) or in ETIB common 
equipment space (CRC/3-3273).
12.14.4Protocol Completion/Sample Destruction 
Once primary research objectives for the protocol are achieved, researchers can request access to 
remaining samples, providing they have both a pproval of the Principal Investigator of the 
original protocol under which th e samples or data were collect ed and either an IRB approved 
protocol and patient c onsent or the OHSRP Exemption Form stipulating that the activity is 
exempt from IRB review..
109
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
109The PDCMF staff will report to the Principal Investigators any destroyed samples, if samples 
become unsalvageable because of environmental fact ors (ex. broken freezer or lack of dry ice in 
a shipping container), lost in transit be tween facilities or misplaced by a researcher. 
The PI will report destroyed samples to the IRB if samples become unsalvageable because of environmental factors (ex. broken freezer or lack of  dry ice in a shipping container) or if a patient 
withdraws consent.  Samples will also be reported as lost if they are lost in transit between facilities or misplaced by a researcher.  Freeze r problems, lost samples or other problems 
associated with samples will also be reported to the IRB, the NCI Clinical Director, and the office of the CCR, NCI.
12.14.5Handling for subjects at ot her Participating Institutions
xBlood speciman obtained from University of Oklahoma and Childrenâ€™ s National Medical 
Center may be frozen as above, stored, and shi pped in batch to NCI. The specimens should be 
shipped to arrive Monday-Friday, to Dr.  Fran  Hakimâ€™s ETIB Core lab (Bldg 10, room 12C216.
Attention Jeremy Rose phone: 301-594 5339, 10 Center Drive, CRC 3-3330, Bethesda, MD 
20892.
110
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
11012.15A PPENDIX 10:DATA COLLECTION ELEMENTS REQUIRED BY PROTOCOL
All of the following elements will be recorded in the C3D database.
A. Patient Enrollment 
Recipient
xDate of birth, age, gender, race, ethnicity
xHeight
xWeight
xPerformance Status
xDate of original diagnosis
xStage at diagnosis
xStage at study entry
xSites of disease at diagnosis and study entry
xTumor Histology and date of confirmation
xDate of Informed Consent signature, c onsent version and date of registration
xBaseline History/Physical
xBaseline Symptoms 
xPrior therapy
xPrior surgery
xFindings of consultations done at screening
xABO
Donor
xDate of birth, age, gender, race, ethnicity
xHeight
xWeight
xBaseline History/Physical (Y/N)
xSerology (CMV)
xABO
B. Study Drug administration and respons e for each course of therapy given
xDates study drugs given
xDose level, actual dose, schedule and route given
xHeight, weight, and body surface area at start of each course
xResponse assessment for each restaging performed
xFor women, the administration of estrogen supplementation will be captured.
C. Laboratory and Diagnostic Test Data
xAll Clinical laboratory and diagnostic test results done at screening  (recipient and 
donor) and until day 365 post transplant with the following exceptions:
111
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
111oDiagnostic tests which are not specified in the protocol, and if the results 
are not needed to document the start or end of an adverse event that 
requires reporting.
xAll clinical laboratory and diagnostic tests done after day 100 that support a possible, probable or definite diagnos is of GVHD, infection or secondary 
malignancy and those done to document a change in grade and the end of these 
adverse events.
xAll tests done to document reso lution of adverse events that occurred in the first 
100 days post transplant
xHLA data (patient and donor).
xSerologies-CMV, HSV, EBV, toxoplasmosis, adenovirus (patient and donor)
xTTV data (patient and donor)
xBlood, bone marrow, and tumor chimerism data 
xFEV1, DLCO (adjusted but not /VA) pre-transplant
xEF pre-transplant
xAcute care, hepatic, and mineral panel plus LDH at transplant 
xGFR or CrCL pre-transplant 
xComplete blood count  pre-transplant
xLymphocyte total number, % CBC, and TB NK at research time points for primary 
endpoint
xIgA, IgM, IGG at research primary endpoints
xEngraftment endpoints: neutrophil, plt, hbg
xLH/FSH/sex hormone levels
xVaccine serologies.
D. Adverse Events
xAll grade 2, 3, or 4 adverse events possibly, probably, or definitely attributable to 
lupron or the IND and all serious adverse events will be recorded.
xData will also be reported to the Center for International Bone Marrow Transplant Registry
E. Concomitant Measures
xBaseline medications 
xAntibiotics
xGVHD prophylaxis and treatment
xOther therapy for recorded adverse events
F. Treatment of Persiste nt/Progressive Disease with Standard Therapy
xChemotherapy
xImmunotherapy
xRadiation therapy
112
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
112xDonor Lymphocyte Infusion
G. Tumor response and measurements
xRestaging studies performed at protocol specified time points and as clinically 
indicated.
H. Off study
xDate and reason for off study
xDate and cause of death
xAutopsy findings
xPI decision to end this study
113
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
11312.16APPENDIX 11: P ROBLEMREPORTFORM
NCI Protocol #: Protocol Title: 
Report version: (select one)
____Initial Report 
____Revised Report
____Follow-up
Site Principal Investigator:
Date of problem:    Location of problem: (e.g.,  patientâ€™s home, 
doctorâ€™s office )
Who identified the problem? (provide role (not name of person): nurse, investigator, 
monitor, etcâ€¦)
Brief Description of Subject (if 
applicable)
(Do NOT include personal 
identifiers)Sex: ___ Male  ___ Female Age:
___ Not applicable (more than subject is involved)
Diagnosis under study:  
Name the problem: (select all that apply)
[  ] Adverse drug reaction  
[  ] Abnormal lab value  
[  ] Death  
[  ] Cardiac Arrest/ code [  ] Anaphylaxis [  ] Sepsis/Infection  
[  ] Blood product reaction
[  ] Unanticipated surgery/procedure  [  ] Change in status (e.g. increased level of care required)   [  ] Allergy (non-medication) 
[  ] Fall 
[  ] Injury/Accident (not fall) [  ] Specimen collection issue  [  ] Informed consent issue  [  ] Ineligible for enrollment  
[  ] Breach of PII 
114
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
114[  ] Tests/procedures not performed on schedule 
[  ] Other, brief  1-2 word description: _________________________
Detailed Description of the problem: (Include any relevant treatment, outcomes or 
pertinent history ):
*Is this problem unexpected? (see the definition of unexpected in the protocol))
__YES __NO  Please explain:
*Is this problem related or possibly rela ted to participation in the research?  
__YES __NO  Please explain:
*Does the problem suggest the research places subjects or others at a greater 
risk of harm than was previously known or recognized?     __YES __NO      
Please explain:
Is this problem? (select all that apply )
[  ] An Unanticipated Problem* that is:       [  ] Serious        [  ] Not Serious 
[  ] A Protocol Deviation that is:                [  ] Serious        [  ] Not Serious[  ] Non-compliance
*Note if the 3 criteria starred above are answered, â€œYESâ€, then this event is also a UP.
Is the problem also (select one) [  ] AE [  ] Non-AE
Have similar problems occurred on this protocol at your site? __YES __NO      
If â€œYesâ€, how many? ____      Please describe:
Describe what steps you have already taken as a result of this problem:
In addition to the NCI IRB, this pr oblem is also being reported to: (select all that 
apply )
[  ] Local IRB[  ] Study Sponsor
[  ] Manufacturer : ____________________[  ] Institutional Biosafety Committee [  ] Data Safety Monitoring Board
[  ] Other: ____________________________________
[  ] None of the above, not applicable
115
Abbreviated Title: Lupron & 18F FLT in allo-HSCT
Version Date: December 28, 2017
115INVESTIGATORâ€™S SIGNATURE: DATE:  